

CITATION REPORT

List of articles citing

Updated clinical classification of pulmonary hypertension

DOI: 10.1016/j.jacc.2013.10.029

Journal of the American College of Cardiology, 2013,
62, D34-41.

Source: <https://exaly.com/paper-pdf/55159102/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2216	The Fifth World Symposium on Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D1-3	15.1	93
2215	Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists. 2013 , 3, 792-801		7
2214	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. 2014 , 9, 71-80		9
2213	Alternatives to the six-minute walk test in pulmonary arterial hypertension. 2014 , 9, e103626		13
2212	Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidity. 2014 , 9, e114392		19
2211	The Significance of Pulmonary Artery Size in Pulmonary Hypertension. 2014 , 2, 243-259		17
2210	Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease. 2014 , 4,		31
2209	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. 2014 , 8, 875-85		19
2208	Pulmonary hypertension and hepatic encephalopathy: lethal complications of Rendu-Osler-Weber disease. 2014 , 44, 126-9		3
2207	Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. 2014 , 10, 825-39		21
2206	Clinical characteristics and survival of Korean idiopathic pulmonary arterial hypertension patients based on vasoreactivity. 2014 , 29, 1665-71		2
2205	Investigating cardiac MRI based right ventricular contractility as a novel non-invasive metric of pulmonary arterial pressure. 2014 , 8, 45-50		3
2204	Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. 2014 , 40, 609-16		13
2203	Anomalous origin of left coronary artery from pulmonary artery associated with pulmonary hypertension. 2014 , 66, 700-3		6
2202	Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. 2014 , 190, 1421-9		70
2201	Nuevos agentes para el tratamiento de la hipertensi3n pulmonar. 2014 , 21, 399-408		
2200	Exercise-based rehabilitation programmes for pulmonary hypertension. 2014 ,		1

2199	Quality of life as a prognostic marker in pulmonary arterial hypertension. 2014 , 12, 130	28
2198	The main pulmonary artery in adults: a controlled multicenter study with assessment of echocardiographic reference values, and the frequency of dilatation and aneurysm in Marfan syndrome. 2014 , 9, 203	26
2197	Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension. 2014 , 12, 1391-9	2
2196	Novel serum biomarkers in pulmonary arterial hypertension. 2014 , 8, 1001-11	4
2195	Macitentan for the treatment of pulmonary arterial hypertension. 2014 , 8, 393-9	2
2194	Sildenafil for the treatment of pulmonary hypertension in children. 2014 , 12, 1157-84	12
2193	TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process. 2014 , 64, 1260-5	26
2192	Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. 2014 , 2014, 704094	12
2191	Presurgical pulmonary evaluation in renal transplant patients. 2014 , 6, 605-12	3
2190	Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE-PAH cured by methylprednisolone pulse therapy. 2014 , 23, 1533-6	15
2189	Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis. 2014 , 2014, 528783	13
2188	Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series). 2014 , 4, 353-62	17
2187	Hepatopulmonary Syndrome and Portopulmonary Hypertension. 2014 , 1-23	
2186	Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases. 2014 , 2014, 247372	27
2185	Pulmonary hypertension in sickle cell disease: diagnosis and management. 2014 , 2014, 425-31	7
2184	Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. 2014 , 11, 1553-9	15
2183	Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. 2014 , 2014, 743868	8
2182	The challenges in paediatric pulmonary arterial hypertension. 2014 , 23, 498-504	21

2181	Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension. 2014 , 15, 1411-9	24
2180	Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. 2014 , 4, e004843	23
2179	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. 2014 , 146, 449-475	200
2178	Epoprostenol (Veletri [®] , Caripul [®]): a review of its use in patients with pulmonary arterial hypertension. 2014 , 14, 463-70	9
2177	Coenzyme Q supplementation in pulmonary arterial hypertension. 2014 , 2, 884-91	21
2176	The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension. 2014 , 63, 114-7	4
2175	Hipertensi ^o pulmonar del adulto. 2014 , 11, 4059-4075	
2174	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. 2014 , 130, 2189-208	209
2173	Connective tissue disease-associated pulmonary arterial hypertension: "Beijing style". 2014 , 44, 839-41	2
2172	Long-term effect of vasodilator therapy in pulmonary hypertension due to COPD: a retrospective analysis. 2014 , 192, 987-95	14
2171	A retrospective study on the effects of pulmonary rehabilitation in patients with pulmonary hypertension. 2014 , 11, 153-162	11
2170	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. 2014 , 44, 1275-88	135
2169	Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. 2014 , 14, 45	43
2168	Experience with exercise right heart catheterization in the diagnosis of pulmonary hypertension: a retrospective study. 2014 , 9, 51	14
2167	The changing landscape of pulmonary arterial hypertension and implications for patient care. 2014 , 23, 450-7	81
2166	Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?. 2014 , 23, 458-68	9
2165	Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis. 2014 , 20, 414-20	16
2164	Progress in the diagnosis and management of pulmonary hypertension in children. 2014 , 26, 527-35	11

2163	Pulmonary arterial hypertension in patients treated with interferon. 2014 , 44, 1627-34	66
2162	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. 2014 , 9, S67-73	7
2161	Schistosomiasis-associated pulmonary hypertension. 2014 , 4, 596-611	40
2160	Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model. 2014 , 2014, 316214	16
2159	Pulmonary arterial hypertension in a patient with β -thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. 2014 , 4, 520-6	7
2158	Breaking barriers in obstructive sleep apnea. Focus on "Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation". 2014 , 306, C724-5	2
2157	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension in children. 2014 , 9, S113-20	3
2156	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Challenges in managing pulmonary hypertension in the developing countries. 2014 , 9, S127-30	7
2155	Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. 2014 , 9, 209-15	17
2154	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
2153	Pulmonary hypertension and right heart dysfunction in chronic lung disease. 2014 , 2014, 739674	50
2152	Beraprost sodium MR for the treatment of pulmonary arterial hypertension. 2014 , 2, 1315-1323	
2151	Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. 2014 , 11 Suppl 3, S178-85	29
2150	Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2882-3	15.1 3
2149	Use of interferon beta for acute respiratory distress syndrome: proceed with caution. 2014 , 2, e2	
2148	Pulmonary hypertension of sickle cell disease beyond classification constraints. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2881-2	15.1 2
2147	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. 2014 , 211, 314-33	12
2146	Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. 2014 , 174, 299-305	73

2145	Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure. 2014 , 11, 428-35	23
2144	Clinical diagnosis of pulmonary hypertension. 2014 , 130, 1820-30	79
2143	Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions. 2014 , 177, 340-7	45
2142	[Pulmonary hypertension--diagnostic and current concepts]. 2014 , 156, 49-52; quiz 53	
2141	Macitentan: a review of its use in patients with pulmonary arterial hypertension. 2014 , 74, 1495-507	7
2140	Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. 2014 , 43, 569-73	12
2139	Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies. 2014 , 43, 561-8	4
2138	Regenerative cell and tissue-based therapies for pulmonary arterial hypertension. 2014 , 30, 1350-60	21
2137	The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. 2014 , 51, 721-9	30
2136	Dual-energy CT for imaging of pulmonary hypertension: challenges and opportunities. 2014 , 34, 1769-90	60
2135	Hypoxemia in a patient with pulmonary arterial hypertension: getting to the heart of the matter. 2014 , 11, 836-40	4
2134	Biomarkers in pulmonary arterial hypertension. 2014 , 11, 477-84	11
2133	Perioperative management of the patient with pulmonary hypertension. 2014 , 18, 310-8	18
2132	Pulmonary endarterectomy: part I. Pathophysiology, clinical manifestations, and diagnostic evaluation of chronic thromboembolic pulmonary hypertension. 2014 , 18, 319-30	33
2131	Molecular imaging of the pulmonary circulation in health and disease. 2014 , 2, 415-426	8
2130	[Pulmonary hypertension: definition, diagnostic and new classification]. 2014 , 43, 935-44	2
2129	[Pulmonary arterial hypertension associated with connective tissue diseases]. 2014 , 43, 957-69	3
2128	Diagnosis of heart failure with preserved ejection fraction. 2014 , 10, 399-406	18

2127	Progress in solving the sex hormone paradox in pulmonary hypertension. 2014 , 307, L7-26	97
2126	Update on chronic thromboembolic pulmonary hypertension. 2014 , 130, 508-18	194
2125	[Pulmonary hypertension in chronic respiratory diseases]. 2014 , 43, 945-56	1
2124	The genetics of pulmonary arterial hypertension. 2014 , 115, 189-202	116
2123	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. 2014 , 15, 65	34
2122	The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. 2014 , 33, 1009-24	377
2121	Riociguat for the treatment of pulmonary hypertension. 2014 , 15, 2419-27	3
2120	[Pulmonary hypertension in liver diseases]. 2014 , 43, 970-80	7
2119	[Pulmonary hypertension in internal medicine]. 2014 , 43, 932-4	
2118	[Cor pulmonale and pulmonary hypertension. Update after the world conference in Nice]. 2014 , 39, 58-65	1
2117	Pulmonale Hypertonie im Kindes- und Jugendalter. 2014 , 162, 248-256	
2116	Attenuated right ventricular energetics evaluated using ¹¹ C-acetate PET in patients with pulmonary hypertension. 2014 , 41, 1240-50	15
2115	Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. 2014 , 190, 208-17	116
2114	Outcome of patients with severe PH due to lung disease with and without targeted therapy. 2014 , 32, 202-8	19
2113	Echocardiographic screening for pulmonary arterial hypertension in HIV-positive patients. 2014 , 42, 737-41	12
2112	Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU. 2014 , 30, 231-240	
2111	Inflammatory cytokines in pulmonary hypertension. 2014 , 15, 47	122
2110	TGF beta and IL13 in Schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups. 2014 , 14, 282	21

2109	Decreased levels of serum Angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease. 2014 , 176, 1399-401	15
2108	Current clinical management of pulmonary arterial hypertension. 2014 , 115, 131-147	48
2107	Physiologie du couplage entre le ventricule droit et la circulation pulmonaire. 2014 , 23, 402-411	1
2106	Ion channels and transporters as therapeutic targets in the pulmonary circulation. 2014 , 144, 349-68	18
2105	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. 2014 , 35, 3033-69, 3069a-3069k	1974
2104	An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. 2014 , 189, 727-40	154
2103	Pulmonary Hypertension. 2014 , 263-281	
2102	Imaging in pulmonary hypertension: Focus on the role of echocardiography. 2014 , 107, 261-71	23
2101	Pulmonary hypertension: smaller kids, smaller steps. 2014 , 2, 348-50	9
2100	Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. 2014 , 100, 1322-8	43
2099	Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. 2014 , 53, 1913-20	3
2098	Guanylate cyclase stimulators for pulmonary hypertension. 2014 ,	1
2097	Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. 2014 , 4, e005950	30
2096	Pulmonary vascular development goes awry in congenital lung abnormalities. 2014 , 102, 343-58	39
2095	Characterization of patients with borderline pulmonary arterial pressure. 2014 , 146, 1486-1493	51
2094	Pulmonary arterial hypertension treatment guidelines: new answers and even more questions. 2014 , 146, 239-241	5
2093	The untapped potential of proteomic analysis in pediatric pulmonary hypertension. 2014 , 8, 862-74	7
2092	Pulmonary arterial hypertension in patients treated with interferon. 2015 , 46, 1851-3	9

2091	Pulmonary hypertension in patients with chronic myeloproliferative disorders. 2015 , 24, 400-10	29
2090	Imaging the heart in pulmonary hypertension: an update. 2015 , 24, 653-64	26
2089	Reply. 2015 , 144, 137-138	
2088	Pulmonary hypertension trials: how can we do better?. 2015 , 9, 551-8	0
2087	Development of macitentan for the treatment of pulmonary arterial hypertension. 2015 , 1358, 68-81	4
2086	Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. 2015 , 20, 805-12	28
2085	Anesthesia for Pulmonary Hypertension. 2015 , 661-676	1
2084	Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing. 2015 , 5, 580-6	4
2083	Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. 2015 , 5, 435-65	154
2082	Gestational pulmonary arterial hypertension. 2015 , 5, 730-3	5
2081	A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. 2015 , 5, 18277	50
2080	Pulmonary arterial hypertension in patients treated with interferon. 2015 , 46, 1849-51	6
2079	Progress in the understanding and management of pulmonary arterial hypertension. 2015 , 2015, 13	3
2078	[Pulmonary hypertension in the elderly]. 2015 , 13, 8-14	
2077	Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. 2015 , 7, 695-713	96
2076	Disease-Targeted Treatment Improves Cognitive Function in Patients with Precapillary Pulmonary Hypertension. 2015 , 90, 376-83	8
2075	Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. 2015 , 10, 59-72	3
2074	Pulmonary hypertension related to congenital heart disease: A comprehensive review. 2015 , 2015, 42	

2073	New insights into the pathology of pulmonary hypertension: implication of the miR-210/ISCU1/2/Fe-S axis. 2015 , 7, 689-91	9
2072	Lungenbeteiligung bei Lebererkrankungen. 2015 , 12, 343-352	
2071	BMPR2 spruces up the endothelium in pulmonary hypertension. 2015 , 6, 703-8	4
2070	Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. 2015 , 4, 209-18	8
2069	Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients. 2015 , 34, 28-34	15
2068	Pulmonary arterial hypertension or pulmonary hypertension in patients with human immunodeficiency virus infection?. 2015 , 144, 137	
2067	Left ventricular diastolic dysfunction in pulmonary hypertension predicts functional capacity and clinical worsening: a tissue phase mapping study. 2015 , 17, 116	32
2066	Lungenbeteiligung bei Kollagenosen. 2015 , 12, 521-530	
2065	Some neonatal risk factors for adult pulmonary arterial hypertension remain unknown. 2015 , 104, 1104-8	12
2064	A 16q deletion involving FOXF1 enhancer is associated to pulmonary capillary hemangiomatosis. 2015 , 16, 94	15
2063	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. 2015 , 15, 118	11
2062	HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. 2015 , 12, 36	22
2061	Riociguat: a novel new drug for treatment of pulmonary hypertension. 2015 , 35, 502-19	21
2060	Pulmonary Hypertension an Independent Risk Factor for Death in Intensive Care Unit: Correlation of Hemodynamic Factors with Mortality. 2015 , 9, 27-33	15
2059	Calcium channel blockers for pulmonary arterial hypertension. 2015 , CD010066	6
2058	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. 2015 , 36, 1113-27	142
2057	Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: results from two institutions. 2015 , 73, 1904-13	94
2056	Pulmonary Arterial Hypertension and the Failing Ventricle: Getting It Right. 2015 , 1, 81-91	

2055	Niflumic Acid Attenuated Pulmonary Artery Tone and Vascular Structural Remodeling of Pulmonary Arterial Hypertension Induced by High Pulmonary Blood Flow In Vivo. 2015 , 66, 383-91	5
2054	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. 2015 , 94, e1800	32
2053	Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. 2015 , 57, 731-4	8
2052	Care of the patient with pulmonary arterial hypertension. 2015 , 34, 340-7	
2051	Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. 2015 , 90, 1060-4	83
2050	Pulmonary hypertension in HIV infection: a prospective echocardiographic study. 2015 , 16, 578-82	18
2049	Imaging Studies for Pulmonary Vascular Disease. 2015 , 22, 307-321	
2048	Echocardiography in pulmonary hypertension. 2015 , 30, 574-86	24
2047	DCCN on the Web. 2015 , 34, 347	
2046	Pulmonary hypertension in sickle cell disease. 2015 , 21, 432-7	7
2045	Significance of obstructive sleep apnea in the patient with pulmonary hypertension. 2015 , 21, 569-78	7
2044	. 2015 ,	
2043	12. COPD and Pulmonary Vasculature. 2015 , 232-248	
2042	Connective tissue disease-associated pulmonary arterial hypertension. 2015 , 7, 06	32
2041	The limits of oral therapy in pulmonary arterial hypertension management. 2015 , 11, 1731-41	7
2040	Association Between Hemodynamic Profile, Physical Capacity and Quality of Life in Pulmonary Hypertension. 2015 , 104, 387-93	3
2039	A framework for clinical reasoning in adult cardiology. 2015 , 6, 489-95	2
2038	Prognostication in Pulmonary Arterial Hypertension with Submaximal Exercise Testing. 2015 , 3, 15-23	2

2037	Mosaic Pattern of Lung Attenuation on Chest CT in Patients with Pulmonary Hypertension. 2015 , 3, 205-212	6
2036	Balloon Pulmonary Angioplasty: A Treatment Option for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. 2015 , 2, 4	48
2035	Comparison between the Acute Pulmonary Vascular Effects of Oxygen with Nitric Oxide and Sildenafil. 2015 , 3, 16	1
2034	Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. 2015 , 7, 175-83	5
2033	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. 2015 , 10, 99-109	19
2032	Elevated plasma CXCL12βs associated with a poorer prognosis in pulmonary arterial hypertension. 2015 , 10, e0123709	19
2031	Cardiovascular imaging: what have we learned from animal models?. 2015 , 6, 227	14
2030	Pulmonary hypertension: diagnostic and therapeutic challenges. 2015 , 11, 1221-33	26
2029	Pulmonary arterial hypertension associated with congenital heart disease. Personal perspectives. 2015 , 56 Suppl, S1-3	3
2028	Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. 2015 , 22, 263-5	13
2027	Interventions for treating pulmonary hypertension in people with sickle cell disease or thalassaemia. 2015 ,	
2026	Post splenectomy related pulmonary hypertension. 2015 , 5, 69-77	14
2025	Coronary Bypass Surgery in Patients with Pulmonary Hypertension: Assessment of Early and Long Term Results. 2015 , 21, 268-74	1
2024	Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease. 2015 , 9, 75-9	14
2023	Pulmonary rehabilitation and exercise in pulmonary arterial hypertension: An underutilized intervention. 2015 , 11, 74-9	20
2022	[Medical treatment of pulmonary hypertension: what's new?]. 2015 , 56, 573-82	
2021	Positionspapier "Schlafmedizin in der Kardiologie" 2015 , 9, 140-158	19
2020	The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension. 2015 , 13, 467-76	1

2019	Scope of problem of pulmonary arterial hypertension. 2015 , 128, 844-51		20
2018	Lung function in pulmonary hypertension. 2015 , 109, 1244-9		32
2017	Pulmonary hypertension in patients undergoing transcatheter aortic valve replacement: discussion of the current evidence. 2015 , 8, e002253		2
2016	Connexin-mediated regulation of the pulmonary vasculature. 2015 , 43, 524-9		2
2015	Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. 2015 , 211, 118-33		30
2014	Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. 2015 , 38, 419-35		21
2013	Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. 2015 , 184, 198-207		73
2012	Signs of RV overload on the athlete's ECG. 2015 , 48, 399-406		3
2011	Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2433-48	15.1	117
2010	Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2015 , 41, 489-506		8
2009	Scleroderma and pulmonary hypertension complicating two pregnancies: use of neuraxial anesthesia, general anesthesia, epoprostenol and a multidisciplinary approach for cesarean delivery. 2015 , 24, 375-82		5
2008	Pulmonary Arterial Hypertension. 2015 , 313-332		1
2007	Is endoscopic lung volume reduction able to reverse pulmonary hypertension in patients with severe emphysema?. 2015 , 89, 12-4		2
2006	Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling. 2015 , 308, H1298-305		28
2005	Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?. 2015 , 17, 56		5
2004	Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. 2015 , 192, 859-72		89
2003	Approaching atrial septal defects in pulmonary hypertension. 2015 , 13, 693-701		13
2002	. 2015 ,		

2001	Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. 2015 , 147, 495-501	46
2000	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. 2015 , 46, 1211-4	3
1999	Pulmonary tumour thrombotic microangiopathy: unclassifiable pulmonary hypertension?. 2015 , 46, 1214-7	26
1998	Inflammation in chronic thromboembolic pulmonary hypertension: accomplice or bystander in altered angiogenesis?. 2015 , 46, 303-6	8
1997	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. 2015 , 132, 2037-99	624
1996	Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension. 2015 , 107, 20-31	22
1995	Under pressure: pulmonary hypertension associated with left heart disease. 2015 , 24, 665-73	17
1994	Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. 2015 , 5, 640-8	28
1993	Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. 2015 , 24, 642-52	79
1992	Challenges in pulmonary hypertension: managing the unexpected. 2015 , 24, 674-81	7
1991	Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension. 2015 , 9, 559-69	3
1990	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. 2015 , 101, 1792-9	64
1989	Non-BMP2 mutation heritable pulmonary arterial hypertension in Southeast Asia. 2015 , 23, 481-3	
1988	Physiologie, Klassifikation, Pathologie und Pathophysiologie. 2015 , 12, 373-380	1
1987	Emergency hepatectomy for hepatic arteriovenous malformation combined with pulmonary hypertension in an infant. 2015 , 3, 534-536	1
1986	Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. 2015 , 148, 1055-1062	46
1985	Acute hemodynamic effects of adaptive servoventilation in patients with pre-capillary and post-capillary pulmonary hypertension. 2015 , 16, 137	6
1984	Cough in interstitial lung disease. 2015 , 35, 122-8	10

1983	Phase I safety study of ranolazine in pulmonary arterial hypertension. 2015 , 5, 691-700	23
1982	[Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014]. 2015 , 40, 1048-54	19
1981	The Assessment of the Right Heart Failure Syndrome. 2015 , 36, 934-42	2
1980	Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study Inoperable chronic thromboembolic pulmonary hypertension. 2015 , 34, 777.e1-777.e5	
1979	Pulmonary arterial hypertension and portal hypertension in a patient with hereditary hemorrhagic telangiectasia. 2015 , 144, 261-264	
1978	Treatment of pulmonary arterial hypertension. 2015 , 144, 566-570	
1977	Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study. 2015 , 34, 777.e1-5	
1976	Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. 2015 , 28, 108-15	62
1975	Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2015 , 97, 88-102	51
1974	Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. 2015 , 14, 13-5	7
1973	"Porto-pulmonary hypertension: a comprehensive review". 2015 , 39, 157-67	19
1972	Portopulmonary hypertension: an update. 2015 , 20, 235-42	13
1971	Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. 2015 , 82, 50-62	46
1970	Treating pulmonary hypertension in pediatrics. 2015 , 16, 711-26	13
1969	Neonatal hyperoxic lung injury favorably alters adult right ventricular remodeling response to chronic hypoxia exposure. 2015 , 308, L797-806	25
1968	Long-term data from the Swiss pulmonary hypertension registry. 2015 , 89, 127-40	54
1967	[Pulmonary arterial hypertension or pulmonary hypertension in patients with human immunodeficiency virus infection?]. 2015 , 144, 137	
1966	Pulmonary hypertension secondary to heart failure with preserved ejection fraction. 2015 , 31, 430-9	21

1965	Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension. 2015 , 185, 302-4	
1964	Clinical and morphologic features of acute, subacute and chronic cor pulmonale (pulmonary heart disease). 2015 , 115, 697-703	7
1963	An evidence-based approach to screening and diagnosis of pulmonary hypertension. 2015 , 31, 382-90	10
1962	Mitochondrial dynamics in pulmonary arterial hypertension. 2015 , 93, 229-42	86
1961	Pulmonary arterial hypertension exacerbated by ruxolitinib. 2015 , 100, e244-5	25
1960	Proteomics of pulmonary hypertension: could personalized profiles lead to personalized medicine?. 2015 , 9, 111-20	9
1959	A global perspective on the epidemiology of pulmonary hypertension. 2015 , 31, 375-81	22
1958	A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System. 2015 , 31, 367-74	12
1957	Imaging the right heart: a challenging road map. 2015 , 32 Suppl 1, S1-2	4
1956	Portopulmonary hypertension. 2015 , 212-224	
1955	Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. 2015 , 17, 151-8	32
1954	Management of Scleroderma-Associated Pulmonary Involvement. 2015 , 1, 51-67	
1953	Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. 2015 , 11, 437-49	20
1952	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. 2015 , 185, 356-71	116
1951	Pulmonary arterial hypertension and portal hypertension in a patient with hereditary hemorrhagic telangiectasia. 2015 , 144, 261-4	3
1950	Clinical evaluation and management of pulmonary hypertension in the adult with congenital heart disease. 2015 , 131, 200-10	28
1949	The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. 2015 , 308, L229-52	119
1948	Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. 2015 , 17, 320-8	15

1947	Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension. 2015 , 13, 193-207	7
1946	Normal resting pulmonary artery wedge pressure: a diagnostic trap for heart failure with preserved ejection fraction. 2015 , 17, 132-4	6
1945	FDG PET imaging for identifying pulmonary hypertension and right heart failure. 2015 , 17, 555	14
1944	Aneurysms of the pulmonary artery. 2015 , 131, 310-6	106
1943	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. 2015 , 47, e105-10	93
1942	O-linked N-acetylglucosamine transferase directs cell proliferation in idiopathic pulmonary arterial hypertension. 2015 , 131, 1260-8	35
1941	Connective tissue disease-associated pulmonary arterial hypertension. 2015 , 41, 295-313	13
1940	Influence of pulmonary hypertension on survival in advanced lung disease. 2015 , 193, 213-21	10
1939	Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. 2015 , 12, 269-73	8
1938	Serum Bcl-2 values in children with pulmonary hypertension. 2015 , 36, 579-83	3
1937	Multimodality imaging in pulmonary hypertension. 2015 , 31, 440-59	16
1936	Pulmonary hypertension in antiphospholipid syndrome. 2015 , 17, 478	21
1935	Pregnancy and pulmonary arterial hypertension: A clinical conundrum. 2015 , 5, 157-64	18
1934	Prevalence of variants in methylenetetrahydrofolate reductase and the severity of pulmonary vascular disease. 2015 , 36, 524-30	2
1933	A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. 2015 , 88, 579-83	45
1932	Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes. 2015 , 5, 327-34	18
1931	Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. 2015 , 5, 220-7	53
1930	Pulmonary hypertension and pregnancy: the experience of a tertiary institution over 15 years. 2015 , 18, 153-60	19

1929	Derivation of a screening tool to identify patients with right ventricular dysfunction or tricuspid regurgitation after negative computerized tomographic pulmonary angiography of the chest. 2015 , 5, 171-83	8
1928	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. 2015 , 5, 356-63	32
1927	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. 2015 , 5, 305-12	13
1926	Advances in the management of chronic thromboembolic pulmonary hypertension. 2015 , 17, 582	5
1925	Trends in Hospitalization for Pediatric Pulmonary Hypertension. 2015 , 136, 241-50	32
1924	Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. 2015 , 56, 45-51	14
1923	Diseases of the thoracic aorta and pulmonary arteries. 2015 , 661-705	
1922	HIPERTENSIÓN PULMONAR: IMPORTANCIA DE UN DIAGNÓSTICO PRECOZ Y TRATAMIENTO ESPECÍFICO. 2015 , 26, 344-356	
1921	Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. 2015 , 192, 965-73	58
1920	Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. 2015 , 5, 211-6	5
1919	Hypoxic Pulmonary Hypertension. 2015 , 4169-4209	1
1918	Chronic thromboembolic pulmonary hypertension: a distinct disease entity. 2015 , 24, 246-52	62
1917	Epidemiology and Disease Classification of Pulmonary Hypertension. 2015 , 21-35	1
1916	Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. 2015 , 8, 1032-43	70
1915	Outcomes of Eb blocker use in pulmonary arterial hypertension: a propensity-matched analysis. 2015 , 46, 750-60	38
1914	Investigation of Lung Involvement in Connective Tissue Disorders. 2015 , 90, 2-24	19
1913	Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. 2015 , 308, L1002-13	44
1912	Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. 2015 , 5, 364-9	23

1911	Peripheral pulmonary artery stenosis as a cause of pulmonary hypertension in adults. 2015 , 5, 204-10	19
1910	Pulmonary hypertension and hepatic cirrhosis. 2015 , 215, 324-330	0
1909	Biomarkers and prognostic indicators in pulmonary arterial hypertension. 2015 , 17, 556	4
1908	Mechanism by which nuclear factor-kappa beta (NF- κ B) regulates ovine fetal pulmonary vascular smooth muscle cell proliferation. 2015 , 4, 11-8	5
1907	Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009. 2015 , 5, 339-48	28
1906	Riociguat: Something new in pulmonary hypertension therapeutics?. 2015 , 6, 3-6	4
1905	An Update on Pulmonary Arterial Hypertension. 2015 , 11, 551-559	5
1904	[Antisynthetase syndrome with pulmonary hypertension: 4 original observations]. 2015 , 36, 794-9	3
1903	Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. 2015 , 170, 96-103, 103.e1-14	14
1902	Pulmonary hypertension in heart failure: measurable, but how meaningful?. 2015 , 34, 310-1	2
1901	Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. 2015 , 34, 312-8	11
1900	What's new in the treatment of portopulmonary hypertension?. 2015 , 9, 983-92	20
1899	New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. 2015 , 147, 529-537	109
1898	Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis. 2015 , 51, e19-21	2
1897	Clinical and Molecular Study of 4 Cases of Pulmonary Hypertension Associated With Sarcoidosis. 2015 , 51, e19-e21	
1896	Pulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the Literature. 2015 , 3, 25	6
1895	Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. 2015 , 31, 416-29	25
1894	Pulmonary vascular remodeling before and after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a cardiac magnetic resonance study. 2015 , 31, 613-9	7

1893	Metabolic Dysfunction in Pulmonary Arterial Hypertension. 2015 , 17, 20	33
1892	Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. 2015 , 189, 134-40	52
1891	Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension?. 2015 , 147, 943-950	30
1890	Capillary pCO ₂ helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction. 2015 , 16, 34	8
1889	Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension. 2015 , 10, 1	50
1888	Journey of a patient with chronic thromboembolic pulmonary hypertension. 2015 , 20, 20	1
1887	Pulmonary hypertension and hepatic cirrhosis. 2015 , 215, 324-30	1
1886	Portopulmonary Hypertension. 2015 , 177-186	
1885	Pulmonary Hypertension: A Nomogram Based on CT Pulmonary Angiographic Data for Prediction in Patients without Pulmonary Embolism. 2015 , 277, 236-46	16
1884	Perioperative Care of Children with Eisenmenger Syndrome Undergoing Non-cardiac Surgery. 2015 , 36, 1120-8	4
1883	Perioperative management of patients with pulmonary hypertension for non-cardiac surgery. 2015 , 17, 15	10
1882	Impact of Severe Tricuspid Regurgitation on Accuracy of Echocardiographic Pulmonary Artery Systolic Pressure Estimation. 2015 , 32, 1483-90	11
1881	Loss of microRNA-17~92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. 2015 , 191, 678-92	56
1880	Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. 2015 , 193, 567-70	15
1879	Management of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1976-97	15.1 229
1878	Patient Study 32. 2015 , 224-230	
1877	Pulmonary Hypertension in Pregnancy and Anesthetic Implications. 2015 , 5, 82-90	
1876	Are transcutaneous oxygen and carbon dioxide determinations of value in pulmonary arterial hypertension?. 2015 , 22, 249-56	3

1875	Serious adverse events during a 6-min walk test in patients with pulmonary hypertension. 2015 , 45, 1179-82	11
1874	Transesophageal echocardiography in thoracic anesthesia: pulmonary hypertension and right ventricular function. 2015 , 28, 38-44	18
1873	Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. 2015 , 184, 717-723	56
1872	Management of pulmonary hypertension and right heart failure in the intensive care unit. 2015 , 17, 32	6
1871	Right ventricular adaptation and failure in pulmonary arterial hypertension. 2015 , 31, 391-406	98
1870	Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. 2015 , 275, 71-9	88
1869	Building the case for novel clinical trials in pulmonary arterial hypertension. 2015 , 8, 114-23	14
1868	The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced emphysema. 2015 , 193, 223-9	6
1867	Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world. 2015 , 192, 777-9	5
1866	MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH. 2015 , 193, 901-10	10
1865	Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. 2015 , 35, 8-16	91
1864	Intraoperative mechanical ventilation strategies to prevent postoperative pulmonary complications in patients with pulmonary and extrapulmonary comorbidities. 2015 , 29, 341-55	5
1863	B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. 2015 , 174, 1267-75	22
1862	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification. 2015 , 8, e002358	63
1861	The pathophysiology of pulmonary hypertension in left heart disease. 2015 , 309, L924-41	40
1860	Supraventricular Arrhythmias in Patients With Pulmonary Arterial Hypertension. 2015 , 116, 1883-9	22
1859	Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. 2015 , 26, 155-62	9
1858	Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions. 2015 , 13, 1377-92	3

1857	Novel investigational therapies for treating pulmonary arterial hypertension. 2015 , 24, 1571-96	11
1856	Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats. 2015 , 35, 1467-81	25
1855	Current Treatment Strategies, Guidelines and New Therapies. 2015 , 81-145	
1854	The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension. 2015 , 192, 998-1008	51
1853	Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. 2015 , 31, 1793-807	12
1852	New pharmacotherapy options for pulmonary arterial hypertension. 2015 , 16, 2113-31	17
1851	Resolvin E1 normalizes contractility, Ca ²⁺ sensitivity and smooth muscle cell migration rate in TNF- α and IL-6-pretreated human pulmonary arteries. 2015 , 309, L776-88	27
1850	Pulmonary Hypertension. 2015 , 179-197	
1849	High shear stress-induced pulmonary hypertension alleviated by endothelial progenitor cells independent of autophagy. 2015 , 11, 171-6	8
1848	[RV meets LV - "State-of-the-Art"]. 2015 , 140 Suppl 1, S18-9	0
1847	The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. 2015 , 34, 1264-77	374
1846	Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension. 2015 , 7, 308ra159	95
1845	[Therapy of Pulmonary Arterial Hypertension]. 2015 , 69, 483-93; quiz 494-5	
1844	The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. 2015 , 46, 879-82	47
1843	Interventional Cardiology in the Elderly. 2015 ,	
1842	The Pathophysiology, Presentation and Diagnostic Investigation of Pulmonary Hypertension. 2015 , 1-35	1
1841	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	1672
1840	Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. 2015 , 71, 1165-73	2

1839	4,4'-Methylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats. 2015 , 147, 235-45	4
1838	Potassium channels in pulmonary arterial hypertension. 2015 , 46, 1167-77	49
1837	Pulmonary Hypertension in Congenital Heart Disease: Beyond Eisenmenger Syndrome. 2015 , 33, 599-609, ix	11
1836	Update in Pulmonary Vascular Diseases 2014. 2015 , 192, 544-50	5
1835	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. 2015 , 192, 1102-10	97
1834	Pulmonary Hypertension and Right Ventricular Failure in Emergency Medicine. 2015 , 66, 619-28	41
1833	ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine. 2015 , 12, 1387-97	2
1832	Management of Heart Failure. 2015 ,	1
1831	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. 2015 , 46, 1721-31	55
1830	Translational In Vivo Models for Cardiovascular Diseases. 2016 , 232, 223-34	1
1829	Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. 2015 , 73, 71-7	10
1828	Riociguat for the treatment of pulmonary hypertension. 2015 , 9, 679-95	10
1827	Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. 2015 , 119, 1164-72	66
1826	Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature. 2015 , 53, 175-83	8
1825	Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. 2015 , 70, 56-70	64
1824	Current treatment approaches to pulmonary arterial hypertension. 2015 , 31, 460-77	24
1823	[Echocardiography and pulmonary hypertension: experience of the competence centre in Tours, France]. 2015 , 32, 301-3	
1822	Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. 2015 , 104, 197-207	35

1821	Pulmonary hypertension management in neonates. 2015 , 24, 12-6	6
1820	Early detection of pulmonary arterial hypertension. 2015 , 12, 143-55	84
1819	Diagnosis and treatment of pulmonary hypertension. 2015 , 101, 311-9	9
1818	Evidence of secretory clusterin elevated levels in induced pulmonary arterial hypertension. 2015 , 213, 301-2	
1817	TRPV4: physiological role and therapeutic potential in respiratory diseases. 2015 , 388, 421-36	42
1816	[Treatment of pulmonary arterial hypertension]. 2015 , 144, 566-70	3
1815	MicroRNAs in pulmonary arterial hypertension. 2015 , 52, 139-51	80
1814	The role of nuclear imaging in pulmonary hypertension. 2015 , 22, 141-57	12
1813	Symptom Prevalence, Symptom Severity, and Health-Related Quality of Life Among Young, Middle, and Older Adults With Pulmonary Arterial Hypertension. 2016 , 33, 214-21	16
1812	Portopulmonary Hypertension. 2016 ,	
1811	Portopulmonary hypertension in liver transplant candidates. 2016 , 22, 2024-9	16
1810	Physiopathology of Pulmonary Hypertension: from Bio-Molecular Mechanism to Target Treatment. 2016 , 04,	2
1809	Beneficios del ejercicio en pacientes con hipertensi3n pulmonar: Revisi3n bibliogr3fica. 2016 , 35, 56-64	
1808	Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat. 2016 , 12, 957-64	5
1807	The Cardiomyopathy of Sickle Cell Disease. 2016 ,	
1806	Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?. 2016 , 2,	2
1805	Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension. 2016 , 7, 54263-54273	19
1804	Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. 2016 , 10, 1675-82	9

1803	Risk factors for pulmonary hypertension in patients receiving maintenance peritoneal dialysis. 2016 , 49,	7
1802	[Survival of patients with pulmonary arterial hypertension after the advent of specific pulmonary vasodilator therapies]. 2016 , 144, 829-36	1
1801	Remodelado auricular derecho y niveles plasmáticos de Galectina-3 se relacionan con la capacidad funcional de pacientes con hipertensión arterial pulmonar. 2016 , 35, 19-24	
1800	Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension. 2016 , 57, 234-40	17
1799	D-shaped Left Ventricle in a Smoker with Fatal Pulmonary Langerhans Cell Histiocytosis. 2016 , 17, 164-167	
1798	Elevated galectin-3 level predicts pulmonary artery hypertension. 2016 , 3, 89-97	1
1797	Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2016 , 8, S562-5	2
1796	Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension. 2016 , 26, 545-552	3
1795	Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease). 2016 , 663-674	
1794	The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. 2016 , 2016, 6279250	3
1793	Reactive Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-Occlusive Disease in a Patient with Repaired Scimitar Syndrome. 2016 , 2016, 9384126	4
1792	The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. 2016 , 3, 75-84	88
1791	Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. 2017 , 9, 1-9	19
1790	Pulmonary Hypertension and Indicators of Right Ventricular Function. 2016 , 3, 23	7
1789	Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant. 2016 , 4, 33	46
1788	DNA Damage and Pulmonary Hypertension. 2016 , 17,	63
1787	Cardiac manifestations of idiopathic pulmonary fibrosis. 2016 , 5, 70-5	22
1786	Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials. 2016 , 11, e0168101	6

1785	Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension. 2016 , 7, 142	18
1784	Calcium-Sensing Receptor Regulates Cytosolic [Ca] and Plays a Major Role in the Development of Pulmonary Hypertension. 2016 , 7, 517	39
1783	What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. 2016 , 116, 417-31	42
1782	Update on pharmacotherapy for pulmonary hypertension. 2016 , 205, 271-6	9
1781	Ex-Vivo Lung Perfusion: From Bench to Bedside. 2016 ,	
1780	Ventriculoperitoneal Shunt Insertion Under Monitored Anesthesia Care in a Patient With Severe Pulmonary Hypertension. 2016 , 7, 27-9	3
1779	Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. 2016 , 18, 39	66
1778	Abstracts from the XV CIPP Meeting. 2016 , 51 Suppl 43, S8-S89	
1777	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. 2016 , 95, e2761	43
1776	Emergency Management of Pediatric Pulmonary Hypertension. 2016 , 32, 49-55	1
1775	Association of Intraocular Pressure Changes With Right Ventricular Diameter and Brain Natriuretic Peptide in a Case of Pulmonary Arterial Hypertension. 2016 , 25, e295-8	4
1774	Heart Rate Variability and Arrhythmic Burden in Pulmonary Hypertension. 2016 , 934, 9-22	11
1773	Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects. 2016 , 56, 669-74	7
1772	Cardiac MRI right ventricle / left ventricle (RV/LV) volume ratio improves detection of RV enlargement. 2016 , 43, 1379-85	12
1771	Annulus Tension on the Tricuspid Valve: An In-Vitro Study. 2016 , 7, 270-9	14
1770	ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum. 2016 , 13, 1160-9	1
1769	Who should be referred to a specialist pulmonary -hypertension centre - a referrer's guide. 2016 , 16, 135-41	4
1768	Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells. 2016 , 24, 1342-50	54

1767	Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study. 2016 , 33, 546-54		20
1766	Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 2016 , 102 Suppl 2, ii14-22		50
1765	Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol. 2016 , 5, 89		7
1764	International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. 2016 , 100, 1440-52		188
1763	Quality of life among pulmonary hypertension patients in Finland. 2016 , 3, 26405		9
1762	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2525-2536	15.1	111
1761	"Treat-and-Repair" Strategy for Atrial Septal Defect and Associated Pulmonary Arterial Hypertension. 2016 , 80, 69-71		8
1760	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. 2016 , 48, 1668-1681		49
1759	Pulmonary Langerhans Cell Histiocytosis-associated Pulmonary Hypertension Showing a Drastic Improvement Following Smoking Cessation. 2016 , 55, 491-5		6
1758	Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension. 2016 , 102, 910-8		20
1757	Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat. 2016 , 16, 82		4
1756	Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 2016 , 102 Suppl 2, ii57-66		38
1755	[Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications]. 2016 , 210, 65-78		
1754	Pulmonary Hypertension. 2016 , 17, S140-5		14
1753	CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension. 2016 , 71, 830-7		22
1752	The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study. 2016 , 6, 524-531		6
1751	Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 2016 , 102 Suppl 2, ii42-8		43
1750	Treatment update: pulmonary arterial hypertension. 2016 , 11, 536-542		1

1749	Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. 2016 , 12, 195-198	7
1748	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. 2016 , 62, 505-12	8
1747	Biochemistry of Oxidative Stress. 2016 ,	3
1746	Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 2016 , 102 Suppl 2, ii86-100	67
1745	Complex inheritance in Pulmonary Arterial Hypertension patients with several mutations. 2016 , 6, 33570	12
1744	Pulmonary arterial hypertension in schistosomiasis. 2016 , 22, 408-14	15
1743	Interferon-induced pulmonary hypertension: an update. 2016 , 22, 415-20	23
1742	Pathobiological role of inflammation in pulmonary hypertension. 2016 , 148, 239-243	
1741	New guidelines for managing pulmonary hypertension: what the pediatrician needs to know. 2016 , 28, 597-606	7
1740	Pulmonary hypertension. 2016 , 310-320	
1739	Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. 2016 , 213-226	
1738	Iperensione polmonare post-embolica ed endoarteriectomia delle arterie polmonari. 2016 , 20, 1-13	
1737	Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT [®]) questionnaire: a new patient-reported outcome instrument for PAH. 2016 , 17, 72	31
1736	Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in pulmonary arterial hypertension. 2016 , 6, 576-585	18
1735	Mutational and clinical analysis of the ENG gene in patients with pulmonary arterial hypertension. 2016 , 17, 72	18
1734	In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. 2016 , 6, 551-556	5
1733	BK channels in rat and human pulmonary smooth muscle cells are BK _H functional complexes lacking the oxygen-sensitive stress axis regulated exon insert. 2016 , 6, 563-575	4
1732	Pulmonary Vascular Mechanics in Pulmonary Hypertension. 2016 , 143-160	

1731	Pulmonary veno-occlusive disease. 2016 , 47, 1518-34	134
1730	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. 2016 , 35, 647-56	6
1729	The Prognostic Utility of a Simplified Biventricular Echocardiographic Index of Cardiac Remodeling in Patients with Pulmonary Hypertension. 2016 , 29, 554-60	10
1728	Semi-automated Quantification of Lung Density on Chest CT Used as a Predictive Biomarker of Pulmonary Venous Hypertension. 2016 , 23, 935-9	1
1727	A Diagnosis at Hand: Pulmonary Arterial Hypertension. 2016 , 129, 812-5	
1726	Pulmonary arterial hypertension in heroin users. 2016 , 35, 932-4	3
1725	Pulmonary hypertension: prevalence and risk factors. 2016 , 11, 87-89	9
1724	[Pulmonary hypertension in scleroderma]. 2016 , 146, 21-3	1
1723	Multidetector computed tomography shows reverse cardiac remodeling after double lung transplantation for pulmonary hypertension. 2016 , 58, 277-82	3
1722	Study of sleep related respiratory disorders in patients with idiopathic pulmonary arterial hypertension. 2016 , 65, 233-237	
1721	Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies. 2016 , 165, 50-62	28
1720	The Diagnostic Challenge of Group 2 Pulmonary Hypertension. 2016 , 59, 22-9	12
1719	Echocardiographic findings associated with mortality or transplant in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. 2016 , 24, 374-389	7
1718	Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. 2016 , 149, 362-371	20
1717	Giant retroperitoneal cystic lymphangioma in a patient with Eisenmenger syndrome. 2016 , 203, 635-7	
1716	Right sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities. 2016 , 43, 71-80	2
1715	Update in pulmonary arterial hypertension. 2016 , 216, 436-444	4
1714	Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications. 2016 , 10, 979-90	18

1713	Management of a child with pulmonary arterial hypertension presenting with systemic hypertension. 2016 , 26, 378-81		1
1712	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. 2016 , 10, 755-66		4
1711	Prognostic value of right ventricular free wall strain in pulmonary hypertension patients with pseudo-normalized tricuspid annular plane systolic excursion values. 2016 , 32, 905-12		33
1710	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. 2016 , 150, 27-34		34
1709	Pulmonary complications of type 1 neurofibromatosis. 2016 , 33, 460-73		10
1708	Pulmonary hypertension. 2016 , 25, 4-11		27
1707	Using Registries to Understand Clinical Practice: A Lesson for Rare Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1324-6	15.1	2
1706	An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. 2016 , 193, 792-800		20
1705	Cardiac CT Imaging. 2016 ,		4
1704	Mixed connective tissue disease. 2016 , 30, 95-111		60
1703	Microarray analysis in pulmonary hypertension. 2016 , 48, 229-41		37
1702	Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary Hypertension. 2016 , 37, 756-64		11
1701	Pulmonary hypertension associated with lung diseases and hypoxemia. 2016 , 21, 299-308		6
1700	Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension. 2016 , 150, 367-73		5
1699	Pulmonary arterial hypertension and associated conditions. 2016 , 62, 379-402		5
1698	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. 2016 , 4, 129-37		202
1697	The heart and pulmonary arterial hypertension in systemic sclerosis. 2016 , 71, 1-18		8
1696	Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come. 2016 , 194, 483-5		2

1695	Current Approach to the Diagnosis and Management of Portopulmonary Hypertension. 2016 , 18, 29	7
1694	Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir. 2016 , 149, e69-73	38
1693	Pulmonary hypertension in scleroderma. 2016 , 146, 21-23	
1692	Extra-cardiac manifestations of adult congenital heart disease. 2016 , 26, 627-36	13
1691	MR phase-contrast imaging in pulmonary hypertension. 2016 , 89, 20150995	28
1690	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. 2016 , 133, 1747-60	61
1689	Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?. 2016 , 18, 42	13
1688	[Drug-induced Pulmonary Hypertension - a Current Review]. 2016 , 70, 320-7	
1687	[Management and Outcome of Surgery in Patients with Severe Pulmonary Hypertension--A Single-Center Experience]. 2016 , 70, 117-22	2
1686	Hypertension artifielle pulmonaire associ� aux connectivites. 2016 , 37, A22-A26	
1685	Pulmonary Arterial Hypertension and Neonatal Arterial Switch Surgery for Correction of Transposition of the Great Arteries. 2016 , 69, 836-41	
1684	The emerging role of microRNAs in hypoxia-induced pulmonary hypertension. 2016 , 20, 1059-67	13
1683	[Pulmonary (Arterial) Hypertension]. 2016 , 70, 630-637	3
1682	Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. 2016 , 133, 2413-22	111
1681	The Pulmonary Hypertension Consult: Clinical and Coding Considerations. 2016 , 150, 705-13	6
1680	A Simple Derived Prediction Score for the Identification of an Elevated Pulmonary Artery Wedge Pressure Using Precatheterization Clinical Data in Patients Referred to a Pulmonary Hypertension Center. 2016 , 149, 1261-8	9
1679	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. 2016 , 127, 820-8	84
1678	Genetic analyses in a cohort of children with pulmonary hypertension. 2016 , 48, 1118-1126	54

1677	The importance of patient selection for lung volume reduction. 2016 , 5, 159-167	
1676	Differential regulation of autophagy and mitophagy in pulmonary diseases. 2016 , 311, L433-52	70
1675	Diastolic pulmonary gradient predicts outcomes in group 1 pulmonary hypertension (analysis of the NIH primary pulmonary hypertension registry). 2016 , 119, 81-86	9
1674	Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension. 2016 , 6, 313-21	33
1673	Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. 2016 , 16, 134	25
1672	Care of the Surgical ICU Patient with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. 2016 , 137-148	
1671	Magnetic Resonance Characterization of Cardiac Adaptation and Myocardial Fibrosis in Pulmonary Hypertension Secondary to Systemic-To-Pulmonary Shunt. 2016 , 9,	4
1670	Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy. 2016 , 91, 359-66	22
1669	Executive Summary of the American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. 2016 , 194, 898-906	20
1668	Multidetector computed tomography shows reverse cardiac remodeling after double lung transplantation for pulmonary hypertension. 2016 , 58, 277-282	0
1667	Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. 2016 , 14, 110	8
1666	Left Ventricular Function in Patients with Pulmonary Arterial Hypertension: The Role of Two-Dimensional Speckle Tracking Strain. 2016 , 33, 1326-34	9
1665	The emerging role of epigenetics in pulmonary hypertension. 2016 , 48, 903-17	23
1664	[Pulmonary hypertension : What is new in therapy?]. 2016 , 65, 635-52	1
1663	Association between levels of anti-angiogenic isoform of vascular endothelial growth factor A and pulmonary hypertension. 2016 , 222, 416-420	19
1662	Optical coherence tomography for hypertensive pulmonary vasculature. 2016 , 222, 494-498	6
1661	Guanylate cyclase stimulators for pulmonary hypertension. 2016 , CD011205	8
1660	Cardiopulmonary Exercise Testing as a Tool for Diagnosing Pulmonary Hypertension in Patients with Dilated Cardiomyopathy. 2016 , 21, 263-71	4

1659	Association of Right Atrial Mechanics with Hemodynamics and Physical Capacity in Patients with Idiopathic Pulmonary Arterial Hypertension: Insight from a Single-Center Cohort in Northern Sweden. 2016 , 33, 46-56	18
1658	The Role of Echocardiography in the Evaluation of Pulmonary Arterial Hypertension. 2016 , 33, 105-16	12
1657	Pulmonary Hypertension and Congenital Heart Disease. 2016 , 34, 391-400	23
1656	Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1. 2016 , 134, 1105-1121	73
1655	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. 2016 , 223, 821-826	18
1654	An algorithmic approach to CT of pulmonary arterial disorders. 2016 , 40, 1226-1236	2
1653	Imaging of Pulmonary Hypertension. 2016 , 54, 1133-1149	10
1652	Pulmonary arterial hypertension associated with human immunodeficiency virus infection: study of 4 cases. 2016 , 146, 350-353	
1651	[Pulmonary hypertension: definition, classification and treatments]. 2016 , 210, 53-64	6
1650	Acoustic diagnosis of pulmonary hypertension: automated speech- recognition-inspired classification algorithm outperforms physicians. 2016 , 6, 33182	7
1649	Treat and Repair Strategy in Patients With Atrial Septal Defect and Significant Pulmonary Arterial Hypertension. 2016 , 80, 227-34	25
1648	Essential Echocardiography. 2016 ,	
1647	Pulmonary arterial hypertension in congenital heart disease: Current perspectives and future challenges. 2016 ,	23
1646	The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. 2016 , 35, 1170-1184	379
1645	[Pulmonary complications of sickle cell disease in children]. 2016 , 23, 1094-1106	4
1644	Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go. 2016 , 18, 1129-31	7
1643	Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture. 2016 , 130, 1559-69	7
1642	Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction. 2016 , 6, 15-29	44

1641	Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. 2016 , 6, 191-5		15
1640	Pregnancy as a possible trigger for heritable pulmonary arterial hypertension. 2016 , 6, 381-3		4
1639	An international physician survey of pulmonary arterial hypertension management. 2016 , 6, 338-46		9
1638	Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease. 2016 , 6, 483-497		16
1637	Managing the Patient with Pulmonary Hypertension: Specialty Care Centers, Coordinated Care, and Patient Support. 2016 , 34, 489-500		10
1636	Clinical classification in pediatric pulmonary arterial hypertension associated with congenital heart disease. 2016 , 6, 302-12		18
1635	Pulmonary Hypertension Overlap Syndromes: A Real Entity?. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 379-81	15.1	3
1634	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 368-78	15.1	148
1633	Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. 2016 , 18, 1119-28		103
1632	Thyroid disease in pulmonary hypertension: Strange bedfellows?. 2016 , 35, 1414-1415		
1631	Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. 2016 , 13 Suppl 3, S201-6		62
1630	Mixed connective tissue disease-enigma variations?. 2017 , 56, 326-333		11
1629	Right atrial contractile dynamics are impaired in patients with postcapillary pulmonary hypertension. 2016 , 12, 792-798		5
1628	Pulmonary Hypertension in Children. 2016 , 34, 451-72		28
1627	Classification of Pulmonary Hypertension. 2016 , 34, 359-61		7
1626	Epidemiology of Pulmonary Hypertension in Left Heart Disease. 2016 , 59, 3-10		15
1625	The causes, treatment, and outcome of pulmonary hypertension in Africa: Insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) Registry. 2016 , 221, 205-11		30
1624	Suppression of the expression of hypoxia-inducible factor-1 β by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats. 2016 , 38, 1786-1794		16

1623	Current Expectations for Cardiac Transplantation in Patients With Congenital Heart Disease. 2016 , 7, 685-695	7
1622	MURC deficiency in smooth muscle attenuates pulmonary hypertension. 2016 , 7, 12417	15
1621	How does pulmonary endarterectomy cure CTEPH: A clue to cure PAH?. 2016 , 311, L766-L769	4
1620	[Pulmonary hypertension in grown-ups with congenital heart disease: Recommendations of the Cologne Consensus Conference 2016]. 2016 , 141, S70-S79	6
1619	Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension. 2016 , 91, 132-40	7
1618	Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network endorsed by ISHLT and ESCP. 2016 , 100 Suppl 2, ii1-13	38
1617	BMPII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. 2016 , 468, 1969-1983	12
1616	Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. 2016 , 9,	111
1615	Riociguat for the treatment of pulmonary hypertension: a safety evaluation. 2016 , 15, 1671-1677	4
1614	Sarcoidosis-associated Pulmonary Hypertension. 2016 , 36, 63-66	
1613	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. 2016 , 91, 307-15	15
1612	Intraoperative Monitoring of Pulmonary Artery Physiology With Transesophageal Echocardiography in a Patient With an Extensive Pulmonary Aneurysm Undergoing Partial Nephrectomy. 2016 , 7, 108-11	
1611	Management of pulmonary hypertension in pregnancy. 144-159	
1610	Riociguat for pulmonary hypertension. 2016 , 29, 60-2	
1609	Pulmonary Arterial Hypertension: A Focus on Infused Prostacyclins. 2016 , 39, 315-26	2
1608	Thoracic [18F]fluorodeoxyglucose uptake measured by positron emission tomography/computed tomography in pulmonary hypertension. 2016 , 95, e3976	7
1607	Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. 2016 , 68, 740-8	18
1606	The prognostic impact of thyroid function in pulmonary hypertension. 2016 , 35, 1427-1434	14

1605	Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. 2016 , 32, 1121-30	16
1604	Global research trends in the medical therapy of pulmonary arterial hypertension 2000-2014. 2016 , 39, 21-7	2
1603	Cardiovascular complications and risk of death in sickle-cell disease. 2016 , 387, 2565-74	82
1602	Respiratory Complication in Liver Disease. 2016 , 32, 357-69	9
1601	Dual-energy CT to estimate clinical severity of chronic thromboembolic pulmonary hypertension: Comparison with invasive right heart catheterization. 2016 , 85, 1574-80	46
1600	New Developments in Mast Cell Biology: Clinical Implications. 2016 , 150, 680-93	27
1599	Update on pulmonary arterial hypertension. 2016 , 216, 436-444	
1598	The Future of Vascular Biology and Medicine. 2016 , 133, 2603-9	15
1597	An epidemiological study of paediatric pulmonary hypertension in Turkey. 2016 , 26, 693-7	3
1596	Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective. 2016 , 140, 230-40	43
1595	Women's Health and Lung Development and Disease. 2016 , 43, 307-23	5
1594	Pressure-Flow During Exercise Catheterization Predicts Survival in Pulmonary Hypertension. 2016 , 150, 57-67	31
1593	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. 2016 , 34, 2333-40	485
1592	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. 2016 , 216, 85-91	20
1591	Hipertensi3 arterial pulmonar y cirug3 de switch arterial neonatal para la correcci3 de la transposici3 de grandes arterias. 2016 , 69, 836-841	1
1590	Connective tissue disease-related pulmonary arterial hypertension. 2016 , 30, 22-38	26
1589	Pulmonary Veno-occlusive Disease and Pulmonary Hypertension in Dogs: Striking Similarities to the Human Condition. 2016 , 53, 707-10	2
1588	Salusin-3 contributes to vascular inflammation associated with pulmonary arterial hypertension in rats. 2016 , 152, 1177-87	19

1587	Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti. 2016 , 58, 394-396	7
1586	Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension. 2016 , 20, 463-8	4
1585	Review of the Association between Splenectomy and Chronic Thromboembolic Pulmonary Hypertension. 2016 , 13, 945-54	24
1584	Sleep-Disordered Breathing in Patients with Pulmonary Valve Incompetence Complicating Congenital Heart Disease. 2016 , 11, 678-682	6
1583	Echocardiographic Diagnosis of Acute Pulmonary Embolism in Patients with McConnell's Sign. 2016 , 33, 696-702	22
1582	Comprehensive Functional Assessment of Right-Sided Heart Using Speckle Tracking Strain for Patients with Pulmonary Hypertension. 2016 , 33, 1001-8	24
1581	Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing. 2016 , 168, 22-39	11
1580	A High-Throughput Screening Platform Targeting PDLIM5 for Pulmonary Hypertension. 2016 , 21, 333-41	13
1579	Hemodynamic Thresholds for Precapillary Pulmonary Hypertension. 2016 , 149, 1061-73	23
1578	Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension. 2016 , 102, 230-7	16
1577	Mast cells and their activation in lung disease. 2016 , 174, 60-76	41
1576	Portopulmonary Hypertension and Hepatopulmonary Syndrome: Is Transplant Always the Answer?. 2016 , 15, 8-16	
1575	Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic-pathophysiologic classification. 2016 , 35, 610-8	16
1574	Chronic Pulmonary Complications of Sickle Cell Disease. 2016 , 149, 1313-24	29
1573	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. 2016 , 193, 1410-20	60
1572	Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors. 2016 , 43, 323-9	14
1571	Classification and diagnosis of pulmonary hypertension. 2016 , 21, 229-37	3
1570	IFN-lambda therapy: current status and future perspectives. 2016 , 21, 167-171	18

1569	Essential echocardiographic evaluation in patients with suspected pulmonary hypertension: an overview for the practicing physician. 2016 , 128, 208-22	4
1568	BMP signaling in vascular biology and dysfunction. 2016 , 27, 65-79	96
1567	An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role. 2016 , 29, 67-76	9
1566	Pharmacodynamic considerations in the treatment of pulmonary hypertension in infants: challenges and future perspectives. 2016 , 12, 1-19	6
1565	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. 2016 , 15, 250-7	29
1564	Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications: What Is Reasonable?. 2016 , 67, 319-21	1
1563	BMP2R mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease. 2016 , 211, 132-6	22
1562	Anesthesia for pregnant women with pulmonary hypertension. 2016 , 29, 273-81	19
1561	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. 2016 , 13, 842-9	22
1560	New perspectives on management of idiopathic pulmonary fibrosis. 2016 , 7, 108-20	24
1559	Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. 2016 , 4, 281-90	17
1558	Pulmonary hypertension as a risk factor of mortality after lung transplantation. 2016 , 30, 357-64	19
1557	Acute Pain and Analgesic Requirements After Pulmonary Endarterectomy With Deep Hypothermic Circulatory Arrest. 2016 , 30, 993-6	3
1556	Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. 2016 , 68, 191-200	28
1555	Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. 2016 , 26, 3771-3780	71
1554	Oxygen uptake is more efficient in idiopathic pulmonary arterial hypertension than in chronic thromboembolic pulmonary hypertension. 2016 , 21, 149-56	10
1553	New Diagnostic and Therapeutic Strategies for Pulmonary Hypertension Associated with Left Heart Disease. 2016 , 18, 18	
1552	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. 2016 , 149, 353-361	46

1551	Transplantation and Mechanical Circulatory Support in Congenital Heart Disease: A Scientific Statement From the American Heart Association. 2016 , 133, 802-20	98
1550	Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease. 2016 , 13, 92-102	8
1549	Speckle-tracking imaging in patients with Eisenmenger syndrome. 2016 , 109, 104-12	8
1548	The Management of Supraventricular Tachyarrhythmias in Patients with Pulmonary Arterial Hypertension. 2016 , 25, 442-50	11
1547	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. 2016 , 69, 177.e1-177.e62	137
1546	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. 2016 , 149, 1482-93	33
1545	Persistent Challenges in Pediatric Pulmonary Hypertension. 2016 , 150, 226-36	18
1544	The right ventricle and pulmonary hypertension. 2016 , 21, 259-71	53
1543	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). 2016 , 18, 10	28
1542	Treatment of pulmonary hypertension. 2016 , 4, 323-36	75
1541	The role of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension. 2016 , 37, 81-4	14
1540	Pharmacological treatment of HIV-associated pulmonary hypertension. 2016 , 9, 715-25	5
1539	Management of interstitial lung disease associated with connective tissue disease. 2016 , 352, h6819	137
1538	[Pulmonary arterial hypertension associated with human immunodeficiency virus infection: study of 4 cases]. 2016 , 146, 350-3	
1537	Connective tissue diseases, multimorbidity and the ageing lung. 2016 , 47, 1535-58	20
1536	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. 2016 , 4, 291-305	133
1535	Update in treatment options in pulmonary hypertension. 2016 , 35, 695-703	18
1534	[Pulmonary lymphangiomyomatosis: From pathogenesis to management]. 2016 , 33, 718-734	2

1533	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. 2016 , 194, 464-75	52
1532	Review of the Ongoing Story of Appetite Suppressants, Serotonin Pathway, and Pulmonary Vascular Disease. 2016 , 117, 1691-1696	10
1531	Cardiovascular risk in pulmonary alveolar proteinosis. 2016 , 10, 235-40	1
1530	L'endartérectomie pulmonaire dans l'hypertension pulmonaire post-embolique. 2016 , 2, 35-56	
1529	Increased Red Blood Cell Stiffness Increases Pulmonary Vascular Resistance and Pulmonary Arterial Pressure. 2016 , 138, 021012	15
1528	Molecular pathogenesis and current pathology of pulmonary hypertension. 2016 , 21, 239-57	38
1527	Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes. 2016 , 21, 309-22	10
1526	Selexipag for the treatment of pulmonary arterial hypertension. 2016 , 10, 1-3	10
1525	Optical coherence tomography of the pulmonary arteries: A systematic review. 2016 , 67, 6-14	23
1524	Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. 2016 , 13, 31-9	44
1523	'Hypoxio-spondin': thrombospondin and its emerging role in pulmonary hypertension. 2016 , 109, 1-3	2
1522	The molecular targets of approved treatments for pulmonary arterial hypertension. 2016 , 71, 73-83	87
1521	Pulmonary Hypertension in CKD: Some Answers, Yet More Questions. 2016 , 27, 661-3	2
1520	Prevalence of Pulmonary Hypertension and its Influence on Survival in Patients With Advanced Chronic Obstructive Pulmonary Disease Prior to Lung Transplantation. 2016 , 13, 50-6	18
1519	Differential Mitochondrial Function in Remodeled Right and Nonremodeled Left Ventricles in Pulmonary Hypertension. 2016 , 22, 73-81	7
1518	Left ventricular heart failure and pulmonary hypertension. 2016 , 37, 942-54	316
1517	Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. 2016 , 35, 151-64	22
1516	Estrogen Metabolite 16 β -Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. 2016 , 133, 82-97	66

1515	Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. 2016 , 21, 323-46	18
1514	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). 2016 , 37, 67-110	3455
1513	Targeting BMP signalling in cardiovascular disease and anaemia. 2016 , 13, 106-20	131
1512	Electrocardiographic detection of pulmonary hypertension in patients with systemic sclerosis using the ventricular gradient. 2016 , 49, 60-8	6
1511	Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomy. 2016 , 30, 633-637	19
1510	A case of interferon- β -induced pulmonary arterial hypertension after living donor liver transplantation. 2016 , 31, 1206-8	3
1509	Role of Vasodilator Testing in Pulmonary Hypertension. 2016 , 58, 425-33	14
1508	[Hepatocardiac disorders : Interactions between two organ systems]. 2016 , 111, 447-52	1
1507	Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?. 2016 , 160, 125-9	11
1506	Pulmonary Hypertension in the Intensive Care Unit. 2016 , 31, 369-85	24
1505	Pulmonary Complications of Hematologic Diseases. 2016 , 1653-1670.e11	1
1504	Pulmonary Hypertension Due to Lung Disease. 2016 , 1050-1065.e5	0
1503	Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. 2017 , 18, 86-94	44
1502	The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. 2017 , 11, 682-690	5
1501	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. 2017 , 151, 468-480	57
1500	Mechanical Ventilation Outcomes in Patients With Pulmonary Hypertension in the United States: A National Retrospective Cohort Analysis. 2017 , 32, 588-592	14
1499	Moderate-to-severe obstructive sleep apnea is associated with subclinical myocardial injury and impaired hemodynamics in pulmonary hypertension patients. 2017 , 30, 121-127	10
1498	Update on chronic thromboembolic pulmonary hypertension. 2017 , 27, 29-37	28

1497	The benefit of exercise training in pulmonary hypertension: a clinical review. 2017 , 47, 361-369	14
1496	Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. 2017 , 52, 77-83	26
1495	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. 2017 , 101, 166-181	34
1494	Prevalence of metabolic syndrome in patients with pulmonary hypertension. 2017 , 11, 721-726	16
1493	Exercise-based rehabilitation programmes for pulmonary hypertension. 2017 , 1, CD011285	31
1492	Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature. 2017 , 174, 497-511	11
1491	Pulmonary arterial hypertension associated with interferon therapy: a population-based study. 2017 , 12, 1	20
1490	COUNTERPOINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? No. 2017 , 152, 16-18	0
1489	Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension. 2017 , 20, 45-47	5
1488	Hepatopulmonary Syndrome and Portopulmonary Hypertension. 2017 , 189-209	1
1487	New insights into mechanisms regulating pulmonary adventitial fibroblast proliferation. 2017 , 219, 17-19	1
1486	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. 2017 , 5, 125-134	76
1485	Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness. 2017 , 43, 151-162	4
1484	Pulmonary vascular and cardiac impairment in interstitial lung disease. 2017 , 26,	24
1483	Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. 2017 , 7, 41605	41
1482	Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor. 2017 , 56, 488-496	14
1481	Obstructive Sleep Apnea and Pulmonary Hypertension in Children. 2017 , 23, 33-39	22
1480	Clinical Classification. 2017 , 3-11	

1479	Human Pathology. 2017 , 101-113	1
1478	Pulmonary veno-occlusive disease: characterising a rare but important disease. 2017 , 5, 89-90	0
1477	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. 2017 , 148, 265-270	9
1476	Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry. 2017 , 41, 1164-1168	17
1475	Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition. 2017 , 187, 700-712	18
1474	[Balloon pulmonary angioplasty: An additional treatment option to improve the status of patients with chronic thromboembolic pulmonary hypertension]. 2017 , 73, 50-54	
1473	Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. 2017 , 135, 1532-1546	41
1472	Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. 2017 , 103, 774-782	35
1471	A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. 2017 , 83, 1734-1744	18
1470	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. 2017 , 19, 42	37
1469	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. 2017 , 110, 303-316	31
1468	Cardiac manifestations of parasitic diseases. 2017 , 103, 651-658	44
1467	In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. 2017 , 79, 711-723	8
1466	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. 2017 , 49,	25
1465	Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. 2017 , 26, 1113-1116	16
1464	Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension. 2017 , 69, 532-535	3
1463	Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. 2017 , 49,	18
1462	Galectin-3 Levels Are Elevated and Predictive of Mortality in Pulmonary Hypertension. 2017 , 26, 1208-1215	25

1461	Pulmonary arterial hypertension in children after neonatal arterial switch operation. 2017 , 103, 1244-1249	16
1460	Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease. 2017 , 103, 287-292	49
1459	Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry. A Candidate Clinical Endpoint. 2017 , 196, 220-227	24
1458	Vasopressors induce passive pulmonary hypertension by blood redistribution from systemic to pulmonary circulation. 2017 , 112, 21	5
1457	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. 2017 , 196, 925-928	30
1456	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. 2017 , 103, 599-606	19
1455	A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. 2017 , 21, 62-65	
1454	Pulmonary Hypertension in Pregnancy: A Report of 49 Cases at Four Tertiary North American Sites. 2017 , 129, 511-520	53
1453	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. 2017 , 11, 491-503	39
1452	Unraveling the RV Ejection Doppler Envelope: Insight Into Pulmonary Artery Hemodynamics and Disease Severity. 2017 , 10, 1268-1277	24
1451	Respiratory Complications. 2017 , 1-29	
1450	Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension. 2017 , 112, 30	15
1449	Kardiale Erkrankungen Pathologien verstehen. 2017 , 83-156	
1448	Aging with HIV in the ART era. 2017 , 34, 384-397	41
1447	Ambrisentan: a review of its use in pulmonary arterial hypertension. 2017 , 11, 233-244	12
1446	Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis. 2017 , 26, 1390-1400	14
1445	Pulmonary hypertension due to left heart disease. 2017 , 110, 420-431	7
1444	Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. 2017 , 17, 58	14

1443	Pflegewissen Kardiologie. 2017 ,		2
1442	A diffuse lung emphysema, severe pulmonary hypertension and lack of airflow limitation. 2017 , 21, 74-77		2
1441	Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort. 2017 , 22, 1386-1392		6
1440	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. 2017 , 49,		5
1439	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. 2017 , 49,		5
1438	Pulmonary Hypertension in Infants, Children, and Young Adults. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2551-2569	15.1	78
1437	Ventriculo-arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease. 2017 , 5, e13227		21
1436	ACR Appropriateness Criteria Suspected Pulmonary Hypertension. 2017 , 14, S350-S361		13
1435	Three novel mutations associated with advanced pulmonary arterial hypertension. 2017 , 4, 17010		4
1434	Pulmonary Manifestations of Lymphoma and Leukemia. 2017 , 38, 187-200		14
1433	Pulmonary Hypertension. 2017 , 697-710		1
1432	Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy. 2017 , 7, 643-653		23
1431	Functional magnetic resonance imaging for in vivo quantification of pulmonary hypertension in the Sugen 5416/hypoxia mouse. 2017 , 102, 347-353		4
1430	Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. 2017 , 228, 895-899		17
1429	In Acute Right Ventricular Failure, What are the Effects of Preload and Afterload?. 2017 , 24, 1-5		
1428	Early Onset Noninfectious Pulmonary Syndromes after Hematopoietic Cell Transplantation. 2017 , 38, 233-248		18
1427	Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication. 2017 , 27, 1410-1412		5
1426	Changes in main pulmonary artery diameter during follow-up have prognostic implications in pulmonary arterial hypertension. 2017 , 22, 1649-1655		8

1425	Impact of Left Ventricular Diastolic Dysfunction on Lung Transplantation Outcome in Patients With Pulmonary Arterial Hypertension. 2017 , 17, 2705-2711	14
1424	Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development. 2017 , 282, 129-141	18
1423	Peroxisome proliferator-activated receptor- α enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4. 2017 , 313, L371-L383	17
1422	Chronic Pulmonary Hypertension. 131-140	
1421	Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension. 2017 , 7, 1923	12
1420	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. 2017 , 104, 404-411	15
1419	Prevalence, incidence and aetiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis protocol. 2017 , 7, e014768	3
1418	Identifying "super responders" in pulmonary arterial hypertension. 2017 , 7, 300-311	7
1417	Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA. 2017 , 7, 372-383	10
1416	Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension. 2017 , 7, 572-587	13
1415	Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?. 2017 , 11, 1	1
1414	Epidemiology and treatment of pulmonary arterial hypertension. 2017 , 14, 603-614	182
1413	Pulmonary Hypertension in Pregnancy. 2017 , 38, 148-159	6
1412	Pulmonary Hypertension-Back to the Future. 2017 , 70, 901-904	1
1411	TGF- β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. 2017 , 8, 15494	72
1410	Left Atrium Maximal Axial Cross-Sectional Area is a Specific Computed Tomographic Imaging Biomarker of World Health Organization Group 2 Pulmonary Hypertension. 2017 , 32, 121-126	18
1409	Value of CT signs and measurements as a predictor of pulmonary hypertension and mortality in symptomatic severe aortic valve stenosis. 2017 , 33, 1637-1651	6
1408	Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?. 2017 , 47, 1124-1128	

1407	Critical effects of epigenetic regulation in pulmonary arterial hypertension. 2017 , 74, 3789-3808	10
1406	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. 2017 , 7, 312-325	35
1405	How Pregnancy Impacts Adult Cyanotic Congenital Heart Disease: A Multicenter Observational Study. 2017 , 135, 2444-2447	13
1404	Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension. 2017 , 7, 399-408	8
1403	Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension. 2017 , 121, 341-353	12
1402	The differential effects of systemic vasoconstrictors on human pulmonary artery tension. 2017 , 51, 880-886	5
1401	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. 2017 , 148, 265-270	
1400	Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. 2017 , 38, 2034-2041	42
1399	Adaptaci3n y validaci3n del cuestionario Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) para uso en Espa3a. 2017 , 70, 467-473	4
1398	A Case of Pulmonary Hypertension Due to Fistulas Between Multiple Systemic Arteries and the Right Pulmonary Artery in an Adult Discovered for Occulted Dyspnoea. 2017 , 26, e54-e58	3
1397	Right ventricular free-wall longitudinal speckle tracking strain in patients with pulmonary arterial hypertension under specific treatment. 2017 , 34, 530-536	10
1396	Prognostic stratification in pulmonary hypertension: A multi-biomarker approach. 2017 , 36, 111-125	10
1395	Imaging in Chronic Thromboembolic Pulmonary Hypertension. 2017 , 32, 71-88	29
1394	Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension. 2017 , 312, L609-L624	40
1393	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. 2017 , 14, 896-902	3
1392	Advances in treatment of pulmonary arterial hypertension: patent review. 2017 , 27, 907-918	9
1391	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. 2017 , 8, 47-64	19
1390	The pathophysiology of chronic thromboembolic pulmonary hypertension. 2017 , 26,	187

1389	Reversible Pulmonary Arterial Hypertension Induced by Dasatinib in a Patient With Chronic Myeloid Leukemia. 2017 , 33, 284-289	0
1388	Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target. 2017 , 120, 1246-1262	37
1387	The Evolving Classification of Pulmonary Hypertension. 2017 , 141, 696-703	20
1386	Pulmonary hypertension after timely arterial switch operation in children with simple transposition of the great arteries: a new disease entity?. 2017 , 103, 1227-1228	2
1385	Bone Morphogenetic Protein Signaling in Pulmonary Arterial Hypertension. 2017 , 293-326	
1384	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. 2017 , 21, 181-190	27
1383	Cardiac remodelling amongst adults with various aetiologies of pulmonary arterial hypertension including Eisenmenger syndrome-implications on survival and the role of right ventricular transverse strain. 2017 , 18, 1262-1270	21
1382	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. 2017 , 40, 356-363	9
1381	Pulmonary vascular remodeling in pulmonary hypertension. 2017 , 367, 643-649	112
1380	Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component. 2017 , 36, 754-762	26
1379	Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase. 2017 , 52, 443-457	13
1378	Complications of pulmonary hypertension: a pictorial review. 2017 , 90, 20160745	4
1377	Liver, Lung and Heart Regeneration. 2017 ,	
1376	Cardiac dysfunction of pulmonary artery aneurysm in patients with pulmonary arterial hypertension. 2017 , 228, 1035-1040	8
1375	Regenerative Potential of Mesenchymal Stem Cells: Therapeutic Applications in Lung Disorders. 2017 , 77-117	1
1374	EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. 2017 , 151, 821-828	35
1373	A Mock Circulatory System Incorporating a Compliant 3D-Printed Anatomical Model to Investigate Pulmonary Hemodynamics. 2017 , 41, 637-646	19
1372	Vascular Cells in Blood Vessel Wall Development and Disease. 2017 , 78, 323-350	48

1371	Diagnosis and Treatment of Pulmonary Hypertension. 2017 ,	0
1370	HIV and Nonischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 83-91	15.1 27
1369	Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. 2017 , 105, 48-67	83
1368	Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain. 2017 , 70, 467-473	3
1367	Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis or emphysema alone. 2017 , 70, 896-905	13
1366	Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. 2017 , 23, 31-45	108
1365	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. 2017 , 65, 1683-1692	40
1364	Pulmonary Hypertension and Primary Graft Dysfunction in Lung Transplant Recipients: We Still Have a Long Way to Go. 2017 , 14, 1504-1505	2
1363	Favorable Evolution of a Patient with Thromboembolic Pulmonary Hypertension. 2017 , 23, 94-98	
1362	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. 2017 , 2, 1361-1368	72
1361	What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?. 2017 , 19, 97	7
1360	Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. 2017 ,	78
1359	Pulmonary Hypertension in Adult Congenital Heart Disease. 2017 ,	6
1358	Enfoque de la hipertensi3 pulmonar en el paciente pedi3rico. 2017 , 24, 89-97	1
1357	Evidence on Exercise Training in Pulmonary Hypertension. 2017 , 1000, 153-172	9
1356	Pulmonary Hypertension and Thrombembolism—Long-Term Management and Chronic Oral Anticoagulation. 2017 , 2, 727-741	
1355	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. 2017 , 136, 2022-2033	75
1354	Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities. 2017 , 313, R693-R705	33

1353	Cardiopulmonary Manifestations of Collagen Vascular Diseases. 2017 , 19, 71	9
1352	Definition and Classification of Pulmonary Hypertension in Congenital Heart Disease. 2017 , 23-28	
1351	Genetics of Pulmonary Arterial Hypertension. 2017 , 38, 585-595	7
1350	Screening of Pulmonary Arterial Hypertension. 2017 , 38, 596-605	1
1349	Pathology and Pathobiology of Pulmonary Hypertension. 2017 , 38, 571-584	26
1348	Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy. 2017 , 38, 636-650	6
1347	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. 2017 , 38, 606-618	5
1346	Pulmonary Hypertension: Definition, Classification, and Diagnosis. 2017 , 38, 561-570	5
1345	Medical Treatment of Pulmonary Arterial Hypertension. 2017 , 38, 686-700	6
1344	Prostacyclin for pulmonary hypertension. 2017 ,	78
1343	Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension. 2017 , 967, 241-260	8
1342	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. 2017 , 19, 86	14
1341	El cateterismo derecho como herramienta en el diagnóstico de la hipertensión pulmonar. 2017 , 24, 28-33	1
1340	Emerging Role of MicroRNAs and Long Noncoding RNAs in Healthy and Diseased Lung. 2017 , 967, 343-359	5
1339	Pentose Shunt, Glucose-6-Phosphate Dehydrogenase, NADPH Redox, and Stem Cells in Pulmonary Hypertension. 2017 , 967, 47-55	1
1338	Measurement Variation and Repeatability of Echocardiographic Variables Used to Estimate Pulmonary Artery Pressure in Dogs. 2017 , 31, 1622-1628	7
1337	Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. 2017 , 10, 875-890	4
1336	Controversies in the identification and management of acute pulmonary hypertension in preterm neonates. 2017 , 82, 901-914	25

1335	New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. 2017 , 29, 561-567	3
1334	Dueling Lungs: The Progression of Swyer-James Syndrome. 2017 , 130, e485-e486	1
1333	Pulmonary Vascular Diseases in the Elderly. 2017 , 33, 553-562	4
1332	Management of combined pre- and post-capillary pulmonary hypertension in advanced heart failure with reduced ejection fraction. 2017 , 131, 94-100	1
1331	Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study. 2017 , 7, 635-642	4
1330	Diagnosis and Management of Pulmonary Hypertension in Hospitalized Patients. 2017 , 6, 532-542	
1329	Eisenmenger Syndrome in Patients with Down Syndrome. 2017 , 279-289	1
1328	Exertional dyspnoea in pulmonary arterial hypertension. 2017 , 26,	17
1327	Fisiopatologiã de la hipertensiã arterial pulmonar. 2017 , 24, 11-15	
1326	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. 2017 , 72, 1035-1045	20
1325	ATS Core Curriculum 2017: Part II. Pediatric Pulmonary Medicine. 2017 , 14, S165-S181	3
1324	Evaluaciã diagnosticã en hipertensiã arterial pulmonar. 2017 , 24, 20-27	1
1323	Experience of Lung Transplantation in Patients with Lymphangiomyomatosis at a Brazilian Reference Centre. 2017 , 195, 699-705	7
1322	Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia. 2017 , 94, 242-250	10
1321	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433	330
1320	Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population. 2017 , 14, 484-489	17
1319	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. 2017 , 7, 741-746	10
1318	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. 2017 , 153, 1273-1283.e1	164

1317	Decreased pulmonary arterial proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension. 2017 , 40, 988-992	4
1316	Echocardiographic Pulmonary Hypertension Predicts Post-transplantation Renal Allograft Failure. 2017 , 49, 1256-1261	10
1315	Hipertensi3 pulmonar. Regreso al futuro. 2017 , 70, 901-904	2
1314	Intimal sarcoma of the pulmonary trunk showing broad intimal extension and focal chondrosarcomatous differentiation: an autopsy case. 2017 , 31, 5-8	3
1313	Cor pulmonale. 2017 , 12, 2116-2126	
1312	Disease-related autoantibody profile in patients with systemic sclerosis. 2017 , 50, 414-421	46
1311	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. 2017 , 50,	62
1310	Severe dyspnea in a patient with neurofibromatosis type 1. 2017 , 22, 74-76	4
1309	Smoking intensity and duration is associated with cardiac structure and function: the ECHOCARDIOGRAPHIC Study of Hispanics/Latinos. 2017 , 4, e000614	14
1308	Computed Tomography Pulmonary Angiogram Dynamic Parameter Correlation With Pulmonary Pressure and Pulmonary Hypertension Etiologies. 2017 , 41, 779-783	0
1307	The relationship between pulmonary hypertension and obstructive sleep apnea. 2017 , 23, 517-521	25
1306	Pulmonary Hypertension and Interstitial Lung Disease. 2017 ,	
1305	Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. 2017 , 7, 674-683	21
1304	Diagnosing and managing scleroderma-related pulmonary arterial hypertension. 2017 , 30, 11-18	1
1303	Effects of fasudil on pulmonary hypertension in clinical practice. 2017 , 46, 54-63	46
1302	Fifty Years of Monocrotaline-Induced Pulmonary Hypertension: What Has It Meant to the Field?. 2017 , 152, 1106-1108	24
1301	Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. 2017 , 7, 261-267	8
1300	Orai1, 2, 3 and STIM1 promote store-operated calcium entry in pulmonary arterial smooth muscle cells. 2017 , 3, 17074	26

1299	Clinical Application of Genetic Testing in Heart Failure. 2017 , 14, 543-553		4
1298	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. 2017 , 9,		50
1297	Classifying Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. Hemodynamics Matter. 2017 , 196, 1244-1246		1
1296	TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications. 2017 , 50,		37
1295	Non-invasive assessment of liver changes in Eisenmenger patients. 2017 , 249, 140-144		8
1294	Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2552-2565	15.1	144
1293	Pulmonary Hypertension and Thromboembolic Disease. 2017 , 185-200		
1292	Gallic acid attenuates pulmonary fibrosis in a mouse model of transverse aortic contraction-induced heart failure. 2017 , 99, 74-82		9
1291	Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. 2017 , 7, 598-608		23
1290	Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. 2017 , 33, 2241-2249		12
1289	Kidney dysfunction in patients with pulmonary arterial hypertension. 2017 , 7, 38-54		30
1288	Addressing the challenges of phenotyping pediatric pulmonary vascular disease. 2017 , 7, 7-19		10
1287	Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. 2017 , 7, 126-136		29
1286	MDCT Assessment of Pulmonary Arterial Hypertension. 2017 , 5, 1		1
1285	Idiopathic Pulmonary Arterial Hypertension in Children: A Review. 2017 , 3, 67-92		2
1284	Collaborative Care: A Defining Characteristic for a Pulmonary Hypertension Center. 2017 , 3, 93-111		6
1283	Riociguat in PAH and CTEPH: Strategies for Patient Management. 2017 , 3, 31-43		1
1282	Vasoproliferative process resembling pulmonary capillary hemangiomatosis in a cat. 2017 , 13, 72		7

1281	Imatinib relaxes the pulmonary venous bed of guinea pigs. 2017 , 18, 32	13
1280	Implication of overexpression of dishevelled-associated activator of morphogenesis 1 (Daam-1) for the pathogenesis of human Idiopathic Pulmonary Arterial Hypertension (IPAH). 2017 , 12, 25	3
1279	Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. 2017 , 12, 74	18
1278	Pulmonary arterial hypertension in scleroderma: care gaps in screening. 2017 , 19, 128	3
1277	Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: Number 1 in the Series "Pathology for the clinician" Edited by Peter Dorfmeier and Alberto Cavazza. 2017 , 26,	7
1276	The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension. 2017 , 38, 1-14	18
1275	Pulmonary Hypertension Care Center Network: Improving Care and Outcomes in Pulmonary Hypertension. 2017 , 151, 749-754	15
1274	Pro: Pulmonary Artery Catheter Placement After Anesthetic Induction in Patients Undergoing Pulmonary Thromboendarterectomy. 2017 , 31, 1511-1513	2
1273	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. 2017 , 23, 29-35	14
1272	The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis. 2017 , 411-419	
1271	An Update on the Management of Chronic Thromboembolic Pulmonary Hypertension. 2017 , 42, 7-38	15
1270	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. 2017 , 36, 386-398	12
1269	Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. 2017 , 23, 3-15	7
1268	Acute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension. 2017 , 34, 53-60	11
1267	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. 2017 , 31, 903-910	3
1266	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. 2017 , 151, 204-214	12
1265	Selected Disorders of the Respiratory System. 2017 , 1111-1127	
1264	Efficacy and Safety of Statins for Pulmonary Hypertension: A Meta-Analysis of Randomised Controlled Trials. 2017 , 26, 425-432	8

1263	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. 2017 , 106, 174-182	14
1262	Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. 2017 , 27, 1980-1991	29
1261	Non-Invasive Assessment of Pulmonary Vascular Resistance in Pulmonary Hypertension: Current Knowledge and Future Direction. 2017 , 26, 323-330	15
1260	Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung. 2017 , 56, 131-144	14
1259	Pulmonary Manifestations of Liver Disease. 2017 , 353-364	
1258	59-Year-Old Woman With Fatigue, Dyspnea, and Lower Extremity Edema. 2017 , 92, e167-e171	
1257	Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. 2017 , 26,	31
1256	Computational analysis of pulmonary artery stenosis. 2017 ,	
1255	Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors. 2017 , 56, 1061-1065	8
1254	Pulmonary Hypertension in Systemic Sclerosis. 2017 ,	
1253	Complex, high-risk thoracic surgery—does risk always outweigh the benefit or can we manage it safely?. 2017 , 2, 63-63	2
1252	Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents. 2017 , 16, 1360-1368	2
1251	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. 2017 , 8, 858	18
1250	Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy. 2017 , 8, 614	19
1249	Treatment of pulmonary hypertension with left heart disease: a concise review. 2017 , 13, 415-420	5
1248	Pathophysiology of Persistent Pulmonary Hypertension of the Newborn. 2017 , 1576-1588.e4	1
1247	The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. 2017 , 6,	9
1246	Optimal Dose and Timing of Umbilical Stem Cells Treatment in Pulmonary Arterial Hypertensive Rats. 2017 , 58, 570-580	7

1245	Guidelines for Perioperative Cardiovascular Evaluation and Management for Noncardiac Surgery (JCS 2014) - Digest Version. 2017 , 81, 245-267	14
1244	Sildenafil in Infants and Children. 2017 , 4,	8
1243	The Fetus Can Teach Us: Oxygen and the Pulmonary Vasculature. 2017 , 4,	14
1242	The Pulmonary Circulation in the Single Ventricle Patient. 2017 , 4,	9
1241	Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension. 2017 , 18,	14
1240	Pathophysiology of Pulmonary Hypertension. 2017 , 9, i-104	
1239	D-Shaped Left Ventricle, Anatomic, and Physiologic Implications. 2017 , 2017, 4309165	1
1238	Pulmonary Hypertension due to Lung Diseases and/or Hypoxia: What Do We Actually Know?. 2017 , 2017, 9598089	1
1237	Serum-Free Thyroxine Levels Were Associated with Pulmonary Hypertension and Pulmonary Artery Systolic Pressure in Euthyroid Patients with Coronary Artery Disease. 2017 , 2017, 4832608	0
1236	Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. 2017 , 11, 871-885	12
1235	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. 2017 , 9, 731-739	13
1234	Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis. 2017 , 17, 183	20
1233	Hepatokardiale Wechselwirkungen. 2017 , 20, 130-135	0
1232	The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective. 2017 , 1,	
1231	Changing face of pulmonary arterial hypertension in Canada. 2017 , 1, 242-252	5
1230	Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. 2017 , 64, 1173-1180	6
1229	Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?. 2017 , 6, 163-171	8
1228	Pulmonary Hypertension in Patient with Neurofibromatosis Type 1. 2017 , 32, 227	1

1227	Schistosomiasis and hepatopulmonary syndrome: the role of concomitant liver cirrhosis. 2017 , 112, 469-473	4
1226	Gender disparities in pulmonary hypertension at a tertiary centre in Cameroon. 2017 , 107, 892-899	4
1225	Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. 2017 , 12, 31-33	
1224	Pulmonary hypertension in Nigerian adults with sickle cell anemia. 2017 , 13, 153-160	12
1223	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. 2017 , 14, 820-828	6
1222	A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study. 2017 , 12, 1741-1751	3
1221	Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. 2017 , 56, 2487-2492	5
1220	Outcomes of pregnancy in patients with known Budd-Chiari syndrome. 2017 , 9, 945-952	9
1219	Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension. 2017 , 6,	42
1218	Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?. 2017 , 4, 56	5
1217	Discerning functional hierarchies of microRNAs in pulmonary hypertension. 2017 , 2, e91327	42
1216	Advances in Chronic Obstructive Pulmonary Disease Therapy: A Vascular-Targeted Approach. 2017 , 9, 1179559X1771912	1
1215	Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. 2017 , 9, 2437-2446	7
1214	3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. 2017 , 109, 1-104	11
1213	Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies. 2017 , 7, 405-417	15
1212	Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. 2018 , 7,	13
1211	A case report of acute pulmonary hypertension after hyperthermic intraperitoneal chemotherapy (HIPEC) and review of the literature. 2018 , 27, 26-31	1
1210	Determination of Cardiac Output in Pulmonary Hypertension Using Impedance Cardiography. 2018 , 96, 500-506	12

1209	Drug-associated pulmonary arterial hypertension. 2018 , 56, 801-809	25
1208	Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension. 2018 , 47, 134-143	12
1207	Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis. 2018 , 8, 2045893217753357	1
1206	Severe Pulmonary Hypertension Due to Adult-Onset Still's Disease. 2018 , 6, 2324709618757260	3
1205	Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. 2018 , 8, 2045893218757404	8
1204	Best Practice for Home Physical Therapy for Older Adults with Heart Failure. 2018 , 7, 71-79	1
1203	Pre-operative Evaluation of Patients with Pulmonary Hypertension. 2018 , 8, 44-51	
1202	Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?. 2018 , 8, 2045893218755979	13
1201	Validation of claims-based algorithms for pulmonary arterial hypertension. 2018 , 8, 2045894018759246	15
1200	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. 2018 , 20, 10	15
1199	Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment. 2018 , 25, 52-60	22
1198	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. 2018 , 37, 836-843	14
1197	Pulmonary hypertension: Real-world data from a Portuguese expert referral centre. 2018 , 24, 231-240	6
1196	Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. 2018 , 8, 2045894018775056	10
1195	Cell Autonomous and Non-cell Autonomous Regulation of SMC Progenitors in Pulmonary Hypertension. 2018 , 23, 1152-1165	41
1194	Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. 2018 , 32, 2512-2519	17
1193	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. 2018 , 27,	13
1192	Depression and Anxiety in Patients With Pulmonary Hypertension: The Role of Life Satisfaction and Optimism. 2018 , 59, 575-583	15

1191	Egg-and-Banana Sign: A Novel Diagnostic CT Marker for Pulmonary Hypertension. 2018 , 210, 1235-1239	10
1190	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. 2018 , 8, 2045894018769874	20
1189	[Pulmonary hypertension in connective tissue disease]. 2018 , 77, 219-230	
1188	Comparison of continuous-flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure. 2018 , 5, 695-702	18
1187	S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. 2018 , 23, 771-779	6
1186	[The heart catheter table is not the operating table : Intraindividual comparison of pulmonary artery pressures]. 2018 , 67, 351-358	
1185	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. 2018 , 51,	9
1184	Transient Receptor Potential Melastatin-8 Activation Induces Relaxation of Pulmonary Artery by Inhibition of Store-Operated Calcium Entry in Normoxic and Chronic Hypoxic Pulmonary Hypertensive Rats. 2018 , 365, 544-555	7
1183	Vascular complications of sickle cell disease. 2018 , 68, 205-221	8
1182	National trends and outcomes of hospitalizations for pulmonary hypertension in Spain (2001-2014). 2018 , 263, 125-131	2
1181	Is there a learning effect when the 6-minute walk test is repeated in people with suspected pulmonary hypertension?. 2018 , 15, 339-346	12
1180	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. 2018 , 137, e578-e622	264
1179	Who's Who of Pulmonary Hypertension: Redefining Classification to Advance Precision Care. 2018 , 11, e002116	1
1178	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. 2018 , 154, 126-135	23
1177	Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. 2018 , 33, 939-947	7
1176	Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice. 2018 , 8, 1363	10
1175	Bronchoscopic Lung Volume Reduction. 2018 , 39, 169-180	5
1174	Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension. 2018 , 105, 45-51	11

1173	Approach to Pulmonary Hypertension: From CT to Clinical Diagnosis. 2018 , 38, 357-373	32
1172	Pulmonary Diseases in Refugees and Migrants in Europe. 2018 , 95, 273-286	2
1171	H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. 2018 , 197, 1638-1641	8
1170	Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis. 2018 , 97, e9708	3
1169	Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. 2018 , 11, e003973	95
1168	Dasatinib-induced pulmonary arterial hypertension. 2018 , 84, 835-845	28
1167	Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension. 2018 , 15, 81-93	3
1166	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. 2018 , 198, 166-174	14
1165	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. 2018 , 32, 289-299	48
1164	Disorders of the Cardiovascular System. 2018 , 387-541	9
1163	The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. 2018 , 51,	5
1162	Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. 2018 , 197, 1496-1499	16
1161	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. 2018 , 197, 1364-1365	
1160	Functional assessment of the BMPR2 gene in lymphoblastoid cell lines from Graves' disease patients. 2018 , 22, 1538-1547	2
1159	Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series). 2018 , 8, 2045893217753121	7
1158	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. 2018 , 197, 1364	
1157	Multicenter mortality and morbidity associated with pulmonary hypertension in the pediatric intensive care unit. 2018 , 8, 2045893217745785	6
1156	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. 2018 , 153, 1142-1152	3

1155	A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension. 2018 , 12, 60-66	18
1154	Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension. 2018 , 155, 1661-1669.e4	6
1153	Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. 2018 , 5, e000744	6
1152	Respiratory Complications in Acute and Chronic Liver Disease. 2018 , 137-151	
1151	Modern Invasive Hemodynamic Assessment of Pulmonary Hypertension. 2018 , 95, 201-211	1
1150	[Late-onset systemic sclerosis: A retrospective study of 27 patients diagnosed after the age of 70]. 2018 , 145, 166-172	2
1149	Pulmonary arterial hypertension in adult congenital heart disease. 2018 , 104, 1568-1574	35
1148	miR-322-5p targets IGF-1 and is suppressed in the heart of rats with pulmonary hypertension. 2018 , 8, 339-348	17
1147	Breathing (and Coding?) a Bit Easier: Changes to International Classification of Disease Coding for Pulmonary Hypertension. 2018 , 154, 207-218	7
1146	Pulmonary arterial hypertension: pathogenesis and clinical management. 2018 , 360, j5492	312
1145	Anthropometric Evaluation and Functional Assessment of Patients with Pulmonary Hypertension and its Relationship with Pulmonary Circulation Parameters and Functional Performance. 2018 , 37, 423-428	1
1144	Is hyponatremia associated with mortality in pulmonary arterial hypertension?. 2018 , 8, 2045894018776888	2
1143	Things We "kNOw" and Do Not "kNOw" about Pulmonary Hypertension. 2018 , 198, 151-152	1
1142	Noninvasive Echocardiographic Measures of Pulmonary Vascular Resistance in Children and Young Adults with Cardiomyopathy. 2018 , 31, 807-815	4
1141	Pulmonary arterial hypertension associated to systemic erythematosus lupus: molecular characterization of 3 cases. 2018 , 151, 111-115	
1140	Pulmonary hypertension in patients with interstitial lung disease. 2018 , 50, 38-46	13
1139	Nitrated fatty acids in cardiovascular diseases. 2018 , 78, 146-146	15
1138	Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. 2018 , 8, 2045894018759247	13

1137	Hematocrit-corrected Pulmonary Vascular Resistance. 2018 , 198, 305-309	20
1136	Sirtuin 1 as a potential therapeutic target in pulmonary artery hypertension. 2018 , 36, 1032-1035	0
1135	The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension. 2018 , 8, 2045893217745019	20
1134	Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. 2018 , 50, 1497-1504	7
1133	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. 2018 , 51,	68
1132	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. 2018 , 37, 903-911	45
1131	Cardiovascular parameters of chest CT scan in estimating pulmonary arterial pressure in patients with pulmonary hypertension. 2018 , 12, 572-579	6
1130	Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?. 2018 , 25, 828-832	
1129	Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension. 2018 , 31, 1209-1213	7
1128	Bone Morphogenetic Proteins in Vascular Homeostasis and Disease. 2018 , 10,	77
1127	Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. 2018 , 28, 230-250	48
1126	The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review. 2018 , 18, 93-102	3
1125	Pulmonary hypertension nosography: are all patients classifiable?. 2018 , 13, 35-40	
1124	The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. 2018 , 48, 704-719	10
1123	Genetics in pulmonary arterial hypertension in a large homogeneous Japanese population. 2018 , 94, 70-80	9
1122	Pulmonary Arterial Hypertension With Abnormal V/Q Single-Photon Emission Computed Tomography. 2018 , 11, 1487-1493	10
1121	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. 2018 , 197, 704-706	5
1120	Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. 2018 , 57, 647-661	34

1119	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. 2018 , 37, 647-655	31
1118	Left Heart Disease and Pulmonary Hypertension: Are We Seeing the Full Picture?. 2018 , 27, 301-309	6
1117	Drug-Induced Lung Injury. 2018 ,	0
1116	Dual ET/ET blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. 2018 , 8, 2045893217741429	16
1115	Right ventricular speckle tracking assessment for differentiation of pressure- versus volume-overloaded right ventricle. 2018 , 38, 763-771	13
1114	Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale. 2018 , 59, 1494-1497	3
1113	Distinction Between Precapillary and Postcapillary Pulmonary Hypertension by the Atrial Volume Ratio on Transthoracic Echocardiography. 2018 , 37, 891-896	2
1112	Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement. 2018 , 104, 821-827	25
1111	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. 2018 , 47, 870-876	4
1110	Imaging of the Right Ventricle: Overview of Imaging Modalities for Assessing RV Volume and Function. 2018 , 221-232	
1109	Cardiac Magnetic Resonance Evaluation of Left Ventricular Myocardial Strain in Pulmonary Hypertension. 2018 , 25, 129-135	11
1108	Chronic Thromboembolic Pulmonary Hypertension: Epidemiology, Diagnosis, and Management. 2018 , 26, 62-72	15
1107	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. 2018 , 197, 788-800	49
1106	Exercise training in patients with pulmonary and systemic hypertension: A unique therapy for two different diseases. 2018 , 47, 17-24	13
1105	Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor- β mad Signaling. 2018 , 58, 194-207	46
1104	Modern diagnosis of chronic thromboembolic pulmonary hypertension. 2018 , 163, 260-265	4
1103	Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. 2018 , 153, 310-320	12
1102	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. 2018 , 137, 910-924	60

1101	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. 2018 , 134, 42-46	15
1100	Pulmonary Hypertension. 2018 , 401-420.e3	
1099	Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. 2018 , 314, L443-L460	35
1098	Acute Pulmonary Vasodilator Testing and Long-Term Clinical Course in Segmental Pulmonary Vascular Disease. 2018 , 39, 501-508	5
1097	Pulmonary Hypertension and Pulmonary Artery Acceleration Time: A Systematic Review and Meta-Analysis. 2018 , 31, 201-210.e3	22
1096	IL-13 enhances mesenchymal transition of pulmonary artery endothelial cells via down-regulation of miR-424/503 in vitro. 2018 , 42, 270-280	20
1095	Anesthesia in High-Risk Patients. 2018 ,	
1094	Determinants of mortality in systemic sclerosis: a focused review. 2018 , 38, 1847-1858	30
1093	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. 2018 , 43, 191-216	1
1092	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. 2018 , 43, 217-231	1
1091	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. 2018 , 71, 34-55	11
1090	Pulmonary Hypertension in Patients for Transcatheter and Surgical Aortic Valve Replacement: A Focus on Outcomes and Perioperative Management. 2018 , 32, 2005-2018	0
1089	Pulmonary Arterial Hypertension Emergency Complications and Evaluation: Practical Guide for the Advanced Practice Registered Nurses in the Emergency Department. 2018 , 40, 246-259	3
1088	Spectrum of Multi-Detector Computed Tomography Findings that Alter Pulmonary Artery Diameters in Adults. 2018 , 78, 389	
1087	The aetiology, clinical presentation and treatment of patients with pulmonary hypertension in Cape Town: A preliminary report from the Groote Schuur Hospital Pulmonary Hypertension Registry. 2018 , 24,	
1086	Applying the Optimized CO Rebreathing Method for Measuring Blood Volumes and Hemoglobin Mass in Heart Failure Patients. 2018 , 9, 1603	6
1085	Atrial septal defects and pulmonary arterial hypertension. 2018 , 10, S2953-S2965	18
1084	The epidemiology of obstructive sleep apnoea and cardiovascular disease. 2018 , 10, S4189-S4200	26

1083	Imaging of pulmonary hypertension: an update. 2018 , 8, 279-296	22
1082	Impact of abnormal longitudinal rotation on the assessment of right ventricular systolic function in patients with severe pulmonary hypertension. 2018 , 10, 4694-4704	3
1081	Pregnancy and pulmonary hypertension: An exploratory analysis of risk factors and outcomes. 2018 , 97, e13035	13
1080	Pregnancy and Cardiovascular Disease. 2018 , 160-165	
1079	Hipertensi3 pulmonar en el adulto. 2018 , 12, 3982-3989	
1078	Protocolo diagn3stico de la hipertensi3 pulmonar sin cardiopat3 izquierda. 2018 , 12, 4021-4024	
1077	Chronic pulmonary embolism: diagnosis. 2018 , 8, 253-271	15
1076	Mujer de 57 a3s con disnea progresiva. 2018 , 12, 4025.e1-4025.e4	
1075	Recurrent Pulmonary Embolism and Pulmonary Hypertension in a Patient with ̢Thalassemia Intermedia. 2018 , 08,	
1074	Progenitor Endothelial Cells in Pulmonary Arterial Hypertension. 2018 , 06,	
1073	OBSOLETE: Pulmonary Hypertension. 2018 ,	
1072	Pulmonary Hypertension Associated With Left-Sided Heart Disease. 2018 , 223-229	
1071	Management of ITK pulmonary and pleural adverse effects: Fi-LMC guidelines. 2018 , 24, 134-144	
1070	3 Large Vessels. 2018 ,	
1069	Rare Cardiac Emergencies: Aortic Dissection, Pulmonary Hypertensive Crisis, and Pulmonary Embolism. 2018 , 19, 373-380	0
1068	Tsantan Sumtang Alleviates Chronic Hypoxia-Induced Pulmonary Hypertension by Inhibiting Proliferation of Pulmonary Vascular Cells. 2018 , 2018, 9504158	7
1067	Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction. 2018 , 9, 1777	1
1066	LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through ATR via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension. 2018 , 19, 254	49

1065	Proceedings of 6th European Dirofilaria and Angiostrongylus Days : Belgrade, Serbia. July 5 - 7, 2018. 2018 , 11, 623	3
1064	Pulmonary artery aneurysms: diagnosis & endovascular therapy. 2018 , 8, 350-361	25
1063	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. 2018 , 198, e116-e136	30
1062	Untargeted Metabolic Profiling Cell-Based Approach of Pulmonary Artery Smooth Muscle Cells in Response to High Glucose and the Effect of the Antioxidant Vitamins D and E. 2018 , 8,	5
1061	Pulmonary Hypertension and Eisenmenger Physiology. 2018 , 117-141	
1060	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. 2018 , 3, 242-248	8
1059	Vascular Diseases. 2018 , 98-126.e1	1
1058	Early Diagnostic Features of Left-to-Right Shunt-Induced Pulmonary Arterial Hypertension in Piglets. 2018 , 106, 1396-1405	2
1057	Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study. 2018 , 24, 640-653	14
1056	Classification and pathophysiology of pulmonary hypertension. 2018 , 4, 2-12	16
1055	Docking of Meprin to Heparan Sulphate Protects the Endothelium from Inflammatory Cell Extravasation. 2018 , 118, 1790-1802	6
1054	Active right atrial emptying fraction predicts reduced survival and increased adverse events in childhood pulmonary arterial hypertension. 2018 , 271, 306-311	8
1053	Full Issue PDF. 2018 , 11, e917-e1097	
1052	Preoperative expectations for health-related quality of life after lung transplant. 2018 , 32, e13394	2
1051	Predictive Value of Intraoperative Pulmonary Vascular Resistance in Liver Transplantation. 2018 , 24, 1680-1689	2
1050	Cologne consensus conference on pulmonary hypertension - Update 2018. 2018 , 272S, 1-3	4
1049	Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients. 2018 , 2018, 9629570	10
1048	Acute and Chronic Pulmonary Embolism: Perspectives on Diagnosis and Management. 2018 , 355-366	0

1047 Pulmonary Hypertension. **2018**, 372-379

1046 Cardiogenic Shock. **2018**, 631-639

1045 Pulmonary Hypertension in Pregnancy. **2018**, 775-790

1044 Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. **2018**, 13, e0204610

7

1043 Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. **2018**, 24, 834-842

17

1042 Chronic thromboembolic pulmonary hypertension: emerging endovascular therapy. **2018**, 8, 272-278

3

1041 Ocimum: The Holy Basil Against Cardiac Anomalies. **2018**, 25-36

2

1040 Pulmonary Arterial Hypertension Medical Management of the Adult Patient with Congenital Heart Disease. **2018**, 3, 1-8

1039 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?. **2018**, 52,

3

1038 Management of Severe Pulmonary Hypertensive Disease for Surgical and Nonsurgical Procedures. **2018**, 56, e28-e55

3

1037 How I manage medical complications of ß-thalassemia in adults. **2018**, 132, 1781-1791

37

1036 High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. **2018**, 8, 2045894018798613

12

1035 Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. **2018**, 504-533

1034 Factors Associated with Heritable Pulmonary Arterial Hypertension Exert Convergent Actions on the miR-130/301-Vascular Matrix Feedback Loop. **2018**, 19,

18

1033 Pulmonary Hypertension. **2018**, 315-330

1032 Prevalence of primary Sjögren's syndrome in patients undergoing evaluation for pulmonary arterial hypertension. **2018**, 13, e0197297

9

1031 Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. **2018**, 19,

9

1030 Serum Chloride Levels Track With Survival in Patients With Pulmonary Arterial Hypertension. **2018**, 154, 541-549

12

1029	Endothelial Alterations in Pulmonary Hypertension. 2018 , 439-451	1
1028	Exercise-based evaluations and interventions for pulmonary hypertension with connective tissue disorders. 2018 , 12, 615-622	1
1027	Optimising experimental research in respiratory diseases: an ERS statement. 2018 , 51,	53
1026	Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension. 2018 , 73, 1158-1166	10
1025	Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. 2018 , 8, 2045894018780521	20
1024	Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study. 2018 , 37, 3373-3380	3
1023	Prevalence of iron deficiency in different subtypes of pulmonary hypertension. 2018 , 47, 308-313	9
1022	Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). 2018 , 28, 5100-5110	57
1021	Pulmonary hypertension due to left heart disease: diagnostic and prognostic value of CT in chronic systolic heart failure. 2018 , 28, 4643-4653	11
1020	Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension. 2018 , 8, 2045894018790316	10
1019	Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. 2018 , 13, e0195092	9
1018	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. 2018 , 13, e0197112	24
1017	Phenotyping pulmonary hypertension in systemic sclerosis: a moving target. 2018 , 8, 2045894018785247	1
1016	The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. 2018 , 198, 818-820	1
1015	Right Ventricle Remodeling and Function in Scleroderma Patients. 2018 , 2018, 4528148	4
1014	Eisenmenger Syndrome. 2018 , 528-544	
1013	Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists. 2018 , 14, 271-281	8
1012	Chronic Thromboembolic Pulmonary Hypertension. 2018 , 14, 339-351	6

1011	Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. 2018 , 14, 403-411	2
1010	Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study. 2018 , 2018, 3924517	18
1009	Right Heart Failure in Pediatric Pulmonary Hypertension. 2018 , 399-412	1
1008	Pulmonary arterial hypertension associated to systemic erythematosus: Molecular characterization of 3 cases. 2018 , 151, 111-115	
1007	The Practical Challenges of Diagnosis and Treatment Options in Persistent Pulmonary Hypertension of the Newborn: A Developing Country's Perspective. 2018 , 35, 1366-1375	3
1006	Initial experience with bosentan for the management of pulmonary hypertension after heart transplantation. 2018 , 32, e13364	
1005	Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline. 2018 , 19, 94	16
1004	Pulmonary Hypertension. 2018 , 204-222	
1003	Pulmonary hypertension in patients with 9q34.3 microdeletion-associated Kleefstra syndrome. 2018 , 176, 1773-1777	7
1002	Pulmonary manifestations of systemic lupus erythematosus and Sjögren's syndrome. 2018 , 30, 449-464	15
1001	Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension. 2018 , 13, e0197700	9
1000	Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension. 2018 , 9, 241	19
999	Is the fibroblast growth factor signaling pathway a victim of receptor tyrosine kinase inhibition in pulmonary parenchymal and vascular remodeling?. 2018 , 315, L248-L252	8
998	A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017. 2018 , 315, L502-L516	9
997	Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease. 2018 , 315, L765-L774	19
996	The Role of Sex in the Pathophysiology of Pulmonary Hypertension. 2018 , 1065, 511-528	22
995	Emerging therapeutics in pulmonary hypertension. 2018 , 314, L769-L781	17
994	Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. 2018 , 314, L967-L983	23

993	Bariatric surgery in patients with pulmonary hypertension. 2018 , 14, 1581-1586	6
992	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. 2018 , 8, 2045894018792501	7
991	Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension. 2018 , 5, 204	21
990	Does Nasal Surgery Affect Right Ventricular Myocardial Functions at the Tissue Level in Patients with Nasal Septum Deviation?. 2018 , 7,	2
989	Screening For Pulmonary Hypertension With Multidetector Computed Tomography Among Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. 2018 , 5, 63	3
988	Using Omics to Understand and Treat Pulmonary Vascular Disease. 2018 , 5, 157	8
987	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. 2018 , 5,	10
986	The Voice of the Heart: Vowel-Like Sound in Pulmonary Artery Hypertension. 2018 , 6,	6
985	Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. 2018 , 6,	9
984	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. 2018 , 6,	50
983	Definition and Management of Segmental Pulmonary Hypertension. 2018 , 7,	17
982	Pulmonary Hypertension. 2018 , 597-606	
981	Have Noninvasive Imaging Studies Supplanted the Need for Invasive Hemodynamics: Lessons Learned from Lymphangiomyomatosis. 2018 , 31, 902-904	1
980	Beneficial Effect of (Linn) against Monocrotaline-Induced Pulmonary Hypertension in Rats. 2018 , 5,	7
979	An uncommon cause of dyspnea in the emergency department. 2018 , 36, 2130.e3-2130.e5	
978	A Step Closer to Understanding How Riociguat Results in Remodelling of the Right Ventricle in Chronic Thromboembolic Pulmonary Hypertension. 2018 , 34, 1098-1101	
977	Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. 2018 , 8, 2045894018791358	22
976	The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. 2018 , 70, 521-528	1

975	Pulmonary Arterial Hypertension. 2018 , 181-194	
974	Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. 2018 , 202, 212-219.e2	43
973	Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. 2018 , 27, 1769-1777	11
972	Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients. 2018 , 18, 56	2
971	Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. 2018 , 9, 15	37
970	Hypertension pulmonaire et connectivites. 2018 , 85, 210-220	
969	Using all-cause mortality to define severe RV dilation with RV/LV volume ratio. 2018 , 8, 7200	8
968	Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. 2018 , 8, 2045894018764273	9
967	Chronic Thromboembolic Pulmonary Hypertension: An Update. 2018 , 39, 605-620	12
966	Recent developments in 3-D reconstruction and stereology to study the pulmonary vasculature. 2018 , 315, L173-L183	13
965	Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. 2018 , 20, 185	9
964	Self-reported functional status predicts post-operative outcomes in non-cardiac surgery patients with pulmonary hypertension. 2018 , 13, e0201914	5
963	Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention. 2018 , 9, 955	11
962	Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension. 2018 , 6, 835-844	3
961	El tratamiento de elecci3n en la hipertensi3n pulmonar tromboemb3lica cr3nica: la tromboendarterectomi3 pulmonar. 2018 , 25, 73-76	1
960	Systematic review and meta-analysis of interventions tested in animal models of pulmonary hypertension. 2018 , 110, 55-63	8
959	Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. 2018 , 315, H1322-H1331	78
958	Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. 2018 , 272S, 79-88	30

957	Pulmonary vascular dysfunction secondary to pulmonary arterial hypertension: insights gained through retrograde perfusion. 2018 , 314, L835-L845	7
956	Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. 2018 , 5, G11-G24	86
955	Balloon pulmonary angioplasty is a promising option in thalassemic patients with inoperable chronic thromboembolic pulmonary hypertension. 2018 , 46, 516-520	3
954	Elevated Pulmonary Pressure-Get With the Right Group: A Teachable Moment. 2018 , 178, 1414-1415	
953	Settling the Score in Pulmonary Hypertension?. 2018 , 19, 782-783	
952	Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats. 2018 , 49, 172-189	38
951	Primary and Secondary Pulmonary Hypertension. 2018 , 285-314	
950	Pulmonary Disease and Right Ventricular Function. 2018 , 391-415	
949	Pulmonary arterial enlargement predicts long-term survival in COPD patients. 2018 , 13, e0195640	9
948	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. 2018 , 51,	132
947	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. 2018 , 13, e0191869	10
946	Inhalation of repurposed drugs to treat pulmonary hypertension. 2018 , 133, 34-44	11
945	Pulmonary arterial hypertension associated with abatacept treatment for rheumatoid arthritis: A case report. 2018 , 2, 41-44	0
944	Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs. 2018 , 23, 472-480	2
943	Abnormal Ventilation-Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults. 2019 , 60, 86-92	9
942	Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. 2019 , 597, 1103-1119	19
941	Extracorporeal Membrane Oxygenation in Pulmonary Endarterectomy Patients. 2019 , 33, 60-69	5
940	Treatment Barriers in Portopulmonary Hypertension. 2019 , 69, 431-443	21

939	Idiopathic hypereosinophilic syndrome with pulmonary hypertension. 2019 , 9, 2045894018793999		
938	Intracardiac or intrapulmonary shunts were present in at least 35% of adults with homozygous sickle cell disease followed in an outpatient clinic. 2019 , 104, e1-e3		4
937	Inflammasomes: a novel therapeutic target in pulmonary hypertension?. 2019 , 176, 1880-1896		19
936	Childhood Pulmonary Arterial Hypertension. 2019 , 556-579.e4		
935	Pulmonary Hypertension. 2019 , 194-205		
934	Increased Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Increased Mortality in Group 1 Pulmonary Hypertension. 2019 , 28, 1059-1066		2
933	Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine. 2019 , 33, 127-129		4
932	Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. 2019 , 35, 1881-1892		13
931	Eisenmenger Syndrome in Adults: Treatment Pattern and Prognostic Factors in the Advanced Pulmonary Vasodilator Era. 2019 , 40, 23-28		2
930	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e698-e800		248
929	Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension. 2019 , 597, 1199-1208		2
928	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 73, e81-e192	15.1	279
927	Perioperative Considerations for Patients Diagnosed With Pulmonary Hypertension Undergoing Noncardiac Surgery. 2019 , 34, 240-249		0
926	Pulmonary hypertension and congenital bronchial atresia: A time factor association. 2019 , 28, 100882		1
925	Pulmonary hypertension secondary to respiratory disease and/or hypoxia in dogs: Clinical features, diagnostic testing and survival. 2019 , 251, 105347		17
924	AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment. 2019 , 28, 71-79		11
923	Pulmonary Hypertension. 2019 , 439-447		
922	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. 2019 , 68, 71-75		8

921	Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. 2019 , 40, 519-529	7
920	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. 2020 , 59, 622-633	2
919	Successful right heart remodelling and subsequent pregnancy in a patient with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty: a case report. 2019 , 3,	3
918	EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. 2019 , 2045894019865704	4
917	Pulmonary Hypertension. 2019 , 919-944	
916	Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. 2019 , 28, 100893	3
915	Current organization of specialist pulmonary hypertension clinics: results of an international survey. 2019 , 9, 2045894019855611	1
914	Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia. 2019 , 45, e20180332	2
913	Lung-Kidney Cross-Talk. 2019 , 741-747.e2	
912	Clinical presentation and management of right ventricular dysfunction. 2019 , 19, 183-190	2
911	Relationship between pulmonary artery acceleration time and pulmonary artery pressures in infants. 2019 , 36, 1524-1531	7
910	Radiographic pulmonary vessel volume, lung function and airways disease in the Framingham Heart Study. 2019 , 54,	12
909	Pulmonary Hypertension and Exercise. 2019 , 40, 459-469	7
908	Exercise Pathophysiology in Interstitial Lung Disease. 2019 , 40, 405-420	7
907	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. 2019 , 8,	4
906	Response to Letter to the Editor Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). 2019 , 28, e149-e150	1
905	Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update. 2019 , 11, 71-85	4
904	Potential Contribution of Carotid Body-Induced Sympathetic and Renin-Angiotensin System Overflow to Pulmonary Hypertension in Intermittent Hypoxia. 2019 , 21, 89	9

903	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. 2019 , 32, 1574-1585	6
902	Management of Chronic Kidney Disease and End-Stage Kidney Disease Patients in the Intensive Care Unit. 2019 , 1286-1292.e3	1
901	Benefits of statins in chronic obstructive pulmonary disease patients with pulmonary hypertension: A meta-analysis. 2019 , 70, 39-42	1
900	Comparison of 4D Flow MRI to 2D Flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. 2019 , 14, e0224121	13
899	Histological hallmarks and role of Slug/PIP axis in pulmonary hypertension secondary to pulmonary fibrosis. 2019 , 11, e10061	9
898	Sensory consequences of critical inspiratory constraints during exercise in pulmonary arterial hypertension. 2019 , 261, 40-47	3
897	Clinical Evaluation for Myocardial Dysfunction in Right Ventricular Heart Disease Assessed by Feature Tracking MR Strain [Presidential Award Proceedings]. 2019 , 39, 48-54	
896	Congenital Heart Disease (II). 2019 , 118-154	
895	Increased risk of pulmonary hypertension following premature birth. 2019 , 19, 288	14
894	Bony Breathlessness: Reversible Pulmonary Hypertension in Melnick-Needles Syndrome Using Noninvasive Ventilation. 2019 , 140, 880-885	1
893	Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?. 2019 , 317, H1093-H1101	17
892	Assessing pulmonary hypertension in COPD. Is there a role for computed tomography?. 2019 , 14, 2065-2079	8
891	The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension. 2019 , 8,	9
890	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. 2019 ,	1
889	Aneurysm-type plexiform lesions form in supernumerary arteries in pulmonary arterial hypertension: potential therapeutic implications. 2019 , 317, L805-L815	5
888	Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease. 2019 , 49, 575-585	5
887	Autologous endothelial progenitor cell therapy improves right ventricular function in a model of chronic thromboembolic pulmonary hypertension. 2019 , 157, 655-666.e7	5
886	Diagnosis and treatment of pediatric pulmonary arterial hypertension. 2019 , 17, 161-175	5

885	Perioperative Management of Pulmonary Endarterectomy-Perspective from the UK National Health Service. 2019 , 33, 3101-3109	2
884	Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. 2019 , 124, 904-919	81
883	Birth Size and Gestational Age Specific Outcomes of Inhaled Nitric Oxide Therapy in Preterm Neonates with Clinically Diagnosed Pulmonary Hypertension. 2019 , 36, 1471-1480	1
882	Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method. 2019 , 76, 153-165	6
881	DAN plays important compensatory roles in systemic-to-pulmonary shunt associated pulmonary arterial hypertension. 2019 , 226, e13263	3
880	Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. 2019 , 6, 93	15
879	Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study. 2019 , 24, 7-19	4
878	A review of exercise pulmonary hypertension in systemic sclerosis.. 2019 , 4, 225-237	0
877	A focus on riociguat in the treatment of pulmonary arterial hypertension. 2019 , 125, 202-214	8
876	Pulmonary vascular disease and pulmonary hypertension. 2019 , 25, 304-312	5
875	Effects of drug abuse, smoking and alcohol on donor hearts and lungs. 2019 , 32, 1019-1027	5
874	Pulmonary Hypertension and ATP-Sensitive Potassium Channels. 2019 , 74, 14-22	14
873	CT Imaging of the Heart-Lung Axis. 2019 , 623-634	
872	Challenges in pulmonary hypertension associated with left heart disease. 2019 , 17, 461-472	1
871	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. 2019 , 9, 2045894019851696	5
870	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. 2019 , 124, 1551-1567	24
869	Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. 2019 , 71, 1691-1700	7
868	Active and Passive Vaccination for Pulmonary Arterial Hypertension: A Novel Therapeutic Paradigm. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2581-2583	15.1 2

867	Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis. 2019 , 19, 593-597	7
866	A RASSF1A-HIF1 β loop drives Warburg effect in cancer and pulmonary hypertension. 2019 , 10, 2130	34
865	Pulmonary hypertension and right ventricular function in Nigerian children with sickle cell anaemia. 2019 , 113, 489-496	1
864	Inflammation in pulmonary artery hypertension. 2019 , 118-119, 106562	6
863	Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension. 2019 , 45, 30-41	1
862	The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. 2019 , 9, 2045894019848649	4
861	Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension. 2019 , 7, 2324709619840375	3
860	Pulmonary arterial hypertension: A rare yet fatal complication of Neurofibromatosis Type 1. 2019 , 27, 100832	2
859	The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension. 2019 , 23, 511-524	11
858	"Treat-to-close": Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry. 2019 , 291, 127-133	20
857	Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature. 2019 , 7, 33-44	
856	Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. 2019 , 6, 24	12
855	Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report. 2019 , 12, 313-316	
854	Hemodynamic Evaluation and Echocardiography in the Oncologic Intensive Care Unit. 2019 , 1-21	
853	Pulmonary Hypertension in an Oncologic Intensive Care Unit. 2019 , 1-23	
852	Caspase-1 induces smooth muscle cell growth in hypoxia-induced pulmonary hypertension. 2019 , 316, L999-L1012	18
851	Diagnosis of pulmonary hypertension using spectral-detector CT. 2019 , 285, 80-85	9
850	Acute Vasoreactivity Testing during Cardiac Catheterization of Neonates with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. 2019 , 208, 127-133	16

849	Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. 2019 , 150, 126-130	7
848	Osteopontin plays important roles in pulmonary arterial hypertension induced by systemic-to-pulmonary shunt. 2019 , 33, 7236-7251	6
847	Echocardiography in Pulmonary Arterial Hypertension. 2019 , 21, 22	8
846	Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension. 2019 , 83, 1000-1010	5
845	Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review. 2019 , 10, 75	8
844	Role of BRCA1-associated protein (BRAP) variant in childhood pulmonary arterial hypertension. 2019 , 14, e0211450	2
843	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. 2019 , 10, 54	3
842	Decreased Ambient Oxygen Tension Alters the Expression of Endothelin-1, iNOS and cGMP in Rat Alveolar Macrophages. 2019 , 16, 443-449	4
841	Revisiting the role of hypoxia-inducible factors in pulmonary hypertension. 2019 , 7, 33-40	8
840	Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension. 2019 , 9, 2045894019840646	12
839	Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. 2019 , 16, 797-806	18
838	Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. 2019 , 9, 4061	21
837	Outcome of pregnancies in women with pulmonary hypertension: a single-centre experience from South India. 2019 , 126 Suppl 4, 43-49	10
836	Clinical implication of right-sided augmentation pressure in patients with pulmonary hypertension. 2019 , 9, 2045894019833352	
835	Bioinformatics and Drug Discovery. 2019 ,	1
834	A Bayesian Network Approach to Disease Subtype Discovery. 2019 , 1939, 299-322	1
833	Use of red cell distribution width in a population at high risk for pulmonary hypertension. 2019 , 150, 131-135	6
832	lloprost delivered via the BREELIB nebulizer: a review of the clinical evidence for efficacy and safety. 2019 , 13, 1753466619835497	5

831	Combined automated 3D volumetry by pulmonary CT angiography and echocardiography for detection of pulmonary hypertension. 2019 , 29, 6059-6068	9
830	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. 2019 , 156, 33-44	14
829	Genetics and clinics: current applications, limitations, and future developments. 2019 , 21, B7-B14	
828	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). 2019 , 83, 842-945	67
827	Critical Care of Patients After Pulmonary Thromboendarterectomy. 2019 , 33, 3110-3126	3
826	Preoperative Pulmonary Evaluation. 2019 , 103, 585-599	3
825	Atrial septal defect closure in adulthood is associated with normal survival in the mid to longer term. 2019 , 105, 1014-1019	17
824	Pulmonary arterial hypertension in adults with systemic right ventricles referred for cardiac transplantation. 2019 , 33, e13496	4
823	Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. 2019 , 5,	12
822	Double-lung versus heart-lung transplantation for precapillary pulmonary arterial hypertension: a 24-year single-center retrospective study. 2019 , 32, 717-729	14
821	Right ventricular function and dyssynchrony measured by echocardiography in dogs with precapillary pulmonary hypertension. 2019 , 23, 1-14	7
820	Clinical relevance of pulmonary vasculature involvement in sickle cell disease. 2019 , 185, 317-326	6
819	The Role of Type 2 Inflammation in -Induced Pulmonary Hypertension. 2019 , 10, 27	12
818	The Search for Disease-Modifying Therapies in Pulmonary Hypertension. 2019 , 24, 334-354	17
817	The predictors of complications in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 2019 , 93, E349-E356	17
816	Anesthesia for Patients with End-Stage Lung Disease. 2019 , 509-533	
815	Pulmonary Resection in the Patient with Pulmonary Hypertension. 2019 , 561-580	
814	Diseases of the Chest, Breast, Heart and Vessels 2019-2022. 2019 ,	3

813	Cardiovascular findings on cross-sectional imaging: spectrum of incidental and critical findings and clinical relevance for the abdominal radiologist. 2019 , 44, 1161-1180	2
812	Prevalence of Pulmonary Hypertension in Pediatric Patients With Obstructive Sleep Apnea and a Cardiology Evaluation: A Retrospective Analysis. 2019 , 15, 1081-1087	7
811	Formononetin attenuates monocrotaline-induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats. 2019 , 20, 4984-4992	9
810	Pulmonary Artery Hypertension after Arteriovenous Fistula Creation Subsequently Resolved by Closure of the Fistula. 2019 , 10, 109-114	
809	Increased Endothelin-1 Lung Level in Obesity Mice. 2019 , 1341, 072011	
808	A 34-Year-Old Woman with Fatigue. 2019 , 23-29	
807	Autoantibody clustering of lupus-associated pulmonary hypertension. 2019 , 6, e000356	5
806	Exploring a physiotherapy well-being review to deliver community-based rehabilitation in patients with pulmonary hypertension. 2019 , 9, 2045894019885356	3
805	Assessing Right Ventricular Function in the Perioperative Setting, Part II: What About Catheters?. 2019 , 37, 697-712	0
804	Essential Radiology Review. 2019 ,	1
803	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. 2019 , 10, 125-170	39
802	Outcome of adult congenital heart disease patients undergoing cardiac surgery: clinical experience of dr. Sardjito hospital. 2019 , 13, 16	2
801	The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. 2019 , 8, e014201	16
800	Management of Pulmonary Arterial Hypertension in the Pediatric Patient. 2019 , 21, 162	7
799	Pulmonary hypertension in pediatrics. A feasible approach to bridge the gap between real world and guidelines. 2021 , 34, 3820-3826	3
798	Preoperative balloon pulmonary angioplasty enabled noncardiac surgery of a patient with chronic thromboembolic pulmonary hypertension (CTEPH): A case report. 2019 , 98, e14807	3
797	Retrospective observational analysis of hospital discharge database to characterize primary pulmonary hypertension and its outcomes in Spain from 2004 to 2015. 2019 , 98, e15518	2
796	Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. 2019 , 9, 2045894019895414	10

795	[Exercise Training in Patients with Pulmonary Hypertension: A Systematic Review and Meta-analysis]. 2019 , 73, 677-685	5
794	A Review of Exercise Interventions in Pulmonary Arterial Hypertension and Recommendations for Rehabilitation Programing. 2019 , 39, 138-145	9
793	Bilateral lung transplantation after caesarean section in pregnancy with severe pulmonary arterial hypertension: A case report. 2019 , 98, e18109	2
792	Evaluation of Vascular Parameters in Patients With Pulmonary Thromboembolic Disease Using Dual-energy Computed Tomography. 2019 , 34, 367-372	7
791	Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine. 2019 , 131, 898-907	16
790	Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. 2019 , 29, 1565-1573	14
789	Right Ventricular Failure After Left Ventricular Assist Device Placement-The Beginning of the End or Just Another Challenge?. 2019 , 33, 1105-1121	14
788	Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal Medicine). 2019 , 58, 395-399	11
787	Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review. 2019 , 155, 680-688	14
786	The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study. 2019 , 199, 57-61	19
785	Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction. 2019 , 597, 1143-1156	13
784	Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension. 2019 , 97, 306-312	3
783	Pulmonary Hypertension During Pregnancy in New York State, 2003-2014. 2019 , 23, 277-284	3
782	TGF β and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. 2019 , 24, 703-716	43
781	Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. 2019 , 20, 668-676	10
780	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. 2019 , 36, 298-317	12
779	Redox Biology of Peroxisome Proliferator-Activated Receptor- γ In Pulmonary Hypertension. 2019 , 31, 874-897	9
778	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. 2019 , 53,	37

777	Electrocardiogram signs of right ventricular hypertrophy may help identify pulmonary hypertension in patients with dilated cardiomyopathy. 2019 , 22, 61-66	5
776	Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis. 2019 , 22, 507-515	1
775	Pulmonary hypertension in patients with a history of intravenous drug use. 2019 , 35, 1097-1101	
774	Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review. 2019 , 57, 183-190	10
773	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. 2019 , 33, 3670-3679	14
772	Current understanding and perioperative management of pediatric pulmonary hypertension. 2019 , 29, 441-456	16
771	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. 2019 , 199, 381-384	51
770	Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. 2019 , 9, 2045894018816294	13
769	Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines.. 2019 , 4, 35-42	9
768	The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach. 2019 , 208, 91-99	15
767	How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. 2019 , 17, 11-18	9
766	Serum cardiac troponin elevation predicts mortality in patients with pulmonary hypertension: A meta-analysis of eight cohort studies. 2019 , 13, 82-91	7
765	Gasometric gradients between blood obtained from the pulmonary artery wedge and pulmonary artery positions in pulmonary arterial hypertension. 2019 , 20, 6	2
764	Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. 2019 , 155, 565-586	126
763	Pulmonary Hypertension. 2019 , 327-341.e9	
762	An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence. 2019 , 13, 205-215	2
761	Iron Homeostasis in the Lungs-A Balance between Health and Disease. 2019 , 12,	30
760	Clinical features of canine pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. 2019 , 33, 114-123	7

759	Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension. 2019 , 39, 169-185	11
758	Assessment of quality of life in pediatric patients with pulmonary hypertension. 2019 , 9, 2045894018822985	6
757	Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. 2019 , 9, 2045894019826944	8
756	Evolution of hemodynamic forces in the pulmonary tree with progressively worsening pulmonary arterial hypertension in pediatric patients. 2019 , 18, 779-796	22
755	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. 2019 , 124, 846-855	48
754	Ovine Models of Congenital Heart Disease and the Consequences of Hemodynamic Alterations for Pulmonary Artery Remodeling. 2019 , 60, 503-514	10
753	Low-grade albuminuria in pulmonary arterial hypertension. 2019 , 9, 2045894018824564	6
752	Acute Kidney Injury in Patients With Chronic Kidney Disease. 2019 , 85-89.e2	0
751	MicroRNA-140-5p targeting tumor necrosis factor- β prevents pulmonary arterial hypertension. 2019 , 234, 9535-9550	23
750	Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. 2019 , 597, 1087-1101	18
749	Echocardiographic right ventricular strain from multiple apical views is superior for assessment of right ventricular systolic function. 2019 , 39, 168-176	8
748	Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. 2019 , 199, 891-902	45
747	Pulmonary hypertension in left heart disease. 2019 , 15, 262-273	14
746	Obesity and pulmonary hypertension. 2019 , 201-226	1
745	Clinical and hemodynamic factors in predicting response to fluid challenge during right heart catheterization. 2019 , 9, 2045894018819803	5
744	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. 2019 , 53,	1412
743	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. 2019 , 53,	209
742	Hemodynamic assessment of pulmonary hypertension in mice: a model-based analysis of the disease mechanism. 2019 , 18, 219-243	13

741	Right Heart Catheterisation: How To Do It. 2019 , 28, e71-e78	8
740	Hemostatic Aspects of Sickle Cell Disease. 2019 , 819-842	
739	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. 2019 , 46, 176-183	14
738	The burden of pulmonary hypertension in resource-limited settings. 2014 , 9, 297-310	13
737	Dasatinib-induced pulmonary arterial hypertension - A rare late complication. 2019 , 25, 727-730	1
736	Haemodynamically Derived Pulmonary Artery Pulsatility Index Predicts Mortality in Pulmonary Arterial Hypertension. 2019 , 28, 752-760	12
735	Pulmonary vascular disease is evident in gene regulation of experimental bronchopulmonary dysplasia. 2020 , 33, 2122-2130	3
734	Pulmonary hypertension with a low cardiac index requires a higher PaO level to avoid tissue hypoxia. 2020 , 25, 97-103	3
733	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension. 2020 , 119, 300-309	3
732	Equine congenital heart disease and respiratory disease interactions. 2020 , 32, 460-464	
731	The role of cardiac imaging in the management of non-ischemic cardiovascular diseases in human immunodeficiency virus infection. 2020 , 27, 801-818	
730	EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients?. 2018 , 2045894018785259	4
729	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. 2020 , 10, 2045894019880086	4
728	Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension. 2020 , 318, L98-L111	15
727	Effectiveness of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension despite having lesion types suitable for surgical treatment. 2020 , 75, 182-188	10
726	Molecular genetic framework underlying pulmonary arterial hypertension. 2020 , 17, 85-95	86
725	Assessment of Inflammation in Pulmonary Artery Hypertension by Ga-Mannosylated Human Serum Albumin. 2020 , 201, 95-106	13
724	Acute hypoxic pulmonary hypertension associated with right heart failure. 2020 , 75, 544-548	2

723	Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. 2020 , 106, 467-473	6
722	Role of inflammation, oxidative stress, and autonomic nervous system activation during the development of right and left cardiac remodeling in experimental pulmonary arterial hypertension. 2020 , 464, 93-109	12
721	Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. 2020 , 116, 2021-2030	10
720	Visible light-activated degradation of microcystin-LR by ultrathin g-C3N4 nanosheets-based heterojunction photocatalyst. 2020 , 103, 1281-1292	8
719	Obstructive sleep apnea and cardiovascular disease, a story of confounders!. 2020 , 24, 1299-1313	19
718	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 2020 , 35, 130-141	16
717	Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. 2020 , 300, 228-235	8
716	Echocardiography reporting of pulmonary hypertension and subsequent referral to a specialty clinic. 2020 , 37, 8-13	1
715	Pulmonary hypertension: Pathophysiology beyond the lung. 2020 , 151, 104518	13
714	Linking lncRNAs to regulation, pathogenesis, and diagnosis of pulmonary hypertension. 2019 , 1-15	3
713	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. 2020 , 34, 1506-1513	4
712	Pulmonary Artery Stenosis in a Patient with Prior Histoplasmosis and the Discovery of Complications. 2020 , 34, 832-834	0
711	Feasibility and safety of the antecubital venous access for right heart catheterization in patients with pulmonary hypertension. 2020 , 10, 2045894019875380	1
710	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. 2020 , 59, 932-943	6
709	Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. 2020 , 161, 105850	7
708	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. 2020 , 201, 707-717	40
707	Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea. 2020 , 10, 2045894019891912	7
706	The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers. 2020 , 10, 2045894019892801	11

705	Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. 2020 , 198, 87-94	3
704	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. 2020 , 11, 1623-1639	9
703	Morphologic and Functional Dual-Energy CT Parameters in Patients With Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Disease. 2020 , 215, 1335-1341	2
702	Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis. 2020 , 10, 204589402095415	
701	The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. 2020 , 17, 2594-2602	3
700	Successful treatment for a patient with chronic thromboembolic pulmonary hypertension comorbid with essential thrombocythemia with the JAK2 V617F mutation by balloon pulmonary angioplasty. 2020 , 31, 101235	
699	Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. 2020 , 10, 2045894020962917	3
698	Computed Tomography in the Evaluation of Pulmonary Hypertension. 2020 , 2, 17-36	
697	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. 2020 , 36, 977-992	12
696	Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). 2020 , 19, 102602	4
695	Emerging trends in inhaled drug delivery. 2020 , 157, 63-70	20
694	Vascular Metabolic Mechanisms of Pulmonary Hypertension. 2020 , 40, 444-454	2
693	The outcome of pulmonary hypertension and its association with pulmonary artery dilatation. 2020 , 28, 645-655	0
692	Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGFβ Signaling Pathway: Future Therapeutic Perspectives. 2020 , 7, 575608	3
691	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,	3
690	SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension. 2020 , 5, 1073-1092	1
689	Autophagy, Unfolded Protein Response and Lung Disease. 2020 , 1, 100003-100003	8
688	14 Vascular Diseases. 2020 ,	

687	Vital Roles of Gremlin-1 in Pulmonary Arterial Hypertension Induced by Systemic-to-Pulmonary Shunts. 2020 , 9, e016586	7
686	Prognostic value of pulmonary hypertension in pre-dialysis chronic kidney disease patients. 2020 , 52, 2329-2336	1
685	Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension. 2020 , 63, 652-664	12
684	Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. 2020 , 10, 2045894020911831	2
683	Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. 2020 , 10, 2045894020935291	3
682	A promising approach for screening pulmonary hypertension based on frontal chest radiographs using deep learning: A retrospective study. 2020 , 15, e0236378	8
681	Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature. 2020 , 76, 23-31	1
680	Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. 2020 , 112, 631-639	0
679	Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. 2020 , 10, 12864	12
678	Proceedings of the Intern Section of the Royal Academy of Medicine in Ireland (RAMI) on Saturday 1st February 2020, Venue: The Pillar Centre for Transformative Healthcare, Mater Misericordiae University Hospital, Dublin. 2020 , 189, 29-81	7
677	Targeting Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension (BPD-PH): Potential Role of the FGF Signaling Pathway in the Development of the Pulmonary Vascular System. 2020 , 9,	4
676	Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma. 2020 , 99, e22952	2
675	Pediatric Pulmonary Arterial Hypertension. 2020 , 67, 903-921	2
674	CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy. 2020 , 76, 1147-1160	5
673	Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. 2020 , 50, 1244-1254	6
672	Creatine Supply Attenuates Ischemia-Reperfusion Injury in Lung Transplantation in Rats. 2020 , 12,	1
671	CT-Based Biomarkers for Prediction of Chronic Thromboembolic Pulmonary Hypertension After an Acute Pulmonary Embolic Event. 2020 , 215, 800-806	6
670	Metformin in Pulmonary Hypertension in Left Heart Disease. 2020 , 7, 425	0

669	Experimental Rodent Models of Cardiovascular Diseases. 2020 , 7, 588075	3
668	Tromboendarterectomía pulmonar en pacientes con hipertensión pulmonar tromboembólica crónica y afectación distal. 2020 , 27, 230-235	
667	The impact of increased pulmonary arterial pressure on outcomes after transcatheter aortic valve replacement. 2020 , 96, E723-E734	5
666	Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency Departments. 2020 , 21, 714-721	2
665	Supervised pulmonary hypertension exercise rehabilitation (SPHERE): study protocol for a multi-centre randomised controlled trial. 2020 , 20, 143	1
664	Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. 2020 , 10, 316-324	8
663	miR-182-3p/Myadm contribute to pulmonary artery hypertension vascular remodeling via a KLF4/p21-dependent mechanism. 2020 , 10, 5581-5599	16
662	Sickle cell disease as a vascular disorder. 2020 , 13, 645-653	2
661	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. 2020 , 9,	8
660	An update on the diagnosis and treatment of pediatric pulmonary hypertension. 2020 , 21, 1253-1268	1
659	DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension. 2020 , 279, 103467	
658	Assessment of ventilation-perfusion scans in patients with chronic thromboembolic pulmonary hypertension before and after surgery and correlation with clinical parameters. 2020 , 66, 147-152	2
657	Right ventricular function parameters in pulmonary hypertension: echocardiography vs. cardiac magnetic resonance. 2020 , 20, 259	7
656	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. 2020 , 20, 154	
655	Effects of Different Types of Exercise Training on Pulmonary Arterial Hypertension: A Systematic Review. 2020 , 9,	8
654	The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension. 2020 , 225, 65-73.e5	8
653	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. 2020 , 9,	13
652	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. 2020 , 10, 2040003	2

651	Cardiac Considerations in Chronic Lung Disease. 2020 ,	0
650	Prognostic Value of Right Ventricular Two-Dimensional and Three-Dimensional Speckle-Tracking Strain in Pulmonary Arterial Hypertension: Superiority of Longitudinal Strain over Circumferential and Radial Strain. 2020 , 33, 985-994.e1	14
649	Severe Pulmonary Hypertension as Initial Presentation of SLE: A Case Report and Literature Review. 2020 , 2020, 6014572	1
648	Case 276: Pulmonary Veno-Occlusive Disease and Pulmonary Capillary Hemangiomatosis Disease. 2020 , 295, 240-244	1
647	Potential Contribution of Pulmonary Thromboembolic Disease in Pulmonary Hypertension in Sickle Cell Disease. 2020 , 17, 899-901	2
646	Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension. 2020 , 318, C913-C930	3
645	Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients. 2020 , 111, 877-887	2
644	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. 2020 , 75, 935-945	10
643	Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series. 2020 , 10, 2045894019898377	1
642	Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. 2020 , 10,	26
641	Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm. 2020 , 29, 486-491	2
640	Sugen-morphine model of pulmonary arterial hypertension. 2020 , 10, 2045894019898376	5
639	Identification of Key Players Involved in CoCl Hypoxia Induced Pulmonary Artery Hypertension. 2020 , 11, 232	9
638	Relationships between Pulmonary Hypertension Risk, Clinical Profiles, and Outcomes in Dilated Cardiomyopathy. 2020 , 9,	2
637	Pulmonary hypertension: The diagnostic and prognostic value of novel imaging techniques. 2020 , 61, 71-72	
636	Vascular Homeostasis and Inflammation in Health and Disease-Lessons from Single Cell Technologies. 2020 , 21,	4
635	New Model for Non-Invasive Echocardiographic Assessment of Pulmonary-Capillary Wedge Pressure in Patients With Aortic and Mitral Regurgitation. 2020 , 2, 914-918	1
634	Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. 2020 , 2, 328-336	3

633	Application of DynaCT angiographic reconstruction in balloon pulmonary angioplasty. 2020 , 30, 6950-6957	3
632	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. 2020 , 158, 2546-2555	5
631	Association of clinical predictors with recurrence of atrial fibrillation after catheter ablation. 2020 , 25, e12787	5
630	Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension. 2020 ,	1
629	ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. 2020 , 34, 549-573	62
628	Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. 2020 , 29,	14
627	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. 2020 , 6, 12-28	1
626	Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. 2020 , 17, 439-461	11
625	Effects of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension on remodeling in right-sided heart. 2020 , 36, 1053-1060	4
624	miR-1-5p targets TGF- β 1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension. 2020 , 15, e0229409	4
623	Pulmonary Hypertension in Patients Starting Peritoneal Dialysis. 2020 , 51, 254-260	0
622	Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension. 2020 , 158, 735-738	5
621	Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. 2020 , 158, 330-340	7
620	Identification of a pulmonary arterial hypertension (PAH) patient cohort and study of its burden of illness in Programme de Medicalisation des Systèmes d'information (PMSI). 2020 , 306, 175-180	4
619	Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations. 2020 , 48, e173-e191	25
618	Gender Differences in Risk Factors Associated With Pulmonary Artery Systolic Pressure, Heart Failure, and Mortality in Blacks: Jackson Heart Study. 2020 , 9, e013034	5
617	Physical Therapist Clinical Practice Guideline for the Management of Individuals With Heart Failure. 2020 , 100, 14-43	10
616	Computed Tomography Images of Fibrotic Pulmonary Sarcoidosis Leading to Chronic Respiratory Failure. 2020 , 9,	9

615	RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword. 2020 , 21,	5
614	Lung function in relation to six-minute walk test in pulmonary hypertension. 2020 , 7, 1745492	0
613	Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension. 2020 , 11, 1673	25
612	Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension. 2020 , 11, 145	8
611	Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside. 2020 , 10, 2045894020918846	11
610	miRNAs in Lung Development and Diseases. 2020 , 21,	12
609	Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension awaiting lung transplantation. 2020 , 15, e0227775	2
608	Complications in the adult asplenic patient: A review for the emergency clinician. 2021 , 44, 452-457	4
607	Gadolinium contrast balloon pulmonary angioplasty for a patient with chronic thromboembolic pulmonary hypertension and severe iodine allergy. 2021 , 97, E525-E531	1
606	Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension. 2021 , 26, 92-101	4
605	Anesthesia for Pregnant Women with Pulmonary Hypertension. 2021 , 35, 2201-2211	4
604	Absence of the MFG-E8 gene prevents hypoxia-induced pulmonary hypertension in mice. 2021 , 236, 587-600	4
603	Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. 2021 , 34, 891-914	12
602	Effect of Bariatric Surgery on the Cardiovascular System in Obese Cases with Pulmonary Hypertension. 2021 , 31, 523-530	2
601	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. 2021 , 57,	7
600	Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. 2021 , 26, 23-51	9
599	Pulmonary Manifestations of Congenital Heart Disease in Children. 2021 , 68, 25-40	1
598	Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. 2021 , 19, 1-20	3

597	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. 2021 , 178, 106220	10
596	Mitral Valve Surgery in Pulmonary Hypertension Patients: Is Minimally Invasive Surgery Safe?. 2021 , 111, 2012-2019	4
595	Unrecognized pulmonary arterial hypertension in hospitalized patients. 2021 , 37, 1237-1243	2
594	AAV1-Mediated shRNA Knockdown of in Rat Bronchus Attenuates Hypoxia-Induced Pulmonary Artery Remodeling. 2021 , 32, 796-805	0
593	Predictors of long intensive care need after lung transplantation. 2021 , 35, e14152	0
592	Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. 2021 , 57,	6
591	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. 2021 , 73, 295-304	10
590	Computed tomography appearances of the lung parenchyma in pulmonary hypertension. 2021 , 94, 20200830	3
589	Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. 2021 , 15, 1753466621995040	0
588	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. 2021 , 117, 2309-2325	10
587	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. 2021 , 100, 865-876	3
586	Sarcoidosis: Pitfalls and Challenging Mimickers. 2020 , 7, 594275	4
585	Pulmonary Hypertension. 2021 , 51-55	
584	Dyspnoea and diffuse pulmonary nodules in a patient with pulmonary veno-occlusive disease: a case report and literature review. 2021 , 49, 300060520986689	0
583	[Organ Bath Experiments on Human Pulmonary Vessels: Assessment of Drug Efficacy for Treatment of Pulmonary Arterial Hypertension]. 2021 , 75, 369-376	
582	Endogenous Retroviral Elements Generate Pathologic Neutrophils and Elastase Rich Exosomes in Pulmonary Arterial Hypertension.	2
581	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. 2021 , 452-462	
580	Targeting Molecular and Cellular Mechanisms in Pulmonary Hypertension. 2021 , 395-406	

579	Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. 2021 , 7,	4
578	Pulmonary Arterial Hypertension in Pregnancy. 2021 , 39, 109-118	3
577	Treatment effect prediction using CT after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. 2021 , 31, 5524-5532	
576	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. 2020 , 177, 106241	4
575	A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance. 2021 , 8, 1216-1229	8
574	Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice. 2021 , 14, 52	0
573	Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension. 2021 , 14, 113-124	0
572	Genetic deletion of CMG2 exacerbates systemic-to-pulmonary shunt-induced pulmonary arterial hypertension. 2021 , 35, e21421	
571	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. 2021 , 73, 837-847	9
570	The multisystem nature of isomerism: left isomerism complicated by Abernethy malformation and portopulmonary hypertension. 2021 , 31, 532-540	0
569	Endostatin and Vascular Endothelial Growth Factor-Ab May Contribute to Classification of Pulmonary Hypertension. 2021 , 3, 161-169	2
568	Preoperative Assessment and Perioperative Management of the Patient with Pulmonary Vascular Disease. 2021 , 42, 133-141	1
567	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. 2021 , 23, 352-380	143
566	Obesity, Systemic Hypertension, and Pulmonary Hypertension: A Tale of Three Diseases. 2021 , 46, 100599	4
565	Esclerosis sisthica. 2021 , 13, 1769-1778	
564	Endothelial Dysfunction and Disruption in Pulmonary Hypertension.	1
563	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension after Kidney Transplantation: Analysis of Linked U.S. Registry and Medicare Billing Claims. 2021 ,	2
562	Right ventricular stroke work index by echocardiography in adult patients with pulmonary arterial hypertension. 2021 , 21, 219	

561	Pulmonary arterial hypertension in pregnancy-a systematic review of outcomes in the modern era. 2021 , 11, 20458940211013671	6
560	Survival of Left-to-Right Shunt Repair in Children with Pulmonary Arterial Hypertension at a Tertiary Hospital in a Low-to-Middle-Income Country. 2021 , 16, 25	1
559	Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension. 2021 , 11, 20458940211010371	2
558	The Influence of Bosentan on MicroRNA-27a/PPAR γ /ET-1 Signaling Pathway in Pulmonary Artery Hypertension. 2021 , 42, 1141-1148	2
557	Universal Definition and Classification of Heart Failure. 2021 ,	84
556	Influence of atorvastatin on metabolic pattern of rats with pulmonary hypertension. 2021 , 13, 11954-11968	3
555	Pulmonary Arterial Dilatation: Imaging Evaluation Using Multidetector Computed Tomography. 2021 , 31, 409-420	0
554	Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling. 2021 , 77, 1787-1798	1
553	The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension. 2021 , 22,	6
552	The effects of oral pulmonary vasodilator therapy on poor candidates for fenestration closure in patients with a fontan circulation. 2021 , 3, 100090	
551	Transcatheter Closure of Atrial Septal Defect Associated With Pulmonary Artery Hypertension using Fenestrated Devices. 2021 , 147, 122-128	2
550	Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in Southern Taiwan: A Single-Center 10-Year Longitudinal Observation Cohort. 2021 , 9,	1
549	Direct influence of BMPR2 mutations on cytokine patterns and biomarker effectiveness in pulmonary arterial hypertension.	
548	Is it time for a paradigm shift: Should double-lung transplant be considered the treatment of choice for idiopathic pulmonary arterial hypertension and giant pulmonary aneurysm?. 2021 , 36, 2996-2999	3
547	Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases. 2021 , 100, e26483	1
546	Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. 2021 ,	1
545	Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES). 2021 , 11, 20458940211024206	0
544	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. 2021 ,	0

543	Role of 3D echocardiography-determined atrial volumes in distinguishing between pre-capillary and post-capillary pulmonary hypertension. 2021 , 8, 3975-3983	2
542	The role of imaging in pulmonary hypertension. 2021 , 11, 859-880	1
541	Anti-inflammatory role and mechanism of microRNA-92b-3p in the progression of hypoxic pulmonary hypertension. 2021 , 119725	0
540	2020 KSC/KATRD Guideline for the Diagnosis and Treatment of Pulmonary Hypertension: Executive Summary. 2021 ,	0
539	Pulmonary arterial hypertension associated with systemic scleroderma. 2021 , 99, 68-74	
538	A novel approach to perioperative risk assessment for patients with pulmonary hypertension. 2021 , 7,	0
537	Survival in severe pulmonary hypertension due to chronic lung disease: influence of in-hospital platelet distribution width. 2021 , 11, 20458940211026484	
536	Preoperative Cardiovascular Assessment of the Renal Transplant Recipient: A Narrative Review. 2021 , 10,	1
535	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. 2021 , 160, 1442-1458	4
534	Echocardiographic Ventricular Septal Motion Abnormalities Are Associated With Pre-Capillary Pulmonary Hypertension in Patients With Preserved Left Ventricular Function. 2022 , 31, 119-127	
533	Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. 2021 , 11, 2135-2190	2
532	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. 2021 ,	1
531	Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. 2021 ,	0
530	Quercetin and metabolic syndrome: A review. 2021 , 35, 5352-5364	20
529	Sickle Cell Disease and the Respiratory System: A Tangential Perspective to the Hematopulmonological Dilemma. 2021 , 13, e15562	
528	A Woman with a Repaired Atrial Septal Defect and Pulmonary Hypertension with Worsening Dyspnea. 2021 , 18, 1052-1058	
527	Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism. 2021 , 37, 1483-1491	1
526	Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK). 2021 , 15, 370-403	1

525	Different characteristics of mitochondrial dynamics-related miRNAs on the hemodynamics of pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension. 2021 , 78, 24-30	1
524	Changes in the Pulmonary Artery Wave Reflection in Dogs with Experimentally-Induced Acute Pulmonary Embolism and the Effect of Vasodilator. 2021 , 11,	4
523	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. 2021 , 40, 614-622	0
522	Predictive Modeling of Secondary Pulmonary Hypertension in Left Ventricular Diastolic Dysfunction. 2021 , 12, 666915	2
521	Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease. 2021 , 17, 145-151	1
520	Optimal aerobic exercise intensity and its influence on the effectiveness of exercise therapy in patients with pulmonary arterial hypertension: a systematic review. 2021 , 13, 4530-4540	0
519	Chronic Thromboembolic Pulmonary Hypertension Medical Management. 2021 , 17, e29-e33	1
518	Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension. 2021 , 11,	0
517	Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. 2021 , 13, e17291	
516	The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. 2021 , 12, 684657	5
515	Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure. 2021 , 12, 690341	6
514	Medical management of pulmonary arterial hypertension in pregnancy: A single center experience. 2021 , 4, 100145	0
513	Role of cardiovascular magnetic resonance in pediatric pulmonary hypertension-novel concepts and imaging biomarkers. 2021 , 11, 1057-1069	
512	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. 2021 , 21, 3388-3400	2
511	Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn. 2021 , 48, 595-618	2
510	Impact of Pulmonary Hypertension on In-Hospital Outcomes and 30-Day Readmissions Following Percutaneous Coronary Interventions. 2021 , 96, 2058-2066	0
509	Increased intracellular Cl concentration in pulmonary arterial myocytes is associated with chronic hypoxic pulmonary hypertension. 2021 , 321, C297-C307	0
508	Nerve Growth Factor: A Potential Therapeutic Target for Lung Diseases. 2021 , 22,	10

- 507 Improving guidance for the correctability of congenital cardiovascular shunts with increased pulmonary vascular resistance. **2021**, 4, 100184
- 506 Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. **2021**, 11, e045165
- 505 An Autopsy Case of Pulmonary Veno-Occlusive Disease Complicated with Chronic Obstructive Pulmonary Disease and Severe Pulmonary Hypertension. **2021**, 62, 1186-1190
- 504 How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. **2021**, 0
- 503 Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension. **2021**, 9, 0
- 502 Mediating effect of social support on the relationship between illness concealment and depression symptoms in patients with pulmonary arterial hypertension. **2021**, 50, 706-713 0
- 501 The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. **2021**, 186, 106525 0
- 500 Combined Methylmalonic Aciduria and Homocystinuria Presenting as Pulmonary Hypertension. **2021**, 88, 1244-1246
- 499 Case Report: -Targeted MinION Sequencing as a Tool for Genetic Analysis in Patients With Pulmonary Arterial Hypertension. **2021**, 8, 711694 0
- 498 Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension. **2021**, 12, 712583 1
- 497 Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with gene mutations.. **2021**, 11, 20458940211044577 1
- 496 Unenhanced computed tomography as a diagnostic tool in suspected pulmonary hypertension: a retrospective cross-sectional pilot study. 6, 249 0
- 495 "The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension". **2021**, 71, 102082 5
- 494 Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis. **2021**, 51, 1207-1218 1
- 493 Intensive care unit admission for patients with pulmonary hypertension presenting to U.S. Emergency Departments. **2021**, 50, 237-241
- 492 Common Co-Morbidities in Fibrosing Interstitial Lung Disease. **2022**, 79-87
- 491 Classification of Pulmonary Vascular Disease. **2022**, 560-566
- 490 Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension. **2021**, 1303, 57-69

489	Endothelial cells in the pathogenesis of pulmonary arterial hypertension. 2021 , 58,	30
488	The clinical presentation of systemic lupus erythematosus and laboratory diagnosis. 2021 , 305-323	
487	Clinical Outcome of Closure of a Small Atrial Septal Defect in a Patient with Pulmonary Arterial Hypertension. 2021 ,	
486	Pulmonary and Critical Care Medicine. 2021 , 325-338	
485	Preprocedure CT Findings of Right Heart Failure as a Predictor of Mortality After Transcatheter Aortic Valve Replacement. 2021 , 216, 57-65	5
484	Predicting mortality during long-term follow-up in pulmonary arterial hypertension. 2021 , 7,	3
483	Prostacyclin for pulmonary arterial hypertension. 2019 , 5, CD012785	18
482	Pulmonary Hypertension Associated with Connective Tissue Disease. 2014 , 139-166	1
481	Modern Diagnosis in the Evaluation of Pulmonary Vascular Disease. 2019 , 199-205	1
480	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. 2020 , 89-108	1
479	Pathophysiology and Pharmacotherapy of Adult Congenital Heart Disease. 2015 , 1269-1291	1
478	The Use of Embryonic Stem Cells and Induced Pluripotent Stem Cells to Model Pulmonary Arterial Hypertension. 2015 , 327-341	0
477	Historical Perspective on the Classification and Nomenclature of Pulmonary Hypertension. 2016 , 3-15	1
476	Animal Models of Pulmonary Hypertension. 2016 , 161-172	2
475	Novel Mechanisms of Disease: Network Biology and MicroRNA Signaling in Pulmonary Hypertension. 2016 , 123-133	2
474	Pathogenesis of Pulmonary Arterial Hypertension. 2017 , 385-401	0
473	Pulmonary Hypertension in Cardiac Surgery. 2018 , 39-48	1
472	Mitochondrial and Metabolic Drivers of Pulmonary Vascular Endothelial Dysfunction in Pulmonary Hypertension. 2017 , 967, 373-383	26

471	Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension. 2020 , 31-61	3
470	Mexican registry of pulmonary hypertension: REMEHIP. 2017 , 87, 13-17	2
469	An overview of the biology of a long-acting inhaled treprostinil prodrug. 2020 , 65, 102002	4
468	Pulmonary hypertension in pregnancy: experience from 45 cases at a tertiary care center. 2020 , 1-6	4
467	Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. 2016 , 6, 498-507	12
466	Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report. 2021 , 5, ytaa454	2
465	Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits. 2021 , 28, 127-136	2
464	New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways. 2017 , 23, 377-385	11
463	Gamma heavy chain disease complicated by pulmonary hypertension, which was successfully treated with lenalidomide. 2020 , 13,	0
462	Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis. 2016 , 6, e011921	25
461	Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site. 2020 , 2020, 7265487	10
460	PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. 2017 , 121, 1136-1139	58
459	Pumping it up! Angiogenesis and muscle deconditioning in pulmonary hypertension. 2014 , 190, 250-1	3
458	An Hb-mediated circulating macrophage contributing to pulmonary vascular remodeling in sickle cell disease. 2019 , 4,	9
457	Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. 2018 , 3,	25
456	Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. 2018 , 128, 3704-3715	52
455	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. 2016 , 126, 3207-18	144
454	Endoplasmic reticulum stress and pulmonary hypertension. 2020 , 10, 2045894019900121	5

453	Virtual echocardiography screening tool to differentiate hemodynamic profiles in pulmonary hypertension. 2020 , 10, 2045894020950225	4
452	Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy. 2021 , 7,	0
451	Epidemiology of pulmonary hypertension in the elderly. 2017 , 14, 11-16	6
450	Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertension - Multicenter Study in Japan. 2020 , 2, 255-259	3
449	How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertension - A Report From a Referral Center in Japan. 2020 , 2, 526-530	3
448	Controversies in pulmonary hypertension due to left heart disease. 2015 , 7, 07	13
447	Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients. 2015 , 11, 259-65	15
446	Exercise tolerance improves after pulmonary rehabilitation in pulmonary hypertension patients. 2017 , 13, 214-217	11
445	Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. 2014 , 9, e115219	14
444	Exercise Physiology and Pulmonary Hemodynamic Abnormality in PH Patients with Exercise Induced Venous-To-Systemic Shunt. 2014 , 10, e0121690	13
443	Mutation in BMPR2 Promoter: A 'Second Hit' for Manifestation of Pulmonary Arterial Hypertension?. 2015 , 10, e0133042	20
442	Altered Right Ventricular Kinetic Energy Work Density and Viscous Energy Dissipation in Patients with Pulmonary Arterial Hypertension: A Pilot Study Using 4D Flow MRI. 2015 , 10, e0138365	29
441	Autoimmune disease mouse model exhibits pulmonary arterial hypertension. 2017 , 12, e0184990	9
440	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. 2017 , 12, e0187734	13
439	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. 2018 , 13, e0195047	7
438	PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM. 2018 , 56, 474-485	3
437	Screening for connective tissue disease in pulmonary arterial hypertension. 2014 , 107, 666-9	3
436	Treatment of pulmonary hypertension in three patients with β -thalassemia intermedia using pulmonary arterial hypertension-specific medications. 2016 , 16, 64-6	2

435	Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clinical outcome and survival in pulmonary hypertension groups (SIMURG). 2017 , 18, 242-250	8
434	Pulmonary Arterial Hypertension in Women. 2017 , 13, 224-237	8
433	Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension. 2017 , 14, 190-199	28
432	The role of preoperative sildenafil therapy in controlling of postoperative pulmonary hypertension in children with ventricular septal defects. 2017 , 9, 179-182	6
431	Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. 2018 , 7, 43-48	37
430	Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. 2020 , 53, e20190418	4
429	Impact of pulmonary hypertension on the effectiveness of Cox Maze IV procedure in patients with mitral valve disease and concomitant atrial fibrillation. 2020 , 13, 230	1
428	[The concurrence of kidney and liver dysfunctions in decompensated heart failure]. 2016 , 88, 40-44	1
427	[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]. 2017 , 89, 100-103	2
426	[Circular Sympathetic Pulmonary Artery Denervation in Cardiac Surgery Patients With Mitral Valve Defect, Atrial Fibrillation and High Pulmonary Hypertension]. 2020 , 60, 35-42	4
425	Pulmonary hypertension in sarcoidosis. 2017 , 26, 725-735	3
424	Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression. 2016 , 7, 81241-81254	6
423	<Editors' Choice> Pulmonary Hypertension: Diagnosis, Management, and Treatment. 2019 , 81, 19-30	9
422	Pulmonary hypertension: a long-term risk stratifier in primary mitral regurgitation. 2016 , 4, 541	1
421	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. 2013 , 12, 127-134	1
420	Pulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care. 2014 , 12, 186-192	2
419	Classification of Pulmonary Hypertension. 2014 , 13, 17-20	1
418	Prognostication in Pulmonary Arterial Hypertension and Use of Current Risk Prediction Models. 2015 , 14, 37-43	1

417	Overview of WHO Group 2 Pulmonary Hypertension Due to Left Heart Disease. 2015 , 14, 70-78	4
416	Current and Emerging Biomarkers for Pulmonary Hypertension. 2018 , 16, 136-140	1
415	A Rare Opportunity in a Rare Disease. 2018 , 16, 175-178	1
414	The Basic Science of Metabolism in Pulmonary Arterial Hypertension. 2018 , 17, 95-102	6
413	Genotypes and Phenotypes: Making Progress Toward a Precision Medicine Approach in Pediatric Pulmonary Hypertension. 2018 , 17, 153-158	1
412	Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function. 2019 , 15, 3-11	2
411	Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review. 2020 , 16, 231-240	3
410	Four-Dimensional Flow Magnetic Resonance Imaging for Cardiovascular Imaging: from Basic Concept to Clinical Application. 2018 , 2, 85	3
409	The obesity paradox: the protective effect of obesity on right ventricular function using echocardiographic strain imaging in patients with pulmonary hypertension. 2018 , 66, 523-527	2
408	[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat]. 2020 , 92, 77-84	3
407	Dynamics of echocardiography parameters after circular PADN procedure in patients with mitral valve defects, atrial fibrillation, and high pulmonary hypertension. 2019 , 34, 129-143	1
406	Current and emerging therapeutic approaches to pulmonary hypertension. 2020 , 21, 163-179	20
405	Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations. 2015 , 4, Doc03	3
404	Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease - 2020. 2020 , 114, 849-942	2
403	Effects of 17 β -estradiol and 2-methoxyestradiol on the oxidative stress-hypoxia inducible factor-1 pathway in hypoxic pulmonary hypertensive rats. 2017 , 13, 2537-2543	15
402	Survival benefits of warfarin in Korean patients with idiopathic pulmonary arterial hypertension. 2015 , 30, 837-45	4
401	Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. 2015 , 7, 309-19	20
400	Clinical manifestations of sleep apnea. 2015 , 7, E298-310	48

399	A review of imaging modalities in pulmonary hypertension. 2017 , 12, 61-73	28
398	Severe pulmonary hypertension and right ventricular failure. 2017 , 61, 753-759	6
397	Pulmonary hypertension and post-operative outcome in renal transplant: A retrospective analysis of 170 patients. 2018 , 62, 131-135	4
396	Elevated Mean Pulmonary Artery Pressure and Right Ventricular Dysfunction in Children with Chronic Kidney Disease. 2018 , 28, 109-113	0
395	Successful pulmonary thromboendarterectomy in a patient with sickle cell disease and associated resolution of a leg ulcer. 2018 , 35, 73-77	1
394	MicroRNA and Cardiovascular Diseases. 2020 , 37, 60-71	31
393	Pulmonary hypertension and metabolic syndrome: Possible connection, PPAR α and Caveolin-1. 2014 , 6, 692-705	10
392	Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation. 2015 , 7, 671-84	8
391	Pulmonary hypertension in hereditary haemorrhagic telangiectasia. 2015 , 7, 230-7	28
390	Hematological disorders and pulmonary hypertension. 2016 , 8, 703-718	32
389	Transesophageal Echocardiographic Approach to a Patient with Suspected Pulmonary Hypertension in the Intraoperative Period. 2017 , 5, 49-63	1
388	Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?. 2015 , 4, 274-7	1
387	Pulmonary Arterial Hypertension: A Two-Dimensional Echocardiographic Approach from Screening to Prognosis. 2016 , 4,	1
386	Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study. 2017 , 28, 370-376	2
385	Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. 2018 , 29, 208-212	9
384	. 2017 , 109, 1-76	119
383	Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. 2018 , 10, e2072	10
382	Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. 2019 , 11, e4327	6

- 381 Detection of patients with chronic thromboembolic pulmonary hypertension by volumetric iodine quantification in the lung-a case control study.. **2022**, 12, 1121-1129 2
- 380 Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography. **2021**, 8, 100384 0
- 379 Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. **2021**, 93, 1106-1116 1
- 378 Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry. **2021**, 26, 1171-1180 0
- 377 Endothelial Dec1-PPAR α Axis Impairs Proliferation and Apoptosis Homeostasis Under Hypoxia in Pulmonary Arterial Hypertension. **2021**, 9, 757168 0
- 376 Effects of different anesthesia methods on maternal and neonatal outcomes in pregnant patients with pulmonary arterial hypertension: a meta-analysis. **2021**, 1 0
- 375 Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies.. **2021**, 11, 20458940211057891 0
- 374 Established pulmonary hypertension in rats was reversed by a combination of a HIF-2 β antagonist and a p53 agonist. **2021**, 1 1
- 373 Assessment and Clinical Relevance of Right Ventricular Failure in Pulmonary Arterial Hypertension. **2014**, 223-242 1
- 372 Hypoxic Pulmonary Hypertension. **2014**, 1-49 1
- 371 PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved. **2014**, 13, 65-67 1
- 370 [Clinical utility of inhaled iloprost in pulmonary arterial hypertension]. **2014**, 84, 202-10 1
- 369 [Chronic obstructive pulmonary disease: a cardiologist's point of view]. **2014**, 155, 1480-4 1
- 368 Pulmonary Hypertension in Orphan Lung Diseases. **2015**, 529-539 1
- 367 Pathophysiology and Treatment of Pulmonary Arterial Hypertension. **2015**, 949-974 1
- 366 [Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan]. **2015**, 87, 64-71 1
- 365 Pulmonary Hypertension in the Elderly: Impact of Age on Diagnosis and Therapy Options. **2015**, 109-133 1
- 364 Approach to the Patient with Elevated Pulmonary Arterial Pressure. **2015**, 165-201 1

- 363 Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: Clinical Relevance, Management, and Future Directions. **2015**, 14, 88-94
- 362 Sarcoidosis-Associated Pulmonary Hypertension. **2015**, 125-134
- 361 Selected Disorders of the Respiratory System. **2015**, 1-17
- 360 Pulmonary Hypertension in Chronic Myeloproliferative Disorders. **2015**, 14, 150-154
- 359 Portopulmonary Hypertension and Hepatopulmonary Syndrome with Congenital Portosystemic Venous Shunt. **2015**, 31, 223-226 0
- 358 Pulmonary Vascular Capacitance as a Predictor of Vasoreactivity in Idiopathic Pulmonary Arterial Hypertension Tested by Adenosine. **2015**, 4, e28945 0
- 357 [Inhaled iloprost, a selective pulmonary vasodilator. Clinical evidence from its use in perioperative pulmonary hypertension cardiovascular surgery]. **2015**, 85, 136-44 1
- 356 [Pulmonary arterial hypertension associated to human immunodeficiency virus]. **2015**, 85, 118-23
- 355 Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. **2016**, 16, 491-496 2
- 354 Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community. **2016**, 63-79
- 353 The Defining Characteristics of Pulmonary Arterial Hypertension. **2016**, 17-28
- 352 The Right Heart. **2016**, 145-168
- 351 [Risk factors for pulmonary hypertension at the predialysis stage of chronic kidney disease]. **2016**, 88, 33-39
- 350 Liver and Lung Diseases: Hepatopulmonary Syndrome and Portopulmonary Hypertension. **2016**, 203-220
- 349 Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. **2016**, 29-61
- 348 Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators. **2016**, 307-325 1
- 347 Assessment of Pulmonary Vascular Disease. **2016**, 337-346
- 346 [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension]. **2016**, 88, 89-97

345 Pulmonale Hypertonie. **2016**, 313-329

344 [Programs for Continuing Medical Education: B session; 2. Pulmonary hypertension--Up to date]. **2016**, 105, 477-81

343 Hepatopulmonary Syndrome and Portopulmonary Hypertension. **2016**, 1-24

342 Wood units \square m² or Wood units/m²: does it matter?. **2016**, 16, 360

0

341 Potassium Channels in Pulmonary Arterial Hypertension. **2016**, 32, 189-198

340 Comorbidities and Complications of Idiopathic Pulmonary Fibrosis. **2016**, 67-79

339 CT Imaging of the Heart-Lung Axis. **2016**, 379-392

338 Pulmonary Hypertension Induced by Thalidomide (and Derivatives) in Patients with Multiple Myeloma: A Systematic Review. **2016**, 07, 971-978

1

337 Pulmonary hypertension in children: a global perspective. **2016**, 619-634

336 The Modern View on the Problem of Respiratory Lesions in Patients with Liver Cirrhosis. Clinical Case Description. **2016**, 1, 43-57

335 Group 5 pulmonary hypertension with unclear and/or multifactorial mechanisms. **2016**, 572-576

334 Cor pulmonale chronicum. **2016**, 18, 83-86

333 Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?. **2016**, 31, 345-51

1

332 Pulmonary and Critical Care Medicine. **2017**, 325-337

331 Clinical Assessment of Pulmonary Hypertension. **2017**, 403-409

330 Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population. **2017**, 16, 68-75

329 Perspectives on Shunts in Pulmonary Arterial Hypertension: From Interventions to Create Shunts to the Concept of "treat-and-Repair" **2017**, 267-278

328 Systemic Sclerosis and Other Connective Tissue Diseases. **2017**, 16, 55-60

- 327 Advanced Therapies for the Pharmacological Treatment of Pediatric Pulmonary Arterial Hypertension. **2017**, 33, 297-311
- 326 Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. **2017**, 16, 20-25
- 325 Surgically Curable Pulmonary Hypertension. **2017**, 1, 79-83
- 324 Right Heart Failure. **2017**, 161-173
- 323 Pulmonary Arterial Hypertension in Patients with Previous Reparative Surgery. **2017**, 61-68 1
- 322 Segmental Pulmonary Hypertension. **2017**, 69-89
- 321 Pathology of Vascular Changes in Interstitial Lung Diseases. **2017**, 45-66
- 320 PAH in ACHD: Research, Global Perspective and Future Prospects. An Epilogue. **2017**, 363-368
- 319 Rare Case of Membranous Obstruction at the Origin of Left Pulmonary Artery: Role of Perioperative Echocardiography to Evaluate the Anatomy of Pulmonary Artery. **2017**, 5, 74-76
- 318 Pulmonary Hypertension in Left Heart Disease. **2017**, 341-369
- 317 PAH in Patients with Prevalent Systemic Pulmonary Shunts and PAH in Patients with Small Cardiac Defects. **2017**, 45-60 1
- 316 Interstitial Lung Disease-Associated Pulmonary Hypertension in the Connective Tissue Disorders. **2017**, 165-180
- 315 The Problem of the Preterm Lung: Definitions, History, and Epidemiology. **2017**, 1-14
- 314 Notoginsenoside R_1 Attenuates Hypoxia and Hypercapnia-Induced Vasoconstriction & In Vitro by Reducing the Expression of p38. **2017**, 05, 1-10
- 313 Treatment of Pulmonary Hypertension in Interstitial Lung Disease. **2017**, 67-84
- 312 Architecture générique de l'hypertension pulmonaire : des gènes aux médicaments. **2017**, 201, 879-893
- 311 Pulmonary Arterial Hypertension. **2017**,
- 310 DLI Induced by Herbal Medicine: What Are the Characteristics of DLI due to Herbal Medicines?. **2018**, 177-199

- 309 Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment. **2017**, 27, 216-231 1
- 308 Anticoagulation increases survival in patients with idiopathic pulmonary arterial hypertension. **2017**, 3,
- 307 Autopsy Findings in A Case of Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. **2017**, 18, 1401-1406 1
- 306 Computed Tomography. **2018**, 183-210
- 305 Cardiovascular Assessment. **2018**, 107-136
- 304 Pulmonary Vascular Diseases: Pulmonary Hypertension and HHT—What Are the Roles of Genetic Factors in the Pathogenesis of Pulmonary Vascular Diseases?. **2018**, 161-167
- 303 Pulmonary Pathology. **2018**, 367-372
- 302 OBSOLETE: Pulmonary Arterial Hypertension. **2018**,
- 301 Eisenmenger's Syndrome. **2018**, 185-187
- 300 Case 4 - A 59-Year-Old Woman with Rheumatic Mitral Valve Disease (Severe Stenosis and Regurgitation), Severe Dyspnea, Shock and Pulmonary Condensation. **2018**, 111, 215-222
- 299 Pulmonary Vascular Disease: Specific Evaluation and Timing for Listing Eligible Patients to Receive Lung Transplantation and Management of the Pre-lung Transplant Patient. **2018**, 71-84
- 298 THE CLINICAL INTELLECTION DEVELOPMENT (BASED ON CBCR MODEL) IN INTERNAL MEDICINE BY CLINICAL CASE EXAMPLE: PRELIMINARY PULMONARY HYPERTENSION. **2018**, 1, 226
- 297 OBSOLETE: Pregnancy and Cardiovascular Disease. **2018**,
- 296 Pulmonale Hypertonie. **2018**, 211-218
- 295 Cardiovascular Syndrome: A rare cause of hoarseness in a patient with a history of pulmonary tuberculosis. **2017**, 17, e481-e483
- 294 Stimulants and Pulmonary Arterial Hypertension: An Update. **2018**, 17, 49-54 1
- 293 Anorexigen-Associated Pulmonary Arterial Hypertension and the Serotonin Hypothesis: A Story Worth Telling. **2018**, 17, 63-68
- 292 Pulmonary Hypertension in Pregnancy. **2018**, 499-502

- 291 Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism. **2018**, 20, 174-181 4
- 290 Pulmonary Arterial Hypertension. **2018**, 129-142
- 289 OBSOLETE: Pulmonary Hypertension Associated with Left-Sided Heart Disease. **2018**,
- 288 PH Grand Rounds: A Successful Case of Extracorporeal Membrane Oxygenation As a Bridge to Recovery. **2018**, 16, 201-204
- 287 V. Pulmonary Hypertension Associated with Respiratory Diseases. **2018**, 107, 226-233
- 286 Overview of Pulmonary Hypertension and Nice Classification. **2018**, 107, 191-194
- 285 III. The Particularity of CTD-PH Management. **2018**, 107, 214-218
- 284 Combination therapy is a new standard for treatment of pulmonary arterial hypertension. **2018**, 90, 72-80 3
- 283 Pulmonary hypertension (2013 classification).
- 282 CONTEMPORARY STRATEGY OF PULMONARY HYPERTENSION MANAGEMENT IN PEDIATRICS. **2018**, 17, 101-124 1
- 281 Clinics in diagnostic imaging (186). Atrial septal defect with pulmonary arterial hypertension. **2018**, 59, 279-283
- 280 The Effect of Epicardial Fat on the Right and Left Ventricular Function in Subjects with Various Etiological Types of Pulmonary Arterial Hypertension. **2018**, 3, 84-89 2
- 279 Continuous infusion of epoprostenol as salvage therapy for severe pulmonary arterial hypertension. **2018**, 4,
- 278 Principles of pharmacological correction of pulmonary arterial hypertension. **2018**, 4, 59-76 1
- 277 Organization of pharmacological support of patients with rare diseases in moscow as exemplified by pulmonary arterial hypertension. **2018**, 24-31 1
- 276 A STUDY OF W.H.O. GROUP II PULMONARY HYPERTENSION BY ECHOCARDIOGRAPHY IN A TERTIARY CARE INSTITUTE, TAMILNADU, SOUTH INDIA. **2018**, 5, 2837-2841
- 275 AN EPIDEMIOLOGICAL STUDY OF PULMONARY HYPERTENSION BY ECHOCARDIOGRAPHY IN TERTIARY CARE INSTITUTE, TAMILNADU, SOUTH INDIA. **2018**, 7, 3950-3953
- 274 Impact of Pulmonary Arterial Hypertension on Left Ventricular Function [A Comparative Study between Scleroderma and Coronary Artery Disease. **2018**, 3, 173-180

- 273 Evaluation of endothelial nitric oxide synthase gene expression in mice genetically heterozygous in Cx43 (Cx43 + / - mice).
- 272 Pulmonary Hypertension. **2019**, 231-250
- 271 . **2018**, 58, 93-100
- 270 [Pulmonary arterial hypertension associated with human immunodeficiency virus: thirty years after its description]. **2018**, 88, 503-506
- 269 Estimation of Endostatin level in pulmonary arterial hypertension patients and its relation with some parameters. **2018**, 31, 170-179
- 268 PULMONARY HYPERTENSION IN PEDIATRIC PRACTICE. **2018**, 25, 192-200 1
- 267 PADN procedure in patients with mitral valve disease, atrial fibrillation and high pulmonary hypertension. **2019**, 12, 450
- 266 Pulmonale Hypertonie. **2019**, 110-117
- 265 Pulmonary Hypertension in General Cardiology Practice. **2019**, 113, 419-428 2
- 264 Moving Beyond the Endothelium is Still Challenging-Complex Interplay between Endothelin and Reactive Oxygen Species in Pulmonary Arterial Hypertension. **2019**, 49, 877-878
- 263 Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients. **2019**, 27, 257-265 0
- 262 Pulmonary Artery Hypertension. **2019**, 245-248
- 261 Pneumologie. **2019**, 457-525
- 260 Oxidative Stress in Pulmonary Artery Hypertension. **2019**, 393-402
- 259 Percutaneous Device Closure of Patent Ductus Arteriosus in Adult Patients with 10-Year Follow-up. **2019**, 20, 139-145 0
- 258 Pulmonary Hypertension. **2019**, 289-307
- 257 Pulmonale Hypertonie bei Kindern und Jugendlichen. **2019**, 1-6
- 256 Diagnostic Work-Up of Pulmonary Hypertension - Think About Shunt Flow! A Case Report. **2019**, 20, 154-158 1

- 255 The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!. **2019**, 14, 189-203
- 254 A CLINICO-ETIOLOGICAL STUDY OF PULMONARY HYPERTENSION IN ADULTS IN A RURAL TERTIARY CARE HOSPITAL. **2019**, 8, 685-688
- 253 Pressure vs Flow-Induced Pulmonary Hypertension. **2019**, 18, 19-24 1
- 252 Relationship Between Preoperative Diastolic Transpulmonary Gradient With Pulmonary Vascular Resistance and 1-Year and Overall Mortality Rates Among Patients Undergoing Cardiac Transplant. **2019**, 17, 231-235 1
- 251 Pediatric Pulmonary Hypertension and Relevant Experimental Animal Models: Pulmonary Arterial Hypertension, Bronchopulmonary Dysplasia and Congenital Diaphragmatic Hernia. **2019**, 35, 99-111
- 250 Postoperative pulmonary complications in contemporary cohort of patients with pulmonary hypertension. **2019**, 19, 392-399 3
- 249 Perioperative anesthetic considerations in patients with pulmonary hypertension undergoing non-cardiac and non-obstetric surgeries. **2019**, 2, 31-39 1
- 248 Heart Disease in Pregnancy. **2020**, 237-283 0
- 247 Current Clinical Management and Basic Research in Pediatric Pulmonary Hypertension. **2019**, 35, 136-152
- 246 Pulmonary Hypertension in an Oncologic Intensive Care Unit. **2020**, 675-697
- 245 Pulmonary involvement in antiphospholipid syndrome. **2019**, 124-139
- 244 Relationship between right atrium area and right ventricular ejection fraction on magnetic resonance imaging: comparison with other prognostic markers in patients with pulmonary arterial hypertension. **2019**, 52, 351-355 1
- 243 Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay. **2019**, 18, 141-151 0
- 242 Echocardiography in the ICU. **2020**, 1-24
- 241 Pulmonary arterial hypertension in the elderly: Clinical perspectives. **2020**, 27, 184-193 1
- 240 Pulmonary hypertension associated with congenital heart disease. **2020**, 313-332
- 239 Near syncope is not always benign. **2020**, 211-226
- 238 Association of Pulmonary Hypertension With End-Stage Renal Disease Among the Obese Population. **2020**, 12, e9722

- 237 Evolving Paradigms in the Treatment of Atrial Septal Defects With Pulmonary Arterial Hypertension. **2021**, 29, 305-309
- 236 Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. **2021**, 12, 6177 5
- 235 Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. **2021**, 0
- 234 Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension. **2021**, 10, 0
- 233 Pulmonale Hypertonie. **2020**, 2095-2100
- 232 Pulmonary hypertension. **2020**, 3695-3710
- 231 Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2021**, 23, 442-454
- 230 Imaging of Pulmonary Hypertension in Congenital Heart Disease. **2021**, 499-514
- 229 Pulmonary arterial hypertension (PAH) related to congenital heart disease (CHD): introducing the CHAMPION supplement. **2020**, 4,
- 228 Multimodality Imaging of Pulmonary Hypertension: Prognostication of Therapeutic Outcomes. **2021**, 225-257
- 227 Effect of EZH2 on pulmonary artery smooth muscle cell migration in pulmonary hypertension. **2021**, 23, 2
- 226 Compromiso torácico de la sarcoidosis en tomografía computarizada: claves clínicas y radiológicas. **2020**, 31, 5447-5458
- 225 The Association and Mechanism between Obstructive Sleep Apnea and Systemic/Pulmonary Hypertension. **2020**, 2, 155-159
- 224 Pulmonary Hypertension and Pregnancy. **2020**, 74-83
- 223 WNT Signalling in Lung Physiology and Pathology. **2021**, 269, 305-336 3
- 222 Pulmonary Hypertension. **2020**, 149-163
- 221 Hemodynamic Evaluation and Echocardiography in the Oncologic Intensive Care Unit. **2020**, 753-773
- 220 The Protective Effect of The Interleukin 1 Receptor Antagonist on Chronic Thromboembolic Pulmonary Hypertension Model. **2019**, 73, 944-950

219 Epidemiology of Pediatric Pulmonary Hypertension. **2020**, 1-17

218 Imaging in Chronic Lung Disease: Cardiac Considerations. **2020**, 97-114

217 Effect of Obesity on Pulmonary Vascular Hemodynamics. **2020**, 30, 75-81

216 Hypertensive Vascular Diseases. **2020**, 247-261

215 How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?. **2021**, 25, 30-35

214 Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. **2020**, 123-134 1

213 Specialized Smooth Muscle Cell Progenitors in Pulmonary Hypertension. **2020**, 25-30

212 Chronic Pulmonary Hypertension. **2020**, 465-489

211 Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. **2020**, 61-70

210 Chronic thromboembolic pulmonary hypertension in patients with persistent chest symptoms after acute pulmonary embolism. **2021**, 25, 24-29 0

209 Hypertension and Vasculopathies. **2020**, 565-580

208 Hypertension pulmonaire. **2020**, 159-165

207 Leberzirrhose und deren Komplikationen. **2020**, 345-375

206 ERKRANKUNGEN DER ATMUNGSORGANE. **2020**, C-1-C22-4

205 Pulmonary hypertension - prevalence, risk factors, and its association with vascular calcification in chronic kidney disease and hemodialysis patients. **2020**, 31, 380-387 2

204 Hyponatremia Associated with Pulmonary Arterial Hypertension: Syndrome of Inappropriate Antidiuresis Versus Right Heart Failure. **2020**, 18, 40-43

203 Pulmonary Hypertension. **2020**, 365-378

202 Therapeutic Advances in the Management of Pulmonary Arterial Hypertension. **2020**, 1-23

201	Long-Term Outcomes and Factors Associated with Mortality in Patients with Moderate to Severe Pulmonary Hypertension in Kenya. 2020 , 15, 6	1
200	Evaluation of the Results of Balloon Pulmonary Angioplasty in Patients with Chronic Distal Pulmonary Thromboembolic Disease and Pulmonary Hypertension. 2021 , 06, 157-164	1
199	Cirug� de tromboendarterectom� pulmonar en un paciente con hipertensi� pulmonar tromboemb�lica cr�nica. Estudio de imagen card�ca. 2020 , 3, 49-52	
198	Predictive modeling of secondary pulmonary hypertension in left ventricular diastolic dysfunction.	0
197	Demographics and Risk Factors of Pediatric Pulmonary Hypertension Readmissions. 2021 , 13, e18994	1
196	Prevalence of pulmonary hypertension among children with Down syndrome: A systematic review and meta-analysis. 2021 , 10, 177-191	1
195	The relationship of obstructive sleep apnea and cardiovascular diseases from the perspective of evidence-based medicine. Part 1. 2020 , 19, 2405	2
194	Perioperative Respiratory Care and Complications. 378-422	
193	Pulmonary hypertension. 160-174	
192	Right heart failure. 32-47	
191	Multiple Choice Questions with explanations. 1-544	
190	Question 110. 225-227	
189	Lungs of the Elder. 2020 , 251-280	
188	Incidence and risk factors of pulmonary hypertension after venous thromboembolism: An analysis of a large healthcare database.	
187	Hypoxia in �tero increases the risk of pulmonary hypertension in rat offspring and is associated with vasopressin type-2 receptor upregulation. 2020 , 22, 4173-4182	1
186	Update on pediatric pulmonary arterial hypertension. 2021 , 36, 67-79	3
185	Complications after splenectomy and their prophylaxis. 2020 , 87, 70-78	
184	Multi-detector CT assessment in pulmonary hypertension: techniques, systematic approach to interpretation and key findings. 2015 , 5, 423-32	12

183	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2014 , 39, 749-58	16
182	Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension. 2014 , 4, 341-9	7
181	Contribution of calcium-activated chloride channel to elevated pulmonary artery pressure in pulmonary arterial hypertension induced by high pulmonary blood flow. 2015 , 8, 146-54	6
180	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. 2015 , 67, 169-85	5
179	Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma. 2015 , 8, 15391-5	6
178	Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View. 2015 , 31, 507-15	6
177	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. 2014 , 30, 401-44	11
176	Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?. 2016 , 16, 257-62	1
175	Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension. 2016 , 7, 253-259	14
174	Pulmonary Hypertension in Children - a Practical Approach. 2015 , 10, 237-242	
173	The Changing Landscape of Pulmonary Arterial Hypertension in 21 Century. 2017 , 33, 510-513	6
172	Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI. 2017 , 2017,	5
171	[Acute response of right ventricular function to iloprost inhalations in patients with pulmonary arterial hypertension: preliminary evaluation ?with cardiac magnetic resonance imaging]. 2015 , 18, 167-71	0
170	Exercise rehabilitation programmes for pulmonary hypertension: a systematic review of intervention components and reporting quality. 2018 , 4, e000400	3
169	Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. 2018 , 35, 308-316	1
168	Pulmonary Hypertension in Intensive Care Units: An Updated Review. 2019 , 18, 180-207	3
167	Left atrial diameter and atrial fibrillation, but not elevated NT-proBNP, predict the development of pulmonary hypertension in patients with HFpEF. 2020 , 17, 400-409	1
166	Chronic thromboembolic pulmonary hypertension - still evolving. 2020 , 2020, e202011	1

- 165 Pulmonary capillary hemangiomatosis: a case series and review of literature. **2021**, 11, 239-245
- 164 Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. **2021**, 11, 330-347
- 163 Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report. **2021**, 100, e27334
- 162 Pulmonary hypertension.
- 161 Pulmonary Hypertension in Adults with Congenital Heart Disease. **2022**, 40, 55-67 ○
- 160 Surgical Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 40, 89-101
- 159 Pulmonary Hypertension. **2022**, 40, xi-xii
- 158 Pulmonary Hypertension in Thalassemia Patients.
- 157 Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats. **2021**, 21, 377 ○
- 156 A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. **2021**, ○
- 155 The role of TGF- β 1/BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis. **2021**, 23, 288 1
- 154 k-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension. **2021**, 145, 110035 1
- 153 Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension.. **2021**, 341, 591-604 4
- 152 Effects of BPA on right ventricular mechanical dysfunction in patients with inoperable CTEPH - A cardiac magnetic resonance study.. **2021**, 147, 110111 1
- 151 Chronisches Cor pulmonale/pulmonale Hypertonie. **2015**, 1-18
- 150 Chronic thromboembolic pulmonary hypertension is still evolving. **2020**, 2020, e202011 1
- 149 Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients. **2021**, 100, e27334 1
- 148 Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.. **2022**, 1 1

- 147 Utility of plasma volume status in ambulatory patients with pulmonary hypertension.. **2022**, 12, e12045
- 146 Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.. **2022**, 17, 13 1
- 145 An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension.. **2022**, 12, e12003 0
- 144 Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in one center of Medellin, Colombia.. **2022**, 92, 53-59
- 143 Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease.. **2022**, 101, e28627
- 142 Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada.. **2022**, 12, e12040
- 141 Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension.. **2022**, 1 2
- 140 Appropriate Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Improves Right Ventricular Ejection Fraction via Lung Perfusion Scan.. **2022**, 63, 91-98
- 139 Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension.. **2022**, 0
- 138 Chronic Thromboembolic Pulmonary Hypertension: An Update.. **2022**, 12, 4
- 137 Different cytokine patterns in BMPR2-mutation positive patients and pulmonary arterial hypertension patients without mutations and their influence on survival.. **2022**, 1
- 136 The impact of sex chromosomes in the sexual dimorphism of pulmonary arterial hypertension.. **2022**, 0
- 135 Two Siblings With Peripheral Pulmonary Arterial Stenosis: Pulmonary Angiography of Advanced and Early Stages.. **2022**, 161, e75-e80 1
- 134 Animal models of pulmonary hypertension due to left heart disease.. **2022**, 0
- 133 Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.. **2022**, 141, 104337
- 132 Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.. **2022**, 0
- 131 A Retrospective Population-Based Survival Study of Idiopathic Pulmonary Arterial Hypertension in Korea.. **2022**, 37, e80
- 130 Genetic cause of pulmonary veno-occlusive disease.. **2022**, 39, 191-194

- 129 Pulmonary Hypertension in Chronic Hemodialysis Patients at Aristide Le Dantec University Hospital. **2022**, 12, 93-100
- 128 Noble Gases Therapy in Cardiocerebrovascular Diseases: The Novel Stars?. **2022**, 9, 802783 2
- 127 Giant high-pressure pulmonary artery aneurysm (PAA) in a patient with COPD and chronic pulmonary embolism (PE).. **2022**, 15,
- 126 [The role of cardiac magnetic resonance imaging in pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension].. **2022**, 0
- 125 Dyspnea as a symptom of progressive chronic myeloproliferative disease: a rare case of hemorrhagic alveolitis and pulmonary fibrosis, due to extramedullary erythropoiesis. 1-2
- 124 Insights on the Gut-Mesentery-Lung Axis in Pulmonary Arterial Hypertension: A Poorly Investigated Crossroad.. **2022**, ATVBAHA121316236 0
- 123 Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease.. **2022**, 22, 137
- 122 Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team.. **2022**, 11, 120-127 1
- 121 Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease.. **2022**, 1
- 120 Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension.. **2022**, 11,
- 119 Worsening Dyspnea in Patients With Idiopathic Portal Hypertension.. **2022**, 161, e245-e248 0
- 118 Pulmonary Hypertension and COVID-19.. **2021**, 2
- 117 The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.. **2021**, 21, 607
- 116 Metabolic Reprogramming of the Right Ventricle and Pulmonary Arteries in a Flow-Associated Pulmonary Arterial Hypertension Rat Model.. **2022**, 7, 1273-1287 0
- 115 Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Definition, classification and initial examination of patients. **2021**, 66, 28-37 1
- 114 Predictors of survival in portopulmonary hypertension: a 20-year experience.. **2021**, 34, 0
- 113 New Insights into Pulmonary Hypertension: A Role for Connexin-Mediated Signalling.. **2021**, 23, 2
- 112 Migrasomes. **2022**, 193-202

111 Epigenetics and Vascular Disease. **2022**, 475-510

110 Assessing right ventricle pulmonary artery coupling and uncoupling using echocardiography and cardiopulmonary exercise test in post operative TOF patients.. **2022**, 101214 1

109 Biventricular Myocardial Strain Analysis in Patients with Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Tissue-Tracking Technology.. **2022**, 11,

108 Table_1.PDF. **2018**,

107 Image_1.JPEG. **2018**,

106 Image_2.JPEG. **2018**,

105 Table_1.xlsx. **2018**,

104 Table_2.xlsx. **2018**,

103 Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.. **2022**, 1

102 Hemodynamic Consequences of a Surgical Arteriovenous Fistula. **2016**, 13, 288-91 5

101 Modelling Pulmonary Arterial Hypertension: Clinical Concepts, Engineering Applications and an Integrated Medico-engineering Approach. **2022**, 169-187

100 Update on the roles of imaging in the management of chronic thromboembolic pulmonary hypertension.. **2022**,

99 Recognizing Pulmonary Hypertension Following Pulmonary Thromboendarterectomy A Practical Guide for Clinicians. 1

98 Drug-induced pulmonary artery hypertension. **2022**, 53-63 1

97 Role of Gut Microbiota in Pulmonary Arterial Hypertension. **2022**, 12, 0

96 Quantification of Lung Perfusion Blood Volume in Dual-Energy Computed Tomography in Patients with Pulmonary Hypertension. **2022**, 12, 684

95 Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.. **2022**, 5, CD012809 1

94 EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. **2022**, 11, 677 1

- 93 Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells.. **2022**, ○
- 92 Classificaõ da hipertensõ pulmonar. **2014**, 6-15
- 91 Pulmonary Hypertension. **2017**, 633-650
- 90 CPI Chest Radiology Module 2017. **2017**,
- 89 Exploring Endothelial Colony-Forming Cells to Better Understand the Pathophysiology of Disease: An Updated Review. **2022**, 2022, 1-14 ○
- 88 Right ventricular strain and volume analyses through deep learning-based fully automatic segmentation based on radial long-axis reconstruction of short-axis cine magnetic resonance images.. **2022**, ○
- 87 Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility.. **2022**, 101161HYPERTENSIONAHA1 ○
- 86 Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review. **2022**, 12, 863 ○
- 85 An algorithm to identify cases of pulmonary arterial hypertension from the electronic medical record. **2022**, 23, ○
- 84 Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). **2022**, 6-70
- 83 Mechanistic Insights into Tricuspid Regurgitation Secondary to Pulmonary Arterial Hypertension. **2022**, ○
- 82 Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension. 12,
- 81 Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension. ○
- 80 Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential. 13, ○
- 79 Myocardial Dysfunction in Patients with Cancer. **2022**, 18, 361-374 1
- 78 A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department. **2022**, 58, 210-214
- 77 Unusual case of cerebral embolism after initiation of selexipag for sarcoidosis-related pulmonary hypertension: a case report. **2022**, 17, 3009-3014 ○
- 76 Evaluation of Lung Glucose Uptake with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/CT in Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Left Heart Disease. **2022**,

- 75 Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). **2022**, 6-70
- 74 Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database. 0
- 73 Clinical Assessment for Pulmonary Hypertension in Interstitial Lung Disease.
- 72 An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. 9, 3
- 71 Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification. **2022**, 22,
- 70 Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. **2022**, 13, 14667-14680 0
- 69 A Study on the Molecular Mechanism of High Altitude Heart Disease in Children. Volume 15, 721-731 0
- 68 FEATURES OF PULMONARY ARTERIAL HYPERTENSION IN THE RUSSIAN REGISTER. **2014**, 44-53 1
- 67 Evaluation of Advanced Echocardiographic Parameters of Right Ventricular in Patients with Pulmonary Hypertension. **2022**, 29, 18-25
- 66 Pulmonary Vascular Research Institute GoDeep: A meta-registry merging deep phenotyping data from international PH reference centers. **2022**, 12, 0
- 65 A framework of deep learning networks provides expert-level accuracy for the detection and prognostication of pulmonary arterial hypertension. 0
- 64 Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease. **2022**, 80, 697-718 1
- 63 Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials..
- 62 Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats. **2022**, 79, 2262-2273 0
- 61 A novel echocardiographic estimate of pulmonary vascular resistance employing the hydraulic analogy to Ohm's law. **2022**, 42, 101121 0
- 60 Gaps in knowledge and future directions for research. **2022**, 549-564.e4 0
- 59 Using a knowledge translation program to facilitate guideline- and evidence-based patient management: the PAH-QuERI Extension Program. **2022**, 12, 0
- 58 NADCIENIE PŁCNE I PATOFIZJOLOGIA I LEKI WYKORZYSTYWANE W TERAPII. **2020**, 18, 10-18 0

- 57 Sickle Cell Disease and Its Respiratory Complications. **2022**, ○
- 56 JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients With Congenital Heart Disease Long-Term After Initial Repair. **2022**, 86, 1591-1690 ○
- 55 Pulmonary Hypertension in Scleroderma Evaluation and Management. **2022**, 101468 ○
- 54 Effects of Ion-Transporting Proteins on the Digestive System Under Hypoxia. 13, ○
- 53 A case of transient right ventricular failure secondary to severe pulmonary hypertension in setting of methamphetamine use. **2022**, 7, 6-10 ○
- 52 Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report. **2022**, ○
- 51 Balloon Pulmonary Angioplasty in the Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 42, 1881-1896 ○
- 50 Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA. 9, 1
- 49 Psychometric properties of the sit-to-stand test for patients with pulmonary hypertension: A systematic review protocol. **2022**, 17, e0275646 ○
- 48 Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. 12, ○
- 47 Management of Pulmonary Hypertension Due to Brachycephalic Obstructive Airway Syndrome in a Dog. **2022**, 39, 240-245 ○
- 46 Respiratory Complications. 1-37 ○
- 45 Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis. ○
- 44 Pulmonary Veno-Occlusive Disease Versus Pulmonary Arterial Hypertension. **2022**, 345-348 ○
- 43 Primary Pulmonary Arterial Hypertension Versus Secondary Pulmonary Hypertension. **2022**, 337-340 ○
- 42 The Role of Extracorporeal Membrane Oxygenation Support after Pulmonary Thrombo-Endarterectomy. ○
- 41 Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease Patients Not Treated with Dialysis. **2022**, 14, 4664 ○
- 40 Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. **2022**, ○

39	Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance. 2022 , 2022, 1-8	○
38	Etiology of pulmonary hypertension in multiple myeloma: A case series and literature review. 2023 , 206, 107071	○
37	Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive. 2022 , 71, 801-810	○
36	ACR Appropriateness Criteria [®] Suspected Pulmonary Hypertension: 2022 Update. 2022 , 19, S502-S512	○
35	Right ventricular systolic strain in patients with pulmonary hypertension: clinical feasibility, reproducibility, and correlation with ejection fraction.	○
34	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMP2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. 2022 , 11, 3823	○
33	Impact of diastolic pulmonary gradient and pulmonary artery pulse index on outcomes in heart transplant patientsResults from the Eurotransplant database. 9,	○
32	Differences in disease severity and prognosis of exercise-induced right-to-left shunt between idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients. 9,	○
31	Alleviating experimental pulmonary hypertension via co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries. 2022 ,	1
30	An increased risk of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema: a meta-analysis.	○
29	Outcomes of atrial septostomy and effect on long-term survival in patients with idiopathic pulmonary arterial hypertension: A single-center cohort. 2022 ,	○
28	Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia.	○
27	Pregnancy outcomes in women with pulmonary hypertension: a retrospective study in China. 2023 , 23,	○
26	Effectiveness of Respiratory Muscle Training in Adults With Pulmonary Hypertension. A Systematic Review and Meta-Analysis. 2023 ,	○
25	Moderne Bildgebung des Lungenhilus.	○
24	Soluble Guanylyl Cyclase ActivatorsPromising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. 2023 , 28, 861	○
23	Impact of Rapid Weight Loss after Bariatric Surgery in Systemic Inflammatory Response and Pulmonary Hemodynamics in Severely Obese Subjects with Pulmonary Hypertension. 2023 , 236, 365-372	○
22	Type 4 Tetralogy of Fallot with Pulmonary Hypertension in an American Shorthair Cat. 2022 , 39, 366-372	○

- 21 Antiphospholipid Syndrome and the Lungs. 76-82 ○
- 20 Pulmonary Hypertension in Congenital Heart Diseases. **2023**, 641-654 ○
- 19 Shear Wave Dispersion Slope of the Liver Can Predict Adverse Outcomes in Patients with Pulmonary Hypertension. **2023**, 64, 230-236 ○
- 18 Pulmonary Hypertension and Operative Risk in Mitral Valve and Coronary Surgery. **2023**, 286, 49-56 ○
- 17 The Impact of Underlying Obstructive Sleep Apnea Treatment on Exercise Capacity in Patients With Pulmonary Hypertension Undergoing a Cardiac Rehabilitation Program. Publish Ahead of Print, ○
- 16 Real-world evidence for beneficial effects of dipyron in 4,278 patients with pulmonary hypertension [Analysis of the risk of ventilation, hospitalization, and agranulocytosis. **2023**, 943, 175567 ○
- 15 Machine Learning Based on Computed Tomography Pulmonary Angiography in Evaluating Pulmonary Artery Pressure in Patients with Pulmonary Hypertension. **2023**, 12, 1297 ○
- 14 Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1 /2 pathway. **2023**, 27, 622-633 ○
- 13 Association of Left Ventricular Filling Pressure With Chronic Thromboembolic Pulmonary Hypertension. **2023**, 81, 665-667 ○
- 12 Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension. **2023**, 24, 3979 ○
- 11 Point-of-Care Ultrasonography in a Pulmonary Hypertension Clinic: A Randomized Pilot Study. **2023**, 12, 1752 ○
- 10 iCPET calculator: a web-based application to standardize the calculation of alpha distensibility in patients with pulmonary arterial hypertension. ○
- 9 Fluid management in septic patients with pulmonary hypertension, review of the literature. 10, ○
- 8 The spatial-temporal dynamics of pulmonary blood flow are altered in pulmonary arterial hypertension. **2023**, 134, 969-979 ○
- 7 Inhaled milrinone in cardiac surgical patients: pharmacokinetic and pharmacodynamic exploration. **2023**, 13, ○
- 6 Heart Failure, Transplant, Left Ventricular Assist Devices, Pulmonary Hypertension. **2023**, 272-301 ○
- 5 Novel AGL variants in a patient with glycogen storage disease type IIIb and pulmonary hypertension caused by pulmonary veno-occlusive disease: A case report. 14, ○
- 4 Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprogramming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. 14, ○

- 3 Plasma mid-regional proadrenomedullin level in children with pulmonary hypertension associated with CHD. 1-7 ○
- 2 Comparison of Hemodynamic Effects of Dobutamine and Ephedrine Infusions in Isoflurane-Anesthetized Horses. **2023**, 10, 278 ○
- 1 Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension. **2023**, 10, 756 ○